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Abstract 
Disrupting Androgen Receptor Transactivation Domains to Identify Lead Compounds 
with Potential to be Optimized and Developed into Prostate Cancer Therapeutics 
 
 
Ashley Taylor Fancher, PhD 
 
University of Pittsburgh, 2019 
 
 
Prostate cancer (PCa) is the leading cause of cancer in men in the USA, with more than 
160,000 new cases each year. PCa patients receiving standard of care androgen deprivation therapy 
(ADT) eventually acquire what’s known as castration resistant prostate cancer (CRPC), and 20% 
of all PCa cases progress to this metastatic and incurable form of the disease. PCa is the second 
leading cause of cancer-related death in American men. Current FDA approved drugs for CRPC 
only provide a 2-5-month survival benefit due to the emergence of resistance to these therapies. 
Resistance involves continued androgen receptor (AR) signaling despite castrate serum levels of 
androgens. CRPC cells express elevated levels of both full-length AR (AR-FL), and constitutively 
active AR splice variants which lack the ligand binding domain (LBD) and display altered AR 
coactivator interactions, both of which contribute to persistent AR signaling. Overexpression of 
steroid-receptor coactivators are implicated in the progression of CRPC and amplify AR-mediated 
transcription by binding to either the activation function 2 (AF-2) surface formed by the AR-LBD, 
or the activation function 1 (AF-1) surface located in the amino-terminal domain of the receptor. 
Coactivator binding interactions enhance the recruitment of the basal transcriptional machinery 
and activate the transcription of AR target genes. Our lab has designed a screening paradigm to 
identify compounds with novel mechanisms of action to prevent or delay resistance. The screening 
paradigm uses a primary high content screening assay (HCS) designed to identify  compounds that 
inhibit or disrupt protein-protein interactions (PPI’s) between AR and one of its coactivators, 
transcriptional intermediary factor 2 (TIF2), together with panels of counter screens and 
 v 
characterization assays to prioritize hit compounds that inhibit or disrupt AF-2 and/or AF-1 
transactivation.  The ideal hit compound would prevent the transcription of both AR-FL and AR-
V7 thereby providing a dual approach to preventing CRPC progression. 
 
 vi 
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 1 
 Prostate Cancer (PCa) Overview 
1.1 PCa: An Introduction 
1.1.1  Statistics and Epidemiology 
Prostate Cancer (PCa) is the 2nd leading type of cancer in men in the U.S., behind skin 
cancer, with nearly 200,000 new incidences diagnosed and 30,000 deaths reported annually [1], 
[2]. The 5-year survival rate of men with localized or regional PCa is nearly 100% [3]. However, 
as soon as this disease becomes metastatic, the 5-year relative survival rate drops to nearly 29% 
[4]. Metastatic PCa is an aggressive type of cancer that responds poorly to current standard of care 
therapeutics. PCa that no longer responds to current hormonal therapies is termed Castration 
Resistant Prostate Cancer (CRPC).  20% of PCa patients develop CRPC within 5 years of PCa 
diagnosis. The prognosis for CRPC is terminal, and the mean survival of patients with metastatic 
CRPC is only 9-13 months [5]. 
PCa is a disease of age, with around 6 out of 10 diagnoses detected in patients older than 
65. Patients that are younger than 50 tend to be at lower risk for diagnosis of this disease [6]. 
However, there are certain risk factors that can increase the likelihood of developing PCa in 
younger men. For example, certain countries and ethnicities have an increased tendency to be 
diagnosed with and die from this disease than others. Western countries including those in Europe, 
and North America have a notably higher incidence rate than those in the East. There is a 
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particularly low incidence rate observed in Asia [7]. One possible explanation for the difference 
in PCa incidence is based on the differences in diet observed between western and eastern 
countries, notably, the increased consumption of foods high in saturated fats, dairy, and meat in 
the west [8]. This hypothesis is supported by the finding that, men from Asia who have immigrated 
to either Europe or North America and have adopted a western diet, develop an increased risk of 
PCa incidence [9]. Along the same lines, obesity, although it hasn’t been consistently proven as a 
risk factor for developing PCa, has been associated with a shorter overall survival. Specifically, 
men with a BMI of >35 kg/m2, have a 34% higher rate of prostate cancer death compared to men 
who have a more normal weight [10]. In terms of ethnicity, African American men have an 
elevated rate of diagnosis, with more than double the incidence than Caucasian Americans [7], 
[11]. Similarly, heredity can play a role in developing PCa, as men with a direct relative, such as 
a brother or father, with a PCa diagnosis are at a 2-3 fold increase in likelihood of also being 
diagnosed with this disease than those who do not have a direct relative diagnosed with PCa [12]. 
Despite this fact, 90-95% of all prostate cancers do not have an association with heredity [13]. 
1.1.2  PCa Diagnosis 
Screening for PCa: Physical Examination and Diagnostic Biomarkers 
A PCa diagnosis is typically based on the results of a physical examination of the prostate 
and/or a blood test for serum prostate specific antigen (PSA) levels. If either test suggests the 
possibility of PCa, the physician will usually request that a biopsy be taken. The results of the 
physical prostate exam and serum PSA levels combined with the histological grading of prostate 
tissue obtained by biopsy allow a physician to both confirm the PCa diagnosis, and stage the extent 
of cancer development [14]. 
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The physical examination is a method of palpating the prostate gland for evidence of tumor 
formation. Unfortunately, this type of examination is not very sensitive, as early stage PCa may 
not result in a palpable tumor. The PSA blood test measures the serum levels of a protein called 
prostate specific antigen (PSA) [14]. PSA belongs to a group of serine proteases called kallikreins 
and PSA levels are elevated in the bloodstream of patients with an enlarged prostate due to 
inflammation, or due to the presence of a tumor [15]. Normal PSA levels can differ from patient 
to patient, but many doctors consider patients with PSA levels of ≤4 ng/mL to have a decreased 
risk of having prostate cancer. This type of test is quite sensitive, however, it is not always specific 
for cancer. For example, PSA levels can be elevated in men with benign prostatic hyperplasia 
(BPH), urinary tract infection, or non-cancer related inflammation [16]. Similarly, 65-75% of men 
with PSA levels between 4-10 ng/mL, have negative biopsy results [17], [18]. Furthermore, based 
on recommendations set-forth by the U.S. Preventive Services Task Force, testing for PSA is only 
recommended in men aged 55-69, and this decision is made on a patient to patient basis based on 
potential risk factors of incidence, such as ethnicity and family history [19]. These tests therefore 
can be informative, but must be confirmed by the results from a tissue pathology report to make a 
more accurate diagnosis.   
 
Histological grading   
            Prostate cancer can be classified clinically, as being localized or metastatic, or 
pathologically, which involves the observation of prostate tissue samples taken from a patient. 
The prostate is comprised of glands surrounded by the stroma. The gland is composed of acini 
which consists of epithelial cells which line a central lumen [20]. Prostate epithelium is 
comprised of luminal columnar epithelial cells, and of basal cells that lie adjacent to these. It has 
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been shown that nearly all cells identified as adenocarcinoma, are of luminal origin, with very 
few infiltrating basal cells [21]. Prostate adenocarcinoma can be staged using a scoring system, 
termed as a “Gleason score” or based on the TNM staging system which was developed as a tool 
to stage tumor spread through the extent of the tumor (T), the extent of spread to the lymph 
nodes (N), and the presence of metastasis (M). Both use histopathology as a means for staging a 
primary tumor. A Gleason score enables a pathologist to assign a score to the prostatic tissue as 
an indicator of cancer grade. The Gleason score ranks a biopsy sample with two numbers based 
on patterns observed from retrieved cells. The first number includes the assignment of a Gleason 
grade to the most predominant cell pattern seen in the tissue sample, and the second number 
indicates the second most predominant cell pattern seen in the tissue sample. Each score ranges 
between 1 and 5, where one is the most differentiated and least likely to be cancerous, and 5 is 
the least differentiated and most likely to be cancerous [22]. The two values represent an overall 
score which can inform decision making when determining treatment options. Patients with a 
Gleason score of 6 or lower, are seen to have better outcomes than those with high Gleason 
scores such as those that are 8 or above. The outcomes of patients with a Gleason score of 7 tend 
to be variable, and treatment may or may not be recommended given this score [23]. Of the 
TNM staging system, the T stage includes information regarding the primary tumor itself, where 
T1 indicates results directly obtained from the pathology report. T1 prostatic carcinomas can be 
deemed as T1a, T1b or T1c. T1a and T1b represent pathological grading based on specimens that 
were isolated using transurethral resection of the prostate (TURP). T1a represents tissue with less 
than 5% area of cancerous tissue. T1b represents tissue with more than 5% area of cancerous 
tissue. T1c is represented by pathological grading based on specimens that were isolated using a 
needle biopsy. The physicians request for a needle biopsy is usually as a result of high levels of 
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serum PSA [24]. Results obtained from a histopathology report combined with results of clinical 
staging allow the physician to make a more informed prognosis of the disease.  
1.1.3  Stages of PCa 
There are 4 major stages of PCa. Stage I includes the presence of a localized tumor that is 
typically present in one lobe of the prostate and cannot be detected upon physical examination. 
Stage II involves the growth of the initial tumor, and tumor formation in other lobes of the prostate. 
This stage may be accompanied by inflammation of the prostate. Stage III is generally 
accompanied by a breach in the outer membrane of the prostate by the tumor. It also includes the 
narrowing of seminal vesicles and the ureter which may be symptomatic. Stage IV includes lymph 
node involvement, eventually becoming metastatic. 
Stages of prostate cancer can be determined using the two different types of classification 
systems that have been previously described in the last section: the TNM system, and Gleason 
Scoring [25]. The Gleason scoring system described above uses histopathology to determine 
disease stage, whereas the TNM system is used to determine the extent of disease progression and 
the spread of cancer based on both histopathology and other methods. These methods include 
physical examination of the prostate itself and staging the extent of metastasis via certain imaging 
techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and positron 
emission tomography (PET). T2 is defined by a tumor that is evidenced by palpation or visible by 
imaging techniques. T2 can be subcategorized based on its presence in lobes of the prostate. T3 is 
based on the tumors ability to locally extend past the basement membrane of the prostate gland. 
Stage T4 is represented by a prostate tumor that has invaded adjacent structures/tissues. The N 
stage involves information regarding spread of the cancer to regional lymph nodes. N0 demarcates 
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no regional metastasis, N1-3 represent metastases in regional lymph nodes. M is then 
representative of a distant metastasis. Where M0 represents no distant metastasis, and M1 
represents distant metastasis [24], [25].  Results from the physical examination, PSA blood test, 
TNM staging, and Gleason score can all aid in determining the proper type of therapy for the 
prostate cancer patient to be administered.  
 
Primary, localized tumors: Molecular Hallmarks 
In the earliest events of prostate carcinogenesis, the loss of Nkx3.1 occurs as a result of the 
loss of specific regions of chromosome 8p. Nkx3.1 is a homeobox containing gene, involved with 
prostate development and function, and acts as a prostate specific tumor suppressor gene [26]. This 
is a frequent occurrence, in as many as 80% of prostate tumors [26]. The fusion of TMPRSS2, 
which is an androgen-regulated gene, with ERG, which is part of the family of ETS transcription 
factor genes, has been shown to be an early molecular hallmark of the development of prostate 
cancer itself. It has even been reported in 30-70% of patients who have undergone a surgical 
procedure as a means of PCa treatment [27], [28]. Other drivers include an increase in expression 
of oncogene, MYC, as well as loss of either tumor suppressors PTEN, or p53, both of which are 
associated with poor prognosis [29]. 
 
Castration Resistant, metastatic tumors: Molecular Hallmarks 
Castration resistant prostate cancer is characterized by disease progression – consecutive 
rises in PSA levels and/or an increase in soft tissue or bone lesions - despite treatment with 
androgen deprivation therapies (ADT’s) [30]. ADT’s target the proper functioning of the AR by 
blocking the production of androgens that bind to and activate it, or by antagonizing ligand binding 
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to the AR. Since the progression of PCa relies on the function of the AR signaling axis, targeting 
elements along this pathway is a strategic approach to the treatment of prostate cancer. The types 
of ADT’s used in the treatment of localized prostate cancer and locally advanced disease include 
luteinizing hormone-releasing hormone (LHRH) or gonadotropin releasing hormone (GnRH) 
agonists or antagonists such as Leuprolide, Goserelin, Triptorelin, and Histrelin. These types of 
compounds act by targeting the hypothalamic pituitary gonadal (HPG) axis, which represents three 
endocrine glands that act in concert. The hypothalamus, residing in the brain, secretes GnRH, 
which travels to the pituitary where it binds to receptors of secretory cells which then produce LH 
which travels through the blood stream to the leydig cells of the testis, directing them to produce 
androgen. GnRH agonists cause a negative feedback loop which downregulates GnRH receptors 
in the anterior pituitary gland resulting in a decrease in LH release, and a subsequent decrease in 
testosterone release from the leydig cells [31, 32]. 
 Disease progression occurs due to mechanisms of resistance that arise in the CRPC cell 
against standard of care ADT’s.  This resistance involves molecular events surrounding aberrant 
androgen receptor (AR) function in the prostate cancer cell. The dysregulation of coregulators, 
specifically the overexpression of coactivators, AR mutations, AR overexpression and the 
emergence of constitutively active AR splice variants, such as AR-V7 are other ways in which 
continued AR signaling, and therapeutic resistance occurs [33]. These mechanisms of resistance 
will be described in further detail later in the chapter.  
1.1.4  Current therapeutics approved to treat PCa 
Localized therapeutic treatment options 
 8 
The therapies that are offered to patients who have localized PCa include the following: 
active surveillance, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound 
and focal therapy. Surgery can include a partial or radical prostatectomy, which involves the 
removal of part or all of the prostate gland depending on severity of the cancer, using either 
retropubic or perineal methods. Radiation can also be used as a means to eradicate a more localized 
tumor, the two main types being external beam or brachytherapy, which is a type of seed therapy, 
using internal beams of radiation [34]. Androgen deprivation therapies can be used to complement 
the removal of a tumor by surgery or radiation [34]. These different methods are employed based 
on the severity of the localized disease. PCa is considered to be low risk if a patient has PSA blood 
serum levels of less than 10 ng/mL, tumor staging of T1-T2a based on DRE and pathology report, 
and a Gleason score of less than 6.  PCa is considered to be of intermediate risk if the patient has 
a PSA level of either less than 10 ng/mL, or 10-20 ng/mL, combined with a Gleason score of 7, 
and tumor staging between T1-T2. Finally, patients with high risk disease have a PSA of greater 
than or equal to 20 ng/mL, a Gleason score of 8 or above, and tumor stage of T1-T2. Based on the 
2017 guidelines approved by the American urological association, for a low risk prostate cancer, 
active surveillance is the recommendation [34]. For intermediate-risk localized disease, clinicians 
are suggested to recommend radical prostatectomy or radiotherapy plus androgen deprivation 
therapy (ADT) as the standard of care treatment option [34]. Similarly, for a high-risk localized 
disease, clinicians are encouraged to recommend radical prostatectomy or radiotherapy plus ADT 
as a standard treatment option. Both intermediate risk, and high risk localized PCa staging with 
CT or MRI and a bone scan is suggested. Similarly, for a high risk localized disease, clinicians 
should stage the extent of tumor spread using CT or MRI and bone scan [34]. Treatment options 
such as focal therapy or high intensity focused ultrasound are not standard of care options, but 
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despite not being recommended, they may still be used as a treatment option. ADT’s may be used 
concurrently in patients undergoing radiotherapy, in order to shrink the tumor and prevent possible 
metastasis.  
For patients with non-metastatic castration resistant prostate cancer, apalutamide or 
enzalutamide can be used concurrently with androgen deprivation therapies [35]. 
 
 
Metastatic therapeutic treatment options 
The 2019 National Comprehensive Cancer Network (NCCN) guidelines provide 
recommendations for treating advanced prostate cancer that has failed local therapy. These 
therapeutic options include LHRH agonists, or antagonists, or complete androgen blockade, using 
LHRH agonist or antagonist with an oral antiandrogen [36]. This type of treatment reduces the 
levels of androgen in the blood stream. A decrease in circulating androgens decreases the AR’s 
signaling potential in PCa cells. This reduction in androgen levels can be achieved through either 
surgical or chemical means. Surgery involves an orchiectomy, or removal of the testis, while 
chemical castration involves the use of LHRH agonists or GnRH agonists [31, 32]. Although these 
agonists have been shown to be just as effective as surgical castration, they can lead to an initial 
“flare-up” of the disease, due to the initial increase in androgen production observed [37]. This 
flare up presents clinically with an increase in serum PSA levels observed, but also 
symptomatically [37]. Therefore, antiandrogens, which block the action of androgens at the 
receptor present in different tissues, by targeting the androgen receptor directly at the LBD, can 
mitigate disease flare. Antiandrogens commonly used include bicalutamide, flutamide, or 
nilutamide [37].  
The guidelines set forth by the American Urological Association suggest treating 
metastatic CRPC based on the extent of disease progression [34]. For example, for patients who 
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are asymptomatic or minimally symptomatic, either abiraterone plus prednisone, or enzalutamide 
should be offered [34]. Abiraterone Acetate is a type of ADT which targets the production of 
adrenal androgens. This compound is a pregnenolone analog inhibitor of CYP17A1. Abiraterone 
specifically inhibits the 17alpha-hydroxylase enzyme function of this cytochrome P450. This 
ultimately prevents the synthesis pathway of cholesterol into testosterone [38], [39]. Enzalutamide 
is an AR antagonist that prevents the AR signaling pathway by inhibiting nuclear translocation of 
the receptor, and blocks coactivator recruitment of the AR [40]. Alternatively, docetaxel, if not 
used in prior treatment, or sipuleucel-T can be used to treat patients. For patients who are 
symptomatic, abiraterone plus prednisone, or enzalutamide can be used. Similarly, docetaxel can 
be used. For patients who have mCRPC symptoms related to bone metastasis, such as bone pain, 
and loss of integrity in bone structure that is prone to fracture, therapies such as radium-223 can 
be used in patients who have received prior docetaxel. Patients who have poor bone health can be 
offered preventative treatment (supplemental calcium, vitamin D) for fractures or other skeletal 
related events. Also, clinicians can use zoledronic acid or denosumab as a preventative treatment 
for fracture or other skeletal related events for patients who experience bone metastases [41]. 
1.1.5  Outcomes for approved drugs for Castration Resistant Prostate Cancer (CRPC) 
therapy 
Progression free survival, overall survival 
LHRH agonists and antagonists are used when the cancer has spread too far to be cured by 
surgery or radiation. It is also used if cancer remains or comes back after treatment with surgery 
or radiation therapy [37]. First generation antiandrogens such as flutamide, nilutamide, or 
bicalutamide may be added to the treatment if LHRH agonists or antagonists are no longer working 
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on their own, or used as a first line hormone therapy in conjunction with LHRH agonists [37]. 
Physicians use LHRH agonists and antiandrogens in conjunction with one another to achieve what 
is known as combined androgen blockade or CAB, as a means to prevent AR signaling in the cell 
both directly and indirectly [37]. Unfortunately, despite efforts in treatment with both LHRH 
agonists and antiandrogens, cancer continues to progress. For example, many different studies 
were conducted to determine the efficacy of CAB compared with castration alone. It was found by 
one group, Crawford et al, that patients either undergoing CAB with LHRH plus flutamide, and 
LHRH plus placebo, that PFS was prolonged in the flutamide group compared to the control arm 
by 2.6 months, from 13.7 months to 16.5 months [42]. Conversely, another group, Eisenberger et 
al compared CAB using flutamide and an LHRH agonists compared to placebo and found that 
there were no significant differences in PFS [43]. In either case, patients succumbed to death, 
which is consistent with cancer progression and relapse due castration resistance. 
The two most recently approved CRPC therapeutic agents are Enzalutamide and Abiraterone, 
which antagonize AR and inhibit androgen synthesis, respectively. They have a similar, yet more 
potent mechanism of action than their ADT predecessors. Unfortunately, the survival benefit 
conferred by Enzalutamide and Abiraterone in CRPC patients is only a few months, and these 
drugs fail to prevent the emergence of resistance [38, 44]. 
According to the PREVAIL clinical trial, a multinational study to test the effects of 
enzalutamide compared to placebo, it has been shown that outcomes in terms of overall survival 
of patients who were treated with enzalutamide plus LHRH therapy was 35.3 months, vs. patients 
who were treated with placebo with LHRH therapy was 31.3 months, with an overall advantage 
of 4 months OS of patients taking Enzalutamide compared to placebo control [44]. 
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In a randomized phase 3 study funded by Janssen Research & Development, it was shown 
that in patients who were receiving abiraterone acetate plus prednisone vs. those who were taking 
placebo plus prednisone, the overall survival in the abiraterone acetate arm was longer on average 
than those taking placebo plus prednisone, 34.7 months vs. 30.3 months, respectively, with an 
overall increase in survival of 4.4 months [38]. 
 
Toxicities &/or dose limiting adverse events  
Adverse events from ADT’s such as LHRH and GnRH agonists, used in the treatment of 
localized prostate cancer include osteoporosis, loss of muscle and muscle weakness, weight gain, 
hot flashes, sweats, gynecomastia and decreased libido. Disease flare-up, also associated with 
these compounds can lead to ureteral obstruction, urinary retention, spinal cord compression, or 
even death. Also, men who have cancer that has spread to the bones might experience bone pain 
associated with flare-up. Similarly, a burst in tumor growth could result because of flare up which 
could lead to pain, or other skeletal or spinal cord related injury [37].  
Adverse events associated with antiandrogens are similar to those seen with surgical and 
chemical castration but are less severe than those associated with LHRH and GnRH agonists. 
However, when used in conjunction with LHRH agonists, diarrhea, nausea, liver problems, and 
fatigue often result [42]. The side effects of taking Enzalutamide and apalutamide include diarrhea, 
fatigue, and hot flashes. These drugs have also seen to have effects such as dizziness, and in very 
rare cases, seizures [42]. The side effects of taking Abiraterone include pain in the joints or 
muscles, high blood pressure, hot flashes, nausea, and diarrhea [45]. Given these side effects, it 
would be beneficial for the patient’s quality of life if a therapeutic with lower adverse effects could 
be developed. 
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1.2 Mechanisms of Resistance to Current Therapeutics and Progression into Castration 
Resistant Prostate Cancer (CRPC) 
The majority of PCa patients progress to CRPC despite receiving the current standard of care 
therapeutics because of a variety of mechanisms of resistance. ADT is seen to be effective initially, 
but ultimately patients progress into a castrate resistant state. This progression is due to persistent 
androgen receptor signaling in the cell despite achieving castrate levels of androgen [46]. The 
AR’s normal biological role involves mediating the growth and function of the prostate gland, 
however its aberrant signaling can lead to the development of CRPC [47]. AR dependent 
mechanisms of resistance are due to AR over-expression, continued intra-tumoral androgen 
synthesis, and promiscuous AR activation by non-androgenic ligands [48], [49], [50]. These 
mechanisms occur to compensate for low cellular DHT levels.  
The overexpression of the AR is one such mechanism of resistance. AR protein expression 
is significantly elevated in more advanced stages of PCa, due to either increases in gene copy 
number or by increased transcription of the AR gene. This AR overexpression has been reported 
to occur in 30-80% of PCa cases [51]. Also, around 81% of mCRPC carried AR enhancer region 
amplifications which allowed of the overexpression of AR. This is seen to occur after the exposure 
of patients to ADT’s [52].  
Alternative androgen synthesis is another mechanism of resistance. Despite surgical or 
chemical methods of castration, androgen synthesis can still occur via alternative synthesis 
pathways. These pathways allow for androgen production both intratumorally, and by the adrenal 
glands. Increase in androgen synthesis combined with elevated AR expression leads to increased 
DHT::receptor binding, receptor activation, and reduces patient responses to ADT [53].  
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AR mutations in the ligand-binding domain also lead to ineffective responses to ADT. The 
mutations are generally somatic and allow the AR to become activated by non-androgen based 
steroid hormones, such as progestins, estrogens, and even antiandrogens [54]. These mutations are 
less frequently seen in early stages of the disease and only seem to represent 10% of the population 
in CRPC [54], meaning that there must be other forms of resistance in play that have yet to be 
targeted by drugs.  
The dysregulation of co-regulators, specifically the overexpression of coactivators 
represents another way in which continued AR signaling, and therapeutic resistance occurs [55-
59]. It has been hypothesized that the overexpression of AR coactivators can cause progression of 
PCa into CRPC, no longer responsive to current ADT [60]. Coactivators possess different 
functionality and can aid in the transcription process by recruiting proteins that unwind DNA from 
the histones at the site of transcription, or through their recruitment of general transcriptional 
factors (GTF’s). Some coactivators seen to be overexpressed in CRPC include the family of p160 
coactivators, SRC1, TIF2, and RAC3, as well as Vav3, FKBP51, p300/CBP, MED1, FHL2, and 
others [56-59, 61-63]. These coactivators act as adaptor proteins, allowing for the interaction 
between AR, and the basal transcriptional machinery. Some coactivators also have intrinsic HAT 
(histone acetyltransferase) activity which allows for unwinding of the DNA from the histones for 
gene transcription to occur. Corepressors include proteins such as SMRT, and NCoR. These act to 
control chromatin structure with their endogenous histone deacetyltransferase (HDAC) activity 
[64].  The p160 coactivators act as bridging proteins that recruit proteins with histone acetylating 
function to the DNA bound AR [59]. 
Another form of resistance can be attributed to alternative splicing of full-length AR mRNA, 
leading to the production of truncated receptors [65-69]. Patients that express alternative splice 
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variants like AR-V7 which have lost the ligand-binding domain in the C-terminus of the receptor, 
will not respond to the current antiandrogens [67, 68]. AR-V7 has been shown to be constitutively 
active and drives the expression of cell cycle genes, and some canonical androgen responsive 
genes, including the PCa biomarker PSA, in reporter assays and expression microarray analyses 
[67, 68, 70]. Since the overexpression of coactivators and emergence of AR splice variants remain 
un-broached by current CRPC therapeutics, the targeting of these resistance mechanisms might 
represent an untapped therapeutic strategy. 
 
AR Splice Variants  
 
Identification of 
Splice variants were first identified by two different groups. Dehm et al utilized 3’ rapid 
amplification of cDNA ends (RACE) in which they identified constitutively active proteins that 
only contained exons 1, 2 and/or 3, and cryptic exons derived from introns 2 and 3 of the full 
length AR (AR-FL) [65, 68]. Similarly, Hu et al describe the design of primers and in silico 
sequencing methods to identify 7 different splice variants, AR-V1 to AR-V7 [67]. To date, there 
are 18 identified AR splice variants [69]. Some of these are constitutively active, meaning that 
even in the absence of ligand, these variants are transcriptionally active. Some are conditionally 
active, which means that different cell contexts, produce different extents of transcriptional activity 
[69]. AR-V7 and ARv567es are LBD lacking versions of the full-length AR. These are 
constitutively active and are the most clinically relevant splice variants seen to emerge in CRPC 
patients, due to an upregulation of AR splice variant expression after ADT therapy [71-74].  
Structure and Function  
Whereas wild type FL-AR (wtAR) consists of 8 canonical exons, the AR-V7 splice variant 
contains exons 1-3, and a 3’ untranslated region (3’ UTR), which translates to a protein containing 
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a variable region, uncharacteristic of the full-length receptor [65-68]. Functionally, AR-V7 is 
considered constitutively active because many ARE containing luciferase-based reporter 
constructs become activated by the transfection of AR-V7 without the addition of androgens to 
stimulate reporter response. This demonstrates that these splice variants lacking a LBD have 
constitutive activity, and do not require androgen based stimulation [67, 68, 70]. AR-V7 has been 
shown to regulate the transcription of both genes that are canonically targeted by the AR-FL in 
androgen dependent (AD) forms of PCa, such as PSA, and those non-canonical genes associated 
with androgen independent (AI) forms of PCa, such as ubiquitin conjugating enzyme E2C 
(UBE2C) [70, 75, 76]. Proteins are tagged with ubiquitin as a means of signaling them for 
proteasomal degradation [77]. Ubiquitination involves ubiquitin-activating enzymes, ubiquitin 
conjugating enzymes, and ubiquitin-protein ligases. The UBE2C gene specifically codes for a 
member of the E2 ubiquitin-conjugating enzyme. This protein allows for the destruction of mitotic 
cyclins, which is a necessary process for cells to leave mitosis and enter into cytokinesis. Overall, 
the function of UBE2C leads to cell cycle progression, therefore implicating it in cancer 
progression [70, 75, 76]. CRPC, an AI form of PCa is characterized by a shift from the transcription 
of genes involved in metabolism and biosynthesis to genes involved in cell cycle regulation. For 
example, an increase in transcription of UBE2C, involved in the degradation of mitotic cyclins, is 
observed in patients with CRPC. Specifically, the overexpression of AR-V7 is associated with an 
increase in transcription of UBE2C [70, 75, 76] . Therefore, targeting AR-V7 may be able to target 
the aggressive phenotype of CRPC by decreasing the transcription of these target genes associated 
with cellular proliferation.  
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Clinical Implications 
The emergence of the AR-V7 splice variant has been shown to be clinically relevant in patients 
with CRPC and is one of the mechanisms by which resistance develops to current anti-androgen 
therapies. AR-V7 emerges through a process of mRNA splicing, [65-68] resulting in the truncation 
of the ligand-binding domain (LBD) from the full length AR. This renders current therapeutic 
compounds whose action depends on targeting this domain, ineffective. AR-V7 expression levels, 
determined via immunohistochemistry, have been shown to be elevated in more advanced and 
hormone resistant states of the disease after therapy with ADT’s compared to more hormone naïve 
PCa’s [78]. Similarly, expression of AR-V7 is elevated 20-fold in xenografts from patients that 
have received ADT, when compared to samples taken from hormone naïve PCa patients [71]. Four 
different studies have shown that AR-V7 has been detected in circulating tumor cells CTC’s of 
PCa patients, where between 38-55% CRPC patients were determined as being AR-V7 positive 
[71-74]. Not only is AR-V7 expression increased in CRPC patients, but it has been shown that this 
increase is directly related to treatment with ADT’s. For example, the percentage of patients 
expressing AR-V7 increases dramatically after treatment with the most recently approved ADT 
therapies, abiraterone and enzalutamide. One study has shown that after exposure to abiraterone 
and enzalutamide, the percent of patients expressing the AR-V7 splice variant increases from 12% 
to 67% [71]. Notably, patients who express AR-V7 in PCa have worse clinical outcomes compared 
to those patients who are AR-V7 negative in terms of biochemical recurrence (PSA-progression 
free survival), clinical, and or radiographic progression free survival, and overall survival [71-74]. 
This shows that expression of the AR-V7 splice variant is a major factor contributing to the 
development of resistance in CRPC, and agents that inhibit AR-V7 activity might be of therapeutic 
value. 
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AR-V Interactions with Coactivators 
SRC1, and TIF2 are histone acetyltransferases and when they form protein-protein interactions 
with the AR, they recruit secondary co-activators that possess chromatin remodeling activity that 
allows for recruitment of the transcriptional machinery to promoters of AR target genes [58, 59]. 
These co-activators interact with the AF1 region found in the N-terminal domain of the AR [79-
82]. This allows for these coactivators to bind to and interact with AR splice variants such as AR-
V7. It was discovered by Claessens et al that TAU5 was the required interacting surface in the AR-
NTD and is a prerequisite for p160 recruitment [79, 81, 82]. When TAU5 was deleted from the 
AR-NTD this prevented co-activation by SRC1 [79, 81, 82]. 
1.3 AR and its Role in Prostate Cancer 
1.3.1  Functional Domains of the AR 
The androgen receptor is a 110 kDa type I nuclear receptor located on chromosome Xq11-12, 
consisting of 2.7 kb gene which codes for a 919 amino acid protein. The AR is made up of 8 exons 
that are involved in the protein coding sequence of four functional domains [83] [84]. These are 
exon 1 which codes of the amino-terminal domain (NTD), exons 2 and 3 which encode the DNA 
binding domain (DBD), part of exon 4 which codes for the Hinge Region, and exons 4-8 which 
encode the COOH-terminal domain (CTD), containing the Ligand Binding Domain (LBD) [84]. 
The structure of both the AR-LBD in the CTD, and the DBD have been elucidated via crystal 
structure. 
Amino-Terminal Domain 
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The AR-NTD is intrinsically disordered and is not structured in solution. Therefore, no crystal 
structure has been identified for this domain. The AR-NTD houses one of the transcriptional 
activation domains of the AR, activation function 1 (AF-1) [85].  
DNA-binding Domain 
The DBD of the AR is one of the most highly conserved regions between the different members 
of the steroid hormone nuclear receptor family. The AR’s DBD consists of two zinc fingers which 
allows for homodimerization and binding to the DNA along androgen responsive elements 
(ARE’s). The ARE’s are characterized by a particular binding sequence, typically characterized 
by, 5’AGGTCANNNTGACCT3’, and this binding allows for the receptor to regulate transcription 
of particular AR-target genes [86]. 
Hinge Region 
The DBD is linked to the LBD via the hinge region. The hinge region contains the nuclear 
localization sequence (NLS) which allows for nuclear localization of the AR [86]. 
Ligand-Binding Domain 
The LBD also contains a NLS, and DHT binding allows for the exposure of the nuclear localization 
sequences, and nuclear import of the AR. A nuclear export signal (NES), responsible for export of 
the AR from the nucleus to the cytoplasm in the absence of DHT is located between the DBD and 
hinge region [83, 86]. The AR-LBD also houses one of the transcriptional activation functions of 
the AR, activation function 2 (AF-2), which is implicated in transcriptional activity of the AR [84, 
86]. Classical AR signaling in the cell (Figure 1 on pg. 28), involves androgens, such as 
dihydrotestosterone (DHT). In the absence of androgen, the AR is sequestered in the cytoplasm, 
bound to heat shock protein, Hsp90. Testosterone is converted to the more potent androgen, 
dihydrotestosterone by 5α-reductase. DHT binding of the AR causes a conformational change of 
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the receptor, and leads to the dissociation of Hsp90. When bound by DHT, N/C interactions 
mediated by the FQNLF sequence in the AR NTD binding to the ligand-induced AF-2 surface in 
AR LBD occurs, and the NLS is exposed, allowing for the receptor to transverse the nuclear 
membrane and enter into the nucleus of the cell. There the AR dimerizes, binds ARE’s along the 
genome, binds coactivators that recruit the general transcriptional machinery and leads to the 
transcription of AR target genes [84, 86-88]. PSA, as mentioned previously, is a serine protease 
synthesized by both benign and malignant prostate epithelial cells and used as a measure of PCa 
progression. PSA is a canonical target gene of the AR, and standard marker of AR’s transcriptional 
activity in the cell. Serum PSA levels reflect AR signaling in the PCa cell as both are seen to 
increase in more advanced forms of the disease [89]. 
1.3.2  Transactivation Surfaces of the AR 
The AR has two major transactivation surfaces that serve as binding surfaces involved in the 
interaction of co-regulatory proteins [79-82, 84, 85]. 
Activation Function 1 (AF-1) – Amino Terminal Domain  
Activation function 1 (AF-1) is the binding surface present in the N-terminal domain of the 
receptor. Although this surface is intrinsically disordered, specific regions within this range have 
been mapped according to their transactivation abilities [85]. This mapping was done by deletion 
analysis. The sub-regions within the AF-1 are termed TAU1 and TAU5. TAU1 is mapped to amino 
acid residues 101-370, and TAU5 is mapped to amino acid residues 360-485 [79, 81, 82, 85]. The 
minimum region that is necessary to produce the full AR-NTD based transcriptional activity is 
located between residues 142-485, which contains regions of TAU1, and all of TAU5, with TAU5 
characterized as being necessary for p160 coactivator recruitment [79, 81, 82]. It’s been shown 
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that the AF-1 region of the AR is ligand-independent, as the AR-NTD is able to be transcriptionally 
active even in the absence of androgen. The AR-NTD is able to activate reporter genes even when 
the ligand-binding domain is truncated and is able to achieve reporter activity to the same degree 
as the full-length receptor, and in the presence of ligand. Therefore, the AR AF-1 regions is deemed 
as the ligand-independent activation function [79-82]. 
 
Activation Function 2 (AF-2) - Carboxy-terminal Domain 
Activation function 2 (AF-2) is the binding surface present in the C-terminal domain of the 
receptor [90]. Upon DHT binding to the AR-LBD, helix 12 completes the AF-2 binding surface 
[90]. This surface allows for AR’s interaction with coactivators and corepressors that affect the 
transcriptional activity of the AR. The AR AF-2 surface can also interact intramolecularly with 
motifs such as 23FQNLF27 , and 433WHTLF437, present in the AR-NTD. The AR-NTD competes 
with coregulators with similar interacting motifs such as those with LXXLL and/or FXXLF motifs, 
in its binding to AR AF-2. This intramolecular interaction stabilizes ligand binding to AR and 
prevents the AR from nuclear export and degradation [90-93]. 
1.3.3  AR Coactivators 
Coactivator Expression in CRPC 
Elevated expression levels of several AR coactivators have been associated with CRPC 
[94], [95], [96], [97], [98]. This is because AR coactivators have the ability to activate AR’s 
transcriptional activity even under castrate conditions, or conditions of exceedingly low levels of 
androgens [98]. One family of coactivators implicated in PCa progression includes that of the ARA 
family. The ARA coactivators have been shown to regulate transcriptional activity of the AR; 
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albeit, they are not AR‐specific. ARA55 is one example of those belonging to this family of 
coactivators that contributes to tumor progression by regulation of Wnt signaling [62]. ARA55 is 
a transforming growth factor‐beta inducible coactivator, and is also crucial for facilitating stromal 
epithelial interactions in benign and malignant prostate [62]. ARA54 is also a coactivator which 
mediates growth and differentiation through interaction with the AR [63]. The beta isoform an AR 
coactivator ARA70 has been shown to be up‐regulated in PCa. ARA70 has multiple functions in 
prostate cancer; however, it is established that this coactivator also regulates activity of other 
steroid receptors [99]. 
Vav3 is another such coactivator that enhances both WT AR, and AR splice variant, AR-
V7. Vav3 is a Rho GTPase guanine nucleotide exchange factor. It’s been shown that expression 
of vav3 becomes elevated during the progression to castration therapy resistance. Furthermore, the 
overexpression of vav3 in LNCaP cells abolished requirement for androgens in cell growth [61]. 
Next, there is Tip60, which is another coregulatory that is upregulated by androgen ablation in 
PCa cell lines. It’s also involved with AR-mediated proliferation of cells in the absence of 
androgens [100]. The next group of coactivators includes the transcriptional integrators CBP/p300. 
These are coactivators who modulate a large number of transcription factors through chromatin 
remodeling. Both CBP and p300 expression is increased during androgen ablation [101]. Finally, 
FHL2, is an androgen regulated coactivator that is important in regulation of proliferation, in 
particular in castration resistant PCa [102]. FHL2 is important for activation of both AR-FL and 
AR-V7 splice variant. It’s shown that a higher nuclear expression of FHL2 predicts risk of prostate 
cancer recurrence [102].  
The p160 family of coregulators comprise another such group of coactivators that are implicated 
in CRPC and are shown to interact with AR-splice variants, such as AR-V7 [79, 80]. P160’s consist 
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of SRC1, SRC2, and SRC3, which all show sequence homology and possess histone 
acetyltransferase activity [59]. This family of proteins ultimately enhance AR-induced 
transcription by allowing for complex formation between AR and promoter regions of AR target 
genes [59]. Cumulative evidence suggests that elevated TIF2 expression might be especially 
relevant to CRPC; TIF2 stabilizes AR-ligand binding, enhances receptor stability, facilitates AR 
N/C interactions, and promotes both the recruitment of chromatin remodeling coactivators and 
assembly of the transcriptional machinery on the promoters of AR target genes [103], [104]. 
Furthermore, there is a significant correlation between tumor TIF2 expression and PCa 
aggressiveness [49], [105]. Also, in comparison to benign prostatic hyperplasia tissue or androgen-
dependent PCa, TIF2 levels are significantly elevated in relapsed PCa after ADT [96]. Finally, 
over-expression of TIF2 enhanced AR responses to androgens and non-AR ligands, whereas TIF2 
knockdown reduced AR target gene expression and inhibited the growth of androgen-dependent 
and androgen-independent PCa cells [96], [49]. Similarly, SRC1 is found to be expressed in more 
advanced forms of prostate cancer compared to levels found in localized PCa or normal prostate 
tissue, and expression of SRC1 in clinically localized samples were associated with a more 
aggressive disease [106]. It has also been shown that silencing SRC1 reduced growth in AR-
dependent cell lines, LNCaP, and C4-2, as well as decreased androgen receptor target gene 
activation [106]. SRC1 is shown to increase both ligand-dependent, and ligand-independent 
transactivation of the AR to the same degree.   
 
Coactivator Interaction with AR 
Coactivators bind to either of two activation functions in the AR, AF-2 or AF-1. 
Coactivator interaction with AF-2 binding surface 
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AF-2, located in the C-terminal domain of the receptor, binds coactivators with an LXXLL 
containing motif [90-93]. AF-2 is the more canonical binding surface that is also present in other 
steroid hormone receptors (SHR’s). For most NR’s, this is the most important binding surface for 
transcriptional activation [90-93]. 
Coactivator interaction with AF-1 binding surface 
AF-1 resides in the N-terminal domain of the receptor, and tends to bind coactivators with non-
canonical motifs. Since the AF-2 region has been truncated in AR splice variants like AR-V7, 
coactivators must bind to the AF-1 region. It has been shown that for the AR, the AF-1 
transactivation domain located in the AR-NTD, is also an important coactivator binding surface, 
leading to transcriptional activation [79-82].  Some coactivators that have been shown to interact 
with the AR-NTD at the AF-1 surface are p160’s SRC1, and TIF2. The AR AF-1 domain contains 
Tau-1 and Tau-5 regions. Tau-1 and Tau-5 regions are both required for AR transcriptional activity 
[79-82]. Tau-5 is characterized by a WHTLF motif, which represents a binding motif for p160 
coactivators [67, 79, 80]. 
1.3.4  AR Target Gene Activation 
AR-FL is most commonly involved in activating a set of genes responsible for prostate cell 
proliferation, communication, biosynthesis and differentiation. As well as steroid synthesis, and 
ultimately cancer progression. There are different transcriptional profiles associated with androgen 
dependent (AD) and androgen independent (AI) PCa. Some of the most common genes targeted 
in AD PCa include PSA/KLK3 and KLK2, serine proteases, NKX3.1, an androgen-regulated gene, 
and prostatic tumor suppressor gene [26], TMPRSS2, a gene that is seen to fuse with ETS genes 
which acts as a driver of PCa [27], FKBP5, involved in protein folding and transport and 
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trafficking, and TMEPA1 [107], [108]. Those transcriptional profiles associated with AI PCa, or 
CRPC include E2F, STAT, and MYC. In CRPC tissue, it’s been shown that there is a higher AR 
binding enrichment at the promoters of target genes compared to binding sites in untreated PCa 
tissue. These genes are involved in cell proliferation, and regulation of progression through cell 
cycle  [109]. 
1.4 Objectives and Hypothesis 
             Existing FDA approved PCa drugs target the AR-LBD, either in a direct or indirect 
manner. Currently, there are no compounds that block or disrupt the AF-2 or AF-1 regions of the 
receptor. The AF-2 region of AR is important because it engages in coactivator interactions and 
leads to androgen dependent transcriptional activity. The AF-1 region is important because it’s the 
region of the AR involved in androgen independent transcription. Furthermore, the AF-1 domain 
is the only transactivation region present in LBD lacking AR splice variants whose emergence 
coincides with the development of CRPC after ADT therapy. Therefore, a compound able to target 
either or both transactivation regions would represent an untapped therapeutic strategy that might 
avoid the development of resistance observed with current ADT’s. 
Our lab has developed an AR-TIF2 biosensor HCS assay that can identify compounds that 
can prevent or disrupt interactions between the DHT-induced AF-2 region of AR and its 
coactivator, TIF2. We then developed a panel of AR AF-2 based assays to further determine the 
mechanism of action of these compounds identified in an HCS campaign of 143,000 compounds 
screened in the AR-TIF2 biosensor assay. The AF-2 assays include an AR-LBD H3-DHT 
Radioligand Binding assay, AR-LBD::TIF2-LXXLL peptide binding assay, a PSA6.1 luciferase 
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reporter assay, and TIF2 and SRC1 Mammalian 2-hybrid assays.  In addition, we conducted PCa 
growth inhibition assays in AR positive and AR null cell lines. 
We also wanted to address the emergence of AR splice variants, since they represent a 
mechanism of disease progression, resistance and persistent AR activity in CRPC cells after ADT 
treatment.  To do this we developed a series of assays to identify compounds that inhibit or disrupt 
the AF-1 surface of the androgen receptor. These assays include a pGal4-AR-NTD transactivation 
assay, and two reporter assays driven by AR-V7, the PSA6.1-Luc and UBE2C-Luc reporter assays. 
The AF-1 assays can be used to determine if the hits identified in the primary HCS are also capable 
of modulating AR-NTD transactivation. 
A compound that could target both the AF-2 and AF-1 transactivation regions to prevent 
the transcription of both AR-FL and AR-V7 would be the ideal type of drug candidate, providing 
a dual approach to the treatment of PCa and the emergence of CRPC.  
Hypothesis We believe that small molecule inhibitors with the ability to block or disrupt androgen 
receptor interactions with the TIF2 p160 coactivator will provide effective therapies against more 
advanced forms of PCa by decreasing AR transcriptional activity. Compounds that inhibit or 
disrupt both the AF-2 and AF-1 transactivation domains of AR would have therapeutic potential 
for both the androgen dependent and independent forms of PCa.  
Objectives 
- (Chapter 3) Develop a suite of AF-2 directed assays to help characterize small molecule 
inhibitors/disruptors of AR-TIF2 PPIs identified in the primary AR-TIF2 biosensor HCS 
campaign  
1) AR-LBD H3-DHT RadioligandBinding Assay 
2) AR AF-2:: TIF2-LXXLL peptide binding ALPHAScreen Assay  
3) Mammalian 2-Hybrid Assay developed with both TIF2 and SRC1  
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4) PSA6.1-Luc Reporter-Based Assay in PC3-GFP-AR-FL cells  
5) Growth Inhibition assays developed in 5 different cell lines 
- Test compounds that are known AR-modulators through the suite of AF-2 
characterization assays 
 
- (Chapter 4) Develop a suite of AF-1 directed assays to determine whether AR-TIF2 PPI 
prioritized hits can also block or disrupt AR-NTD’s transcriptional activity in cells  
1) pGal4-AR-NTD Transactivation Assay  
2) PSA6.1-Luc Reporter Assay in PC3-GFP-AR-V7 cells 
3) UBE2C-Luc Reporter Assay in PC3-GFP-AR-V7 cells 
- Test compounds that are known AR-modulators through the suite of AF-1 
characterization assays 
 
- (Chapter 5) Characterize Selected Hits Identified in 143,000 compound Primary AR-
TIF2 PPIB HCS campaign in the suite of AF-2 and AF-1 profiling assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Androgen receptor signal transduction pathway 
DHT binding to the AR induces dissociation from HSPs and receptor phosphorylation. Next, the AR 
dimerizes and can bind to androgen-response elements in the promoter regions of target genes.. Coactivator 
recruitment by the AR complex allows for its interaction with the general transcriptional apparatus (GTA). 
Subsequent activation of target genes leads to biological responses including growth, survival and the 
production of PSA, a biomarker of disease progression.  
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 Identification of Hit Compounds Targeting the AR AF-2 Interaction Surface 
2.1 Introduction 
Prostate cancer’s progression into CRPC is due to  continued androgen receptor (AR) 
transcriptional activity in cells [110]. The primary therapy for PCa is androgen deprivation therapy 
(ADT) which targets AR functions by blocking the production of androgen ligands or by 
antagonizing AR binding. Although ADT drugs are effective initially, ultimately patient’s progress 
to a castrate resistant state [48, 111]. This progression is due to continued AR signaling after ADT, 
due to AR amplification, intra-tumoral androgen synthesis, AR mutations that lead to receptor 
promiscuity, the emergence of AR splice variants, and androgen-independent AR activation [48, 
66, 111]. Furthermore, most cases of CRPC are accompanied by overexpression of AR 
coactivators, which lead to poor patient outcomes by increasing AR-transcriptional activity [103, 
112] of target genes associated with cellular biosynthesis, survival, and proliferation, leading to 
disease progression [113]. Therefore, therapeutics that block AR-transcriptional activity represent 
an alternate strategy for slowing the progression of CRPC [46, 114]. One way to inhibit AR’s 
transcriptional activity would be to block the recruitment of the transcriptional machinery to target 
gene AREs by preventing or disrupting the interactions between AR and its co-activators [56, 94-
97, 115]. Elevated expression levels have been observed in relapsed PCa for several AR 
coregulators, including TIF2, SRC1, RAC3, p300, CBP, Tip60, MAGE-11, and ARA 70 [49, 56, 
94-98]. AR-transcriptional intermediary factor 2 (TIF2/SRC-2/NCoA-2/GRIP1) protein-protein 
interactions (PPIs) are promising targets for CRPC because TIF2 overexpression occurs in more 
advanced stages of PCa compared to benign prostate tissue, and increased TIF2 levels correlate 
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with biochemical recurrence, and a rise in prostate specific antigen (PSA) levels in PCa patients. 
Similarly, knockdown of TIF2 by siRNA reduced AR target gene expression and slowed the 
proliferation of androgen-dependent and androgen independent PCa cells [96]. The AR interacts 
with TIF2 through the hydrophobic activation function 2 (AF2) region formed by helix 12 of the 
androgen receptor ligand binding domain (AR-LBD) when dihydrotestosterone (DHT) is bound 
[79, 116].  TIF2 modulates AR-transcriptional activity and its overexpression has been shown to 
result in cellular resistance to AR antagonists such as bicalutamide [117]. Therefore, our lab has 
developed a high-content screening (HCS) assay to identify small molecules that inhibit the 
formation of agonist-induced AR-TIF2 PPIs or disrupt preexisting AR-TIF2 complexes [118, 
119]. A detailed description of the development, optimization, and validation of the AR-TIF2 PPIB 
HCS assay together with suitable counter screens has been described in our previous publications 
[119-126]. 
 In this chapter I will describe how we identified the hit compounds that were to be run in 
the characterization assays that I developed (discussed in chapters 3 and 4).  I will briefly describe 
the implementation of the AR-TIF2 PPIB assay to screen the Library of Pharmacologically Active 
Compounds (LOPAC) and to screen three larger compound libraries totaling 143,000 compounds. 
I will also provide descriptions of the counter screens that were used to triage the actives from the 
primary HCS to generate a hit list, made up of concentration dependent compounds that were 
active in the primary screen and inactive in the counter screens. The confirmed hit compounds 
along with commercially available structurally related analogs progressed into the characterization 
assays that were developed to target either the AF-2 or AF-1 transactivation domains of AR 
(described in detail in chapters 3 and 4).  
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2.2 AR-TIF2 Biosensor High Content Screen 
2.2.1  Description of the AR-TIF2 Biosensor 
The AR-TIF2 PPIB HCS assay utilizes two adenovirus constructs to express AR-LBD residues 
662–919 in one biosensor component, and TIF2 residues 725–840 in the other biosensor 
component. AR-LBD was cloned into an adenovirus expression biosensor construct which drives 
its expression as a chimeric fusion protein with red fluorescent protein (RFP) that contains both a 
nuclear localization sequence (NLS) and a nuclear export sequence (NES), which are part of the 
chimera and not specific to AR (Figure 2, on pg. 48). In cells infected with the AR-RFP biosensor 
alone, AR-RFP expression is localized predominantly to the cytoplasm. However, after exposure 
to AR agonists such as DHT, the subcellular localization of the AR-RFP shifts to a predominantly 
nuclear distribution (Figure 2). The TIF2 insert contains the receptor interacting domain box III 
LXXLL motif that mediates binding to ligand-bound AR-LBD. The TIF2 residues are expressed 
as a chimeric fusion protein with green fluorescent protein (GFP) and high-affinity nuclear 
localization (NLS) and nucleolar localization (NoLS) sequences derived from HIV Rev, which 
tethers the TIF2-GFP biosensor in the nucleolus of the cell (Figure 3, on pg. 49) [127]. In cells 
infected with the TIF2-GFP biosensor alone, TIF2-GFP expression is restricted to the nucleolus 
within the nucleus. The nucleolar localization of the TIF2-GFP biosensor remains constant and 
does not change when exposed to AR agonists, antagonists or test compounds (Figure 3). In cells 
that are co-infected with both AR-RFP and TIF2 biosensors, TIF2-GFP expression is localized 
only in the nucleoli and AR-RFP expression is predominantly cytoplasmic – as is shown by images 
of the cells, red present in the cytoplasm, and blue Hoechst-stained nuclei containing bright green 
TIF2-GFP puncta (Figures 4 & 5, on pgs. 50 & 51). After exposure of cells co-infected with both 
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biosensors to DHT, the AR-RFP biosensor traffics from the cytoplasm into the nucleus where the 
PPI’s between the AR and TIF2 components of the fusion proteins causes them to co-localize 
within the nucleoli, as indicated in the images by the bright yellow AR-TIF2 puncta present in the 
nucleoli (Figures 4 & 5) [127].  
To quantify AR-TIF2 PPIs, digital images of the cells were acquired on an IXM imager, and 
then analyzed with a translocation enhanced TE image analysis module as described in previous 
publications [118, 119, 121-123]. The TIF2-GFP biosensor component acquired in the FITC 
channel was used to create a translocation mask of the nucleoli within Hoechst-stained nuclei. The 
TIF2-GFP remains localized to bright fluorescent puncta anchored within the nucleolus, and 
objects in Ch2 that had TIF2-GFP fluorescent intensities above background with appropriate 
morphologic characteristics (width, length, and area) were classified by the image segmentation 
as nucleoli and used to create a TIF2 mask and count the number of TIF2-GFP-positive nucleoli 
(Figure 6, on pg. 52). Objects that met these criteria were used to create masks of the nucleoli 
within the Hoechst-stained nuclei of each cell. AR-RFP images from the Texas Red channel were 
segmented into an ‘‘Inner’’ nucleolus region with a mask set using the edge of the detected TIF2-
GFP-positive nucleoli in the FITC channel (Figure 6). The TE image analysis module outputs 
quantitative data such as the average fluorescence intensities of the TIF2-GFP-stained objects in 
the FITC channel; the selected object or nucleoli count in the FITC channel; and the integrated 
and average fluorescent intensities of the AR-RFP signal in the TIF2-positive nucleolus (inner) 
region. The mean average inner fluorescent intensity (MAIFI) of AR-RFP within the TIF2-GFP-
positive nucleolus output of the TE image analysis module was used to quantify AR-TIF2 PPIs. 
The sub-cellular distribution phenotype of the AR-RFP “prey” biosensor is influenced by two 
major factors, whether the cells have been exposed to AR agonists, demonstrated by the nuclear 
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translocation of AR-RFP in the presence of increasing concentrations of DHT (Figure 7, on pg. 
53), and the presence of the TIF2-GFP “bait” protein in the nucleolus.  In the AR-TIF2 PPIB 
LOPAC pilot screen and the 143K HCS campaign the assay was conducted in two formats (Figure 
4). In the first format U-2 OS cells co-infected with the AR-TIF2 biosensors were exposed to 
compound 3h before treatment with 25 nM DHT for 90 min. This allowed us to determine if 
compounds inhibited DHT-induced AR-TIF2 PPI formation. In the second format U-2 OS cells 
co-infected with the AR-TIF2 biosensors were exposed to 25 nM of DHT for 90 min before 
treatment with compounds for 3h. This allowed us to determine if compounds disrupted preexisting 
AR-TIF2 PPI complexes (Figures 4 & 5).  
We also developed the AR-TIF2 biosensor assay in PC3’s, a PCa cell background that could 
capture disease relevant expression levels of AR coactivators and corepressors. It’s been shown 
that small molecules can elicit tissue selective effects, because the cells of distinct tissues express 
different levels and cohorts of coregulatory proteins [115, 128-130].  Reconfiguring the AR-TIF2 
PPI biosensor (PPIB) assay in the PC3 PCa cell line therefore allowed us to determine whether 
AR modulators and hits from an AR-TIF2 PPIB screen conducted in U-2 OS cells would behave 
differently in the PCa cell background. We did not observe any significant differences in the 
compound responses between the assays performed in osteosarcoma and PCa cells. However, 
compared with the AR-TIF2 PPIB assay performed in U-2 OS cells [131] , PC3 cells required 10-
fold more rAV for infection, the maximum co-infection rate achieved was only ~50%, and we 
needed to seed 2.4-fold more PC3 cells per well in the 384-well assay plates. From a purely 
logistical standpoint therefore, the AR-TIF2 PPIB assay performed in U-2 OS cells would be more 
amenable to screening, because both the virus and cell culture demands are lower [118]. 
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After determining whether compounds run in the AR-TIF2 biosensor were active or 
inactive, we needed a way to remove outliers that included compounds that were cytotoxic or 
fluorescent, or those that acted in the AR-TIF2 biosensor in a non-specific, or non-selective 
manner. To flag and eliminate such compounds, the following methods and counter screens were 
applied. 
2.2.2  Identifying cytotoxic compounds and auto-fluorescent outliers 
In order to identify cytotoxic and auto-fluorescent outlier compounds, a z-score plate-based 
statistical scoring method was applied to flag compounds that behaved as outliers, compared to 
the other substances tested on the plate. These outlier analyses were performed on an n = 320 
compounds, as no controls were used in these analyses. These analyses were run based on certain 
HCS multiparameter measurements by the image analysis module, Z – score = (Xi - X )/σ, where 
Xi is the raw measurement on the ith compound, and X  and σ are the mean, and standard deviation 
of all the sample measurements on a plate. The number of compartments that represents the number 
of TIF2-GFP-positive nucleoli identified in the FITC channel was used to flag compounds that 
were cytotoxic. Compounds with z-scores <-3 were flagged as cytotoxic. We also calculated z-
scores for the average and integrated fluorescence intensity parameters from the DAPI, FITC, and 
Texas Red channels, and compounds with z-scores >3 in one or more of the intensity parameters 
in any channel were flagged as fluorescent outliers. 
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2.3 Description of Counter Screening Assays to Run hits from the AR-TIF2 Biosensor 
2.3.1  P53-hDM2 PPIB Counter Screening Assay 
The p53-hDM2 PPIB HCS assay was used as a counter screen to determine if compounds 
identified in the AR-TIF2 PPIB interfered with the assay format or were non-specific PPI 
disruptors. The p53-hDM2 PPIB counter screen uses the same adenovirus chimeric biosensor co-
infection assay format and PPI detection strategy in U-2 OS cells as the AR-TIF2 assay, except 
that the protein-interacting partner components of the chimeric GFP and RFP fusion protein 
biosensors contain the interacting domains from p53 and hDM2, respectively [121-123]. The p53-
hDM2 PPIB assay therefore serves as both an assay format interference and PPI selectivity counter 
screen [118].   
2.3.2  AR Nuclear Localization Counter Screen 
The AR-GFP nuclear localization assay was used as a counter screen to identify compounds that 
reduced expression levels of AR, and/or shifted the predominant nuclear localization of AR into 
the cytoplasm [124]. If compounds were reducing nuclear expression levels of AR, or shifting 
localization of AR to the cytoplasm in the AR-GFP nuclear localization counter screen, they could 
also be reducing AR-RFP biosensor expression levels, or promoting AR-RFP nuclear exit, and 
therefore inhibiting the AR-TIF2 PPI’s in the AR-TIF2 HCS assay in an indirect manner. 
Therefore, any compounds identified in this assay would be deprioritized. 
 36 
2.3.3  Dex-Induced GR Translocation Counter Screen 
The dexamethasone induced GR-GFP nuclear translocation assay was used as a counter screen to 
identify compounds that potentially inhibited shared elements of nuclear receptor trafficking to the 
nucleus [125]. This assay was also used to determine if compounds were able to target other 
nuclear receptors and were therefore non-selective for the androgen receptor. Confirmed actives 
in the AR-TIF2 PPIB assay that also inhibit GR nuclear translocation either lack AR specificity or 
selectivity, or they may inhibit a shared trafficking component of the AR and GR signaling 
pathways. 
2.4 AR-TIF2 PPIB Assay Protocol 
In the AR-TIF2 PPIB HCS assay protocol, rAV expression constructs bearing the 
individual TIF2-GFP (TagGFP; Evrogen, Inc., Moscow, Russia) and AR-RFP (Tag RFP; Evrogen, 
Inc.) PPI partners were utilized to infect U-2 OS cells according to the manufacturer’s (Cyprotech 
US, Watertown, MA) instructions. Typically, 1 x 106 U-2 OS cells were co-infected with the TIF2-
GFP and AR-RFP adenovirus expression constructs by incubating cells with the manufacturer’s 
recommended volume of virus (usually 5 uL/106 U-2 OS cells) in 1.0 mL of culture medium for 1 
h at 37C, 5% CO2, and 95% humidity with periodic shaking (every 10 min) to maintain cells in 
suspension. Co-infected cells were then diluted to 6.25 x 104 cells/mL in culture media, and 40 uL 
(2,500 cells) was seeded in each well of a 384-well collagen-coated barcoded microplate 
(#781956; Greiner Bio-One) using a Matrix pipettor (ThermoFisher), and plates were incubated 
overnight at 37C, 5% CO2, and 95% humidity. Pre-diluted compounds or DMSO (5 uL) were 
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added to appropriate wells using the Janus MDT automated liquid handling platform (Perkin 
Elmer), for a final screening concentration of 50 μM and 0.2% DMSO. Compound-treated assay 
plates were incubated at 37C, 5% CO2, and 95% humidity for 3h min, pre- or post- 90 min 
treatment with DHT. DHT (5 uL) was added to maximum plate control wells and compound-
treated wells, and 5 uL of media was added to minimum plate control wells using a Matrix pipettor 
(ThermoFisher), for a final DHT concentration of 25 nM. After treatment with compound and 
DHT, assay plates were fixed by the addition of 50 μL of pre-warmed (37°C) 7.4% formaldehyde 
and 2 mg/mL Hoechst 33342 in PBS using a Matrix pipettor (ThermoFisher) and incubated at 
room temperature for 30 min. Liquid was then aspirated and plates were then washed twice with 
85 uL PBS using a Matrix pipettor (ThermoFisher) and sealed with adhesive aluminum plate seals, 
with the last 85 uL wash of PBS in place. Fluorescent images were then acquired on an IXU 
automated HCS platform (Molecular Devices LLC), and images were analyzed with the TE image 
analysis module of the MetaXpress software (Molecular Devices LLC) as described in our 
previous publications [118, 127, 131]. 
2.5 Compound Libraries Screened in Primary and Counter Screens 
Four compound libraries were screened in the AR-TIF2 PPIB HCS including: A Library of 
Pharmaceutically Active Compounds (LOPAC) set  (Sigma Aldrich) [118, 131], a 10K non-
peptide peptido-mimetic library (ChemDiv),  a 50K diversity library (ChemBridge),  and a 83K 
library selected for cancer drug screening (NCI) [127]. 
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The LOPAC set is comprised of 1,280 pharmaceutically active compounds that show 
biological activity towards some of the most common targets in drug discovery. The LOPAC set 
is frequently used to validate new drug discovery assays such as the AR-TIF2 PPIB HCS assay.  
The 10K non-peptide peptido-mimetic library (ChemDiv) was specifically designed with 
PPI targets in mind. This is a diversity subset of the ChemDiv 142K PPI library that includes 
mimetics of α-helices and β- and γ- turns based on many combinatorial templates modified with 
both flexible and rigid substituents. The geometry of the designed fragments was compared 
computationally with the dihedral angles reported for ‘natural’ β- and γ- turn motifs to select for 
the best match.  
The 50K diversity library (ChemBridge) was selected from the ChemBridge 410K core 
library. It was designed to provide the widest coverage of pharmacophore space within 50K 
compounds while still maintaining structural diversity. Compounds were filtered for enhanced 
physiochemical properties while allowing exploration of available chemical space, and the rule of 
five was applied to each of the compounds.  
The 83K library selected for cancer drug screening (NCI) was specifically assembled for 
anti-cancer drug screening and contains a 12K legacy set selected from the NIH MLSMR 
collection and two diversity subsets that contain 15 privileged scaffolds. 
Compounds from each of these libraries were run in the AR-TIF2 biosensor at one 
concentration in singlicate to determine activity. If they were able to produce inhibition of ≥45% 
for the 10K library or ≥40% for the other two libraries, and were not cytotoxic or fluorescent, they 
were cherry picked, and confirmed in the AR-TIF2 PPIB at one concentration in triplicate and run 
in three developed counter screening assays. Confirmed actives that passed this testing paradigm 
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were progressed into concentration response assays to determine their relative potencies and 
efficacies at inhibiting/disrupting AR-TIF2 PPIs.  
2.6 Results 
2.6.1  LOPAC Set Performance in the AR-TIF2 HCS and Counter Screen Assays 
To confirm that the optimized AR-TIF2 PPIB assay would perform well in the presence of 
compounds, we screened the 1,280-member LOPAC at 20 μM to identify compounds that could 
either inhibit the DHT-induced formation of AR-TIF2 PPIs or disrupt preexisting AR-TIF2 
complexes.  Although the majority of compounds exhibited AR-TIF2 PPI responses that coincided 
with those of the Max controls, indicating that they were inactive, 24 compounds achieved ≥50% 
inhibition of DHT-induced AR-TIF2 PPI formation (g, on pg. 54) compared with only three 
compounds that disrupted preexisting AR-TIF2 complexes by ≥50%. An additional 13 compounds 
disrupted preformed AR-TIF2 complexes by ≥30% (Table 1). To qualify compounds flagged as 
actives in either format, we used parameters output by the image analysis algorithm to identify and 
eliminate compounds that were acutely cytotoxic (z-score cell counts <−4) or that were average of 
integrated fluorescent intensity outliers (z-scores <−4 or >4) in the Hoechst (Ch1), GFP (Ch2), and 
RFP (Ch3) channels. Any active compounds that were not eliminated were cherry picked the 
compounds flagged as inhibitors of AR-TIF2 formation (>50%) or disruptors of preexisting AR-
TIF2 complexes (>30%) into a 384-well hit confirmation daughter plate and rescreened them at 
20 μM in triplicate wells in both assay formats. A total of 17 compounds were confirmed to 
reproducibly inhibit the DHT-induced formation of AR-TIF2 PPIs by ≥50% at 20 μM. Eleven of 
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the inhibitors are known modulators of steroid family nuclear hormone receptors (NRs): 
nilutamide and cyproterone acetate are antiandrogens; mifepristone, 17alpha-hydroxy-4-pregnene-
3,20-dione, and allopregnan-3-alpha-ol-20-one are progesterone receptor (PR) modulators; 
spironolactone and cortexolone are mineralocorticoid receptor (MR) modulators; 2-
hydroxyestradiol 2-methyl ether and estrone are estrogen receptor (ER) modulators; guggulsterone 
is a farnesoid X receptor (FXR) antagonist; and budesonide is a glucocorticoid receptor (GR) 
modulator (Figure 9, on pg. 56). The remaining six inhibitors are not NR ligands (Figure 8, on pg. 
55): 1-chloro-3-tosylamido-4-phenyl-2-butanone (TPCK), Bay 11-7085, N-Carbobenzyloxy-L-
phenylalanyl chloromethyl ketone (ZPCK), parthenolide, 4-phenyl-3-fluroxane carbo-nitrile, and 
(±) Bay K 8644. Although none of the qualified actives achieved ≥50% disruption of preexisting 
AR-TIF2 complexes, nine compounds were confirmed to reproducibly disrupt preformed AR-
TIF2 PPIs by between 32% and 42% at 20 μM. Five compounds inhibited DHT-induced formation 
of AR-TIF2 PPIs by ≥50% and also disrupted preformed AR-TIF2 PPIs by ≥34% at 20 μM. 
 
To determine the potencies of actives confirmed in triplicate, in the two AR-TIF2 PPIB 
assay formats, we purchased dry powder samples for 15 compounds and conducted three 
independent 10-point concentration–response experiments starting at a maximum of 50 μM 
(Figure 8, on pg. 55).  Exposure of U-2 OS cells to the indicated concentrations of the 15 
compounds for 3 h before treatment with 20 nM DHT inhibited AR-RFP translocation into TIF2-
GFP-positive nucleoli in a concentration-dependent manner with IC50s ranging from 12 nM to 
3 μM. The five non-NR ligand AR-TIF2 PPI inhibitors exhibited high-quality curve fits with IC50s 
in the 0.5–1.0 μM range. Five of the NR ligand AR-TIF2 PPI inhibitors also produced high-quality 
curve fits with IC50s in the 0.7–3.0 μM range: 17alpha-hydroxy-4-pregnene-3,20-dione, 
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nilutamide, cortexolone, 2-hydroxyestradiol 2-methyl ether, and estrone (Figures 8 & 10 on pg. 
57). However, the activity of the other five NR ligand AR-TIF2 PPI inhibitors was not ≤50 μM in 
the concentration range tested, and their corresponding IC50s were extrapolated from incomplete 
curve fits: mifepristone, guggulsterone, spironolactone, budesonide, and cyproterone. The 
corresponding AR-RFP distribution phenotypes for some of these NR ligand AR-TIF2 PPI 
inhibitors were also less definitive. Guggulsterone displayed a predominant cytoplasm AR-RFP 
distribution phenotype, whereas both spironolactone and budesonide produced a diffuse AR-RFP 
nuclear distribution phenotype. However, the other NR ligand AR-TIF2 PPI inhibitors exhibited a 
mixed and diffuse AR-RFP distribution phenotype in both the cytoplasm and nuclear 
compartments. Exposure of U-2 OS cells to the indicated concentrations of compounds for 3 h 
after a 30 min pretreatment with 20 nM DHT disrupted the preexisting AR-TIF2 complexes in a 
concentration-dependent manner. Although none of the compounds achieved >90% disruption of 
the preformed AR-TIF2 complexes and their corresponding IC50s were typically ≥10-fold less 
potent than for the inhibition of DHT-induced AR-TIF2 PPIs, these data indicate that the AR-TIF2 
biosensor is reversible. All 10 disruptors of preexisting AR-TIF2 complexes produced a mixed 
and diffuse AR-RFP distribution phenotype in both the cytoplasm and nuclear compartments.  
When we ran the compounds in the developed counter screens none of the 15 AR-TIF2 
PPI LOPAC hits were active in the p53-hDM2 PPIB assay, indicating that they are unlikely to 
interfere with either the biosensor assay format or to be non-selective PPI inhibitors. To evaluate 
the NR selectivity of the AR-TIF2 PPI LOPAC hits, we tested their activity in a dexamethasone 
(Dex)-induced glucocorticoid receptor (GR) nuclear translocation assay [132, 133]. Since none of 
the 10 steroid NR ligands inhibited Dex-induced GR nuclear translocation [132, 133] these AR-
TIF2 PPI hits appear to be selective for AR over GR. In contrast, the five non-steroid hits all 
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inhibited the agonist-induced trafficking of GR to the nucleus. Finally, when run in the AR nuclear 
localization counter screen, the AR-TIF2 PPIB hits from the LOPAC set either enhanced AR-GFP 
nuclear localization or were inactive, suggesting that some hits were partial AR agonists and 
therefore would not be expected to inhibit or disrupt AR-TIF2 PPIs [118]. 
We were able to use the LOPAC set as a pilot screen to confirm that the AR-TIF2 PPIB performed 
well in HTS and to prove that our testing paradigm would effectively identify and eliminate false 
positives or interference compounds.  
Therefore, we then screened 143,000 compounds, from three larger compound libraries 
previously described in the AR-TIF2 PPI biosensor [127]. These compound libraries were 
specifically chosen to increase the structural diversity of compounds run in the AR-TIF2 PPI HCS 
to increase the probability of success. Compound performance in the AR-TIF2 PPIB assay, and 
hit confirmation is described below.  
2.6.2  143,000 Compound Performance in the AR-TIF2 PPIB and Counter Screen Assays 
2.6.2.1 HTS performance and QC statistics of AR-TIF2 PPIB 
We successfully implemented the AR-TIF2 PPIB assay in an HCS campaign of 143,000 
compounds from three distinct compound libraries. The AR-TIF2 PPIB assay performed robustly 
and reproducibly throughout the primary HCS campaign which enabled us to identify compounds 
that inhibited DHT-induced AR-TIF2 PPI formation and disrupted preexisting AR-TIF2 PPIs. Our 
assay QC statistics were based on the maximum plate control wells (n=32), and minimum plate 
control wells (n=32), on each assay plate. Maximum plate control wells were in columns 1 and 2 
and were exposed to 25 nM DHT and 0.25% DMSO, and minimum plate control wells (n=32) 
were in columns 23 and 24, and were treated with 0.25% DMSO. In the format to find inhibitors 
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of AR-TIF2 PPI formation, the mean Z’-factor coefficient was 0.71 ± 0.08 (n = 451) and the mean 
S:B ratio was 7.8 ± 1.1 (n = 451). Similarly, in the format to find disruptors of preexisting AR-
TIF2 PPI complexes, the mean Z’-factor coefficient was 0.78 ± 0.07 (n = 451) and the mean S:B 
ratio was 19.5 ± 3.3 (n = 451). None of the assay plates in either assay format met our failed plate 
criteria of having both a Z’-factor coefficient ≤ 0.25 and an S:B ratio ≤ 3.  
2.6.2.2 AR-TIF2 PPIB Primary HCS and Active Confirmation 
Compounds were screened at concentrations of 10 µg/mL, 25 µM, and 20 µM for the 10K 
ChemDiv PPI, 50K ChemBridge diversity, and 83K NCI CBC libraries, respectively. The % 
inhibition threshold for active compounds was set at ≥ 45% for the 10K ChemDiv library, and ≥ 
40% for the other two libraries. In the primary HCS to find inhibitors of DHT-induced AR-TIF2 
PPI formation, the median % inhibition was 11.5%, and 97.5%, or 139969 compounds were below 
our active thresholds and were considered inactive (Table 1). In the primary screen to identify 
disruptors of preexisting AR-TIF2 PPI complexes, the median % inhibition was 7.6%, and 99.3%, 
or 142560 of all compounds were below our active thresholds and were considered  inactive (Table 
1).  
Actives were triaged to identify and eliminate for cytotoxic and fluorescent outliers and 
then cherry picked and confirmed in the testing paradigm described above.  
 
2.6.2.3 Testing Paradigm to identify and eliminate compound artifacts 
 
Cytotoxic and auto-fluorescent outlier compounds  
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After applying the cytotoxic and fluorescent compound outlier analysis to the AR-TIF2 
multiparameter HCS data, we flagged 1224, and 454 compounds for elimination from the AR-
TIF2 inhibitor and disruptor screens, respectively (Table 1). All three of the compound libraries 
exhibited similar cytotoxic and fluorescent outlier rates, and essentially similar qualified active 
rates in the AR-TIF2 disruptor screen. In the AR-TIF2 inhibitor format, however, the qualified 
active rate for the three libraries was higher than in the disruptor format and differed among the 
libraries. A total of 1,930 qualified active compounds were cherry picked and confirmed in 
triplicate wells at the original screening concentrations in both assay formats. Confirmed actives 
were then run in a series of counter screens.  
 
p53-hDM2 PPIB Counter Screening Assay 
None of the confirmed AR-TIF2 PPI inhibitors or disruptors from the current HCS campaign was 
active in a p53-hDM2 PPIB counter screen that utilizes the same PPI assay format and biosensor 
design but different interacting partners. Since these compounds were not able to alter the hDM2- 
RFP subcellular distribution phenotype in this assay, this indicates that they are unlikely to be 
either nonselective PPI inhibitors or to interfere with the biosensor assay format.  
 
 
 
AR Nuclear Localization Counter Screen 
Compounds that could reduce AR-RFP biosensor expression levels or restrict its localization to 
the cytoplasm would be expected to inhibit the AR-TIF2 PPIB assay. Similarly, compounds that 
inhibit AR-RFP trafficking and nuclear entry, or that promote its nuclear export, might also be 
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expected to inhibit the AR-TIF2 PPIB assay. Previously, it has been shown that known AR 
antagonists such as flutamide and bicalutamide, and the HSP 90 inhibitor 17-AAG, inhibit the AR-
TIF2 PPIB assay and produce a predominantly cytoplasmic AR-RFP distribution phenotype [118, 
119, 131]. AR antagonists block DHT binding to the AR-RFP biosensor, and HSP 90 inhibitors 
prevent the molecular chaperone-mediated maturation of the AR-RFP biosensor into a 
conformational state capable of high-affinity ligand binding. AR antagonists and HSP 90 inhibitors 
block DHT-induced translocation of the AR-RFP biosensor into the nucleus, thereby preventing 
the PPIs with the TIF2-GFP biosensor anchored in the nucleolus that results in the accumulation 
and colocalization of AR-RFP in TIF2-GFP positive nucleoli [118, 119, 131]. Any compounds 
with a similar mechanism of action of those previously described could be acting in an indirect 
manner in the AR-TIF2 biosensor. Twenty-nine of the confirmed AR-TIF2 PPI 
inhibitors/disruptors also reduced AR-GFP nuclear localization by >50%, suggesting that they 
might be indirectly inhibiting the AR-TIF2 PPIB assay rather than directly blocking/disrupting 
PPIs.  
 
Dex-Induced GR Translocation Counter Screen 
Next, compounds were run in the Dex-induced GR translocation counter screen. Both AR and GR 
are members of the steroid receptor subfamily of [120, 125] Like AR, the folding of de novo 
synthesized GR and its maturation to a conformational state capable of high-affinity hormone 
binding occurs in the cytoplasm and involves contributions from molecular chaperones and 
cochaperones [120, 125]. Ligand binding induces GR trafficking from the cytoplasm to the 
nucleus, entry through the nuclear pore complex, binding to specific glucocorticoid response 
element DNA sequences in the promoter/enhancer regions of target genes, and modulation of gene 
transcription levels [120, 125]. The Dex-induced GR-GFP nuclear translocation assay provides a 
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steroid NR selectivity counter screen that also shares components of the AR signaling pathway. 
Components shared by the AR and GR signaling pathways include the HSP 90 and HSP 70 
chaperones that maintain both NRs in high-affinity structural conformations for ligand binding, 
ligand-bound AR and GR that are both cargos of dynein-mediated retrograde trafficking along 
microtubules to the nucleus, and the importin-α/β adaptor system that mediates entry through the 
nuclear pore complex for both NRs [120, 125, 134-136]. Eight confirmed AR-TIF2 PPIB actives 
that also inhibited GR-GFP nuclear translocation by >50% were deprioritized.  
 
2.6.2.4 IC50 Determinations – Potency & Efficacy 
 
After cytotoxic and fluorescent outliers, and non-specific/non-selective compounds were removed, 
confirmed active compounds were selected for testing in 10-point, two-fold serial dilution AR-
TIF2 PPI inhibitor and disruptor IC50 determinations starting at a maximum concentration of 40 
µM. A total of 178 of the qualified confirmed actives inhibited DHT-induced AR-TIF2 PPI 
formation in a concentration dependent manner with IC50s < 40 µM, and 170 also disrupted 
preexisting AR-TIF2 PPI complexes in a concentration dependent manner (Table 1). The IC50s are 
in the range that one would reasonably anticipate for PPI inhibitors and disruptors from a high-
throughput screen. In the disruption of preexisting AR-TIF2 PPI format, the IC50 data typically 
exhibited response curves with maximal inhibition levels around 80%, and r2 values in the 0.7 to 
0.9 range.  
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2.7 Conclusion 
The overall hit rate for the 143,000- compound AR-TIF2 PPIB HCS campaign was 0.12% in both 
assay formats. Compounds active in the primary AR-TIF2 HCS were eliminated if they were 
cytotoxic or fluorescent, didn’t confirm in triplicate, or were active in any of the counter screens. 
Confirmed actives that produced calculable IC50s in the AR-TIF2 biosensor might be acting as 
direct disruptors of AR-TIF2 PPI’s. To further prioritize and characterize these hits we developed 
a suite of assays to identify compounds that can disrupt interactions between the AF-2 coactivator 
binding surface of the AR and p160 coactivators such as TIF2 (SRC2) or SRC1 or disrupt the AF-
1 transactivation domain. The hit characterization assays include the following: 1) AR::TIF2 and 
AR::SRC1 mammalian 2-hybrid (M2H) assays, 2) PSA6.1-LUC and UBE2C-LUC reporter based 
transcriptional activation assays in PC3 cells stably expressing either GFP-tagged full length AR 
(AR-FL), or GFP-tagged AR-V7, 3) a pGal4-AR-NTD transactivation assay developed in HEK 
293 cells, a 4) H3-DHT radioligand binding assay, 5)  an ALPHAScreen AR-LBD::LXXLL-
peptide binding assay, and 6) tumor growth inhibition assays developed in five different PCa cell 
lines. 
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Figure 2. AR-RFP Recombinant Adenovirus 
Grayscale and color combine images of U-2 OS cells infected with the AR-RFP recombinant adenovirus, 
cultured overnight and treated with or without DHT for 90 min and then fixed and stained with Hoechst, 
were acquired on the IXM platform in the fluorescent channels: Ch1 Hoechst, blue; and Ch3 AR-RFP, 
red.  
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Figure 3. TIF2-GFP Recombinant Adenovirus 
Grayscale and color combine images of U-2 OS cells infected with the TIF2-GFP recombinant adenovirus, 
cultured overnight and treated with or without DHT for 90 min and then fixed and stained with Hoechst, 
were acquired on the IXM platform in the fluorescent channels: Ch1 Hoechst, blue; and Ch2 TIF2-GFP, 
green. 
 
 
 
 
 
 
 50 
 
Figure 4. AR-RFP and TIF2-GFP Co-infected in U-2 OS Cells 
Grayscale and color combine images of U-2 OS cells co-infected with both the TIF2-GFP and AR-RFP 
recombinant adenovirus, cultured overnight and treated with or without DHT for 90 min and then fixed 
and stained with Hoechst, were acquired on the IXM platform in the fluorescent channels: Ch1 Hoechst, 
blue; Ch2 TIF2-GFP, green; and Ch3 AR-RFP, red. This assay was run in two different formats. In the 
first format U-2 OS cells co-infected with the AR-TIF2 biosensors were exposed to compound 3 h before 
treatment with 25 nM DHT for 90 min. This allowed us to determine if compounds acted by (1) blocking 
DHT induced formation of PPI’s. In the second format U-2 OS cells co-infected with the AR-TIF2 
biosensors were exposed to 25 nM of DHT for 90 min before treatment with compounds for 3h. This 
allowed us to determine if compounds were acting by (2) disrupting pre-formed AR-TIF2 PPI’s. 
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Figure 5. AR-TIF2 PPIB Assay Principle 
Cartoon schematic representation of the AR-TIF2 PPIB assay formats and predicted phenotypes. In 
untreated cells, AR-RFP expression is localized predominantly in the cytoplasm and TIF2-GFP is 
restricted to nucleoli within the nucleus. Upon exposure to an AR agonist such as DHT, the AR-RFP 
biosensor translocated to the nucleus where it forms bright fluorescent puncta colocalized with the TIF2-
GFP partner in the nucleolus. The AR-TIF2 PPIB assay therefore recapitulates the ligand-induced 
translocation of AR from the cytoplasm to the nucleus, and colocalization of the AR-RFP with the TIF2-
GFP in the nucleolus reflects the protein-protein interactions between AR and the TIF2 coactivator. The 
AR-TIF2 PPIB assay can therefore be screened in three formats: (1) to screen for any compounds that act 
as AR agonists, or compounds that induce the formation of AR-TIF2 PPI’s; (2) to screen for compounds 
that block DHT induced formation of PPI’s, such as AR-antagonists, Hsp 90 inhibitors, or compounds 
that block trafficking to the nucleus, and (3) to identify compounds capable of disrupting preexisting AR-
TIF2 complexes.  
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Figure 6. Image Segmentation Derived TIF2-GFP Positive Nucleolar Masks in the FITC and Texas Red 
Channels 
Image segmentation derived TIF2-GFP-positive nucleolar masks in the FITC and Texas Red channels. 
Grayscale images of TIF2-GFP (Ch2 TIF2-GFP, green) and AR-RFP (Ch3 AR-RFP, red) from U-2 OS 
cells co-infected with both the TIF2-GFP and AR-RFP adenoviruses, cultured overnight and then treated 
with or without DHT for 90 min. The TE image analysis module utilized the TIF2-GFP biosensor 
compartment in Ch2 to create a mask of the nucleoli based on fluorescent intensity and size. TIF2-GFP-
positive nucleoli were then used to create translocation masks within the nucleus of cells. AR-RFP 
images from Ch3 were segmented into a nucleolus region using the mask derived from the detected TIF2-
GFP-positive nucleoli in Ch2. The red or green color of the nucleolus masks indicate whether both TIF2-
GFP and AR-RFP signals within the nucleoli were below (red) or above (green) a certain fluorescent 
threshold.  
 
 
 
 
 
 
 53 
 
Figure 7. DHT Concentration Response of AR-RFP in the AR-TIF2 PPIB 
U-2 OS cells were co-infected with the AR-RFP and TIF2-GFP rAV biosensors, 2,500 cells were seeded 
into the wells of 384-well assay plates, cultured overnight at 37°C, 5% CO2, and 95% humidity, and then 
treated with the indicated concentrations of DHT for 30 min. Cells were then fixed and stained with 
Hoechst, images in three fluorescent channels were acquired on the IXU automated imaging platform, and 
the DHT-induced AR-TIF2 PPIs were quantified using the TE image analysis module as described 
previously. The mean – SD (n = 3) average inner intensity of AR-RFP within the TIF2-GFP-positive 
nucleoli at concentrations ranging between 0.001 and 100 nM DHT are presented. Representative 
experimental data from five independent experiments are shown. 
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Table 1. Testing paradigm to identify and eliminate compound artifacts from the AR-TIF2 PPIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. To determine if compounds could block DHT-induced AR-TIF2 PPI formation, assay plates were 
pre-exposed to compounds for 3 h prior to treatment with 25 nM DHT for 90 minutes. 
2. To identify compounds that could disrupt pre-existing AR-TIF2 PPI complexes, assay plates were 
pre-exposed to 25 nM DHT for 90 minutes prior to compound transfer and an additional 3 h 
incubation. 
3. Compounds that met the activity threshold % inhibition criterion of ≥50% Inhibition of DHT-
induced AR-TIF2 PPI formation  
4. Compounds that met the activity threshold % inhibition criterion of ≥30% of Disruption of 
preexisting AR-TIF2 complexes.  
5. Compounds that met the activity threshold % inhibition criterion of ≥40% or ≥45% Inhibition of 
DHT-induced AR-TIF2 PPI formation, or disruption of preexisting AR-TIF2 complexes. 
6. A z-score plate-based statistical scoring method was used to flag compounds that behaved as 
outliers compared to the other substances (n=320, no controls) tested on an assay plate. The 
number of compartments which represents the number of TIF2-GFP positive nucleoli identified 
in the FITC channel was used to flag compounds with z-scores <-3 as cytotoxic. Compounds with 
z-scores >3 in one or more of the average or integrated fluorescent intensity parameters in any 
channel were flagged as fluorescent outliers.  
7. Compounds that were active in p53-hdM2 PPIB, AR-Nuclear Localization, or Dex-Induced GR 
Translocation Counter Screens. 
 Inhibition of DHT-
induced AR-TIF2 
PPI formation1 
Disruption of Existing 
AR-TIF2 PPI 
Complexes2 
 Compound then DHT DHT then Compound 
LOPAC Screen   
Active3,4 243 
 
164 
 
Inactive 1256 
 
1264 
 
Eliminated6 16 16 
 
Active in Counter 
Screens7 
5 
 
5 
 Confirmed in Triplicate 17 
 
9 
 
Exhibited Calculable 
IC50 
15 
 
15 
 
10K, 50K, 83K Screen   
Active5 3566 
 
975 
 
Inactive 139969 
 
142560 
 
Eliminated6 1224 
 
454 
 
Active in Counter 
Screens7 
37 
 
37 
 Confirmed in Triplicate 443 
 
49 
 
Exhibited Calculable 
IC50 
178 
 
170 
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Figure 8. Concentration-dependent confirmation of LOPAC active that inhibit the DHT-induced formation of 
AR-TIF2 PPIs or disrupt preexisting AR-TIF2 PPI complexes 
(A) Concentration-dependent inhibition of DHT-induced AR-TIF2 PPI formation by NR ligands. The 
mean – SD (n = 3) percent inhibition of DHT-induced AR-TIF2 PPIs in cells exposed to the indicated 
concentrations 17-alpha-hydroxyprogesterone (17-a-H-PG) (), nilutamide (), 2-methoxyestradiol (2-
MOED) (), or estrone () are presented. Representative experimental data from one of the three 
independent experiments are shown. (B) Concentration-dependent inhibition of DHT-induced AR-TIF2 
PPI formation by non-NR ligands. The mean – SD (n = 3) percent inhibition of DHT-induced AR-TIF2 
PPIs in cells exposed to 4- phenyl-3-furoxancarbonitrile (4-P-3-FOCN) (), Bay 11-7085 (), 
parthenolide (D), 1-chloro-3-tosylamino-4-phenyl-2-butanone (TPCK) (), or N-Carbobenzyloxy-L-
phenylalanyl chloromethyl ketone (ZPCK) () are presented. Representative experimental data from one 
of the three independent experiments are shown. (C) Concentration-dependent confirmation of disruptor 
actives identified in the AR-TIF2 PPIB LOPAC screens. The mean – SD (n = 3) percent disruption of 
preformed AR-TIF2 PPI complexes in cells exposed to the indicated concentrations of mifepristone (), 
4-phenyl-3-fluroxane carbo-nitrile (4-P-3-FOCN) (), and gugglesterone () are presented. 
Representative experimental data from one of the three independent experiments are shown. 
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Figure 9. Non-Nuclear Receptor AR-TIF2 PPIB Actives 
Library of Pharmacologically Active Compounds (LOPAC) run in a 10-point concentration manner in the 
AR-TIF2 biosensor assay. Chemical structures, names, and calculable IC50 values of  Non-Nuclear 
Receptor AR-TIF2 PPIB actives from the LOPAC set that inhibited (C then D) or disrupted (D then C) 
dihydrotestosterone (DHT)-induced androgen receptor (AR)-TIF2 protein–protein interaction (PPI) 
complexes. 
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Figure 10. AR-TIF2 PPIB Actives: Nuclear Hormone Receptor Ligands 
Library of Pharmacologically Active Compounds (LOPAC) run in a 10-point concentration manner in the 
AR-TIF2 biosensor assay. Chemical structures, names, and calculable IC50 values of  nuclear receptor 
ligands from the LOPAC set that inhibited (C then D) or disrupted (D then C) dihydrotestosterone 
(DHT)-induced androgen receptor (AR)-TIF2 protein–protein interaction (PPI) complexes.  
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 Targeting the AR AF-2 Protein-Protein Interactions with Coactivators 
3.1 Introduction: Development of a Panel of Assays to Identify Compounds Targeting the 
AR AF-2 Transactivation Domain/Coactivator Binding Surface 
Prostate cancer progression is largely dependent on AR’s transcriptional activity in PCa cells 
which is reliant on AR’s interaction with coactivators such as TIF2 [110]. TIF2’s involvement in 
PCa disease progression has been well documented, and over-expression of this coactivator in 
recurrent forms of PCa, results in cellular resistance to the standard of care ADT’s [96, 112, 117]. 
AR’s  regulation of gene transcription occurs via ligand-induced  AR nuclear translocation, DNA 
binding to  specific androgen response elements (ARE’s) in target gene promoter and/or enhancer 
regions, and recruitment of coactivators [137]. Some coactivators bind to AR at the AF-2 
hydrophobic activation surface that is formed by helix 12 of the AR-LBD after DHT binding [79, 
116, 138]. These coactivators enable histone remodeling, additional coactivator recruitment, and 
subsequent assembly of the transcriptional machinery [137]. AR target genes associated with 
cellular biosynthesis, survival, and proliferation lead to PCa disease progression [113]. Although 
increased expression of several other AR coactivators have also been associated with PCa disease 
severity, blocking AR mediated transcription by disrupting the interactions between AR and TIF2 
represents an attractive therapeutic strategy for slowing the progression of CRPC.  
We have developed a suite of five assays to be used for the characterization of hit 
compounds that can disrupt interactions between the AF-2 surface of AR and the p160 coactivators 
TIF2 (SRC2) or SRC1. The assays were developed to characterize hit compounds identified in a 
screen of 143,000 compounds conducted in an AR-TIF2 PPI biosensor HCS assay (described in 
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chapter 2). The AR-TIF2 PPIB assay was used to identify compounds that inhibited the DHT-
induced formation of AR-TIF2 PPIs or that disrupted pre-existing AR-TIF2 PPIs.  The hit 
characterization assays include the following: 1) AR::TIF2 and AR::SRC1 mammalian 2-hybrid 
(M2H) assays, which represent the gold-standard assays for detecting co-regulator recruitment to 
nuclear receptors in cells [139-142].  In M2H assays, DHT binding enhances the interactions 
between the AR-LBD and either TIF2 or SRC1, which is detected by enhanced reporter gene 
activity. Compounds that decrease reporter gene activity may be blocking AR AF-2 interactions 
with TIF2 or SRC1 coactivators.  2) We developed a PSA6.1-LUC reporter based transcriptional 
activation assay in PC3 cells stably expressing GFP-tagged full length AR (AR-FL). This assay 
measures the transcriptional activity of AR at AREs in the promoter region of the PCa biomarker 
gene Prostate Specific Antigen (PSA). Any compound that can disrupt PPI’s between AR and its 
coactivator should reduce AR’s ability to transcribe genes, such as PSA in cells. The third assay 
we developed was a 3) H3-DHT radioligand binding assay. The radioligand binding assay 
measures a compound’s ability to displace H3-DHT from binding to the AR-LBD. Since one 
potential mechanism of blocking the formation of DHT-induced AR-TIF2 PPI’s would be to 
antagonize DHT binding to the AR-LBD, we needed an assay to identify compounds that were 
acting in this manner. The fourth assay we developed was an 4) ALPHAScreen AR-
LBD::LXXLL-peptide binding assay. This assay was designed to measure the direct interactions 
between the NR box III LXXLL motif of the TIF2 coactivator with the AR AF-2 binding groove. 
Compounds that effectively inhibit TIF2-LXXLL peptide binding to AR AF-2 would be expected 
to block AR-TIF2 PPIs. Finally, we developed tumor growth inhibition assays in five different 
PCa cell lines, two that are AR negative and three that are AR positive. We would anticipate that 
AR-TIF2 PPI inhibitors/disruptors would be more effective at inhibiting the growth of PCa cell 
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lines that express AR than those that do not express AR. We then ran these assays using a test set 
of 7 compounds comprised of FDA approved therapeutics and investigational drugs for the 
treatment of PCa (Figure 11, on pg. 88) to see if they would perform the way we expected them 
to. The development and optimization of these assays together with the results for these seven test 
compounds are described in this chapter.  
3.2 How Did Test Compounds Perform in the Primary AR-TIF2 PPIB Assay? 
To begin with, we screened our set of test compounds in the AR-TIF2 HCS biosensor to determine 
how these compounds with different mechanisms of action would perform. Flutamide, 
bicalutamide, and enzalutamide are AR-antagonists that are prescribed as components of an 
androgen deprivation therapy (ADT) strategy [143-145]. Similarly, the Cyp17a1 inhibitor 
abiraterone acetate which prevents androgen synthesis is also used as a component of ADT [146]. 
Compounds #10 and EPI-001 target the amino-terminus of AR rather than the ligand binding site 
[124, 147-149], and 17-AAG is an inhibitor of the Hsp90 chaperone involved in the folding, 
maturation and maintenance of AR in a high affinity ligand binding conformation [150] (Figure 
11). The assay was conducted in two distinct assay formats. In the first format, U-2 OS cells co-
infected with the AR-RFP and TIF2-GFP biosensors were exposed to compounds for 3h before 
treatment with 25 nM DHT for 90 min. This allowed us to determine whether compounds could 
prevent DHT induced AR-TIF2 PPI formation. In the second format, U-2 OS cells co-infected with 
both biosensors were exposed to 25 nM of DHT for 90 min before treatment with the indicated 
concentrations of compounds for 3h. This allowed us to determine whether the compounds could 
disrupt pre-existing DHT-induced AR-TIF2 PPI’s. As expected, exposure to the indicated 
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concentrations of the AR antagonists flutamide, bicalutmide, and enzalutamide for 3h prior to 
treatment with DHT inhibited AR-TIF2 PPI formation in a concentration dependent manner 
(Figures 12B-D, on pg. 89 and Table 2, on pg. 90). Flutamide, bicalutamide, and enzalutamide, 
exhibited IC50s of 8.77 +/- 1.59, 2.49 +/- 0.20, and 1.44 +/- 0.16 µM, respectively (Table 2). DHT 
binding facilitates both AR’s entry into the nucleus, and the formation of the AF-2 coactivator 
binding surface of the AR. Through their ability to block DHT binding to the AR-LBD, AR 
antagonists therefore inhibit the DHT-induced PPIs of the AR-TIF2 biosensors. Interestingly, 
flutamide, bicalutmide, and enzalutamide also disrupted pre-exiting AR-TIF2 PPI complexes with 
IC50s of 20.6 ± 4.46, 4.01 ± 1.37, and 2.71 ± 0.27 µM, respectively (Table 2). Similarly, the Hsp90 
inhibitor 17-AAG produced IC50s in the AR-TIF2 biosensor assays, with an IC50 of 0.39 ± 0.01 
µM in the AR-TIF2 PPI formation format, and an IC50 of 0.20 ± 0.01 µM in the disruption of pre-
existing AR-TIF2 PPIs format (Figure 12G and Table 2). Since the Hsp90 chaperone protein 
maintains AR in a high-affinity conformation for ligand binding, inhibition of this function can 
also prevent ligand-induced AR nuclear translocation and AF-2 surface formation. In contrast, 
compound #10, EPI-001, and abiraterone acetate failed to produce a response in the AR-TIF2 HCS 
assay in either format at ≤50 µM (Figure 12E-F, H and Table. 2).  Since compound #10 and EPI-
001 both target the amino-terminal domain of AR, they would not be expected to interfere with 
the interactions between the AR-RFP and TIF2-GFP biosensors because the AR-RFP biosensor 
contains amino acids 622-919 of the AR-LBD derived from the carboxy-terminus of AR.  
Abiraterone acetate is a Cyp17a1 inhibitor and since it does not directly interact with the AR-LBD 
it would not be expected to exhibit activity in the AR-TIF2 biosensor assay. None of the test 
compounds had a significant impact on the total number of U-2 OS cells (Hoechst stained nuclei) 
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detected in the DAPI channel images, suggesting that at 3h of exposure they were not acutely 
cytotoxic at the concentrations tested.      
3.3 Assays Developed to Characterize AR-TIF2 PPIB Inhibitor/Disruptor Hits that Target 
the AR AF-2 Transactivation Domain/Coactivator Binding Surface 
3.3.1  Mammalian 2-Hybrid (M2H) Assay 
3.3.1.1 Assay Principle 
The mammalian 2-hybrid (M2H) assay is the gold standard for measuring the interactions between 
a nuclear receptor and co-regulator proteins to modulate transcriptional activity [139-142]. A gene 
coding for the nuclear receptor of interest, is cloned into a Gal4 vector containing the DNA-binding 
domain of the galactose expression Gal4 protein derived from yeast (Figure 13, on pg. 91). The 
respective co-regulator binding partner, either a coactivator or a corepressor, is cloned into a VP16 
vector which contains the activation domain of the herpes simplex virus transcription factor. The 
M2H assay involves the transfection and expression of three main components including the Gal4-
fused nuclear receptor protein, the VP16-fused coactivator or corepressor protein, and the 5xGal4-
TATA-Luc luciferase reporter [151, 152].  Ligand binding to the nuclear receptor-Gal4 fusion 
protein acts to direct DNA-binding to the 5xGal4-TATA-Luc reporter plasmid, while ligand-
induced binding interactions with the co-regulator-VP16 fusion protein recruits the transcriptional 
machinery of the cell, leading to overall transcription of the luciferase reporter gene, whose levels 
can be quantified as luciferase light output after addition of ATP substrate. This transcriptional 
activity of the reporter is a measure of the nuclear receptor::co-regulator protein interactions in the 
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cell [151, 152]  (Figure 13).  Co-activators enhance reporter activity while corepressors reduce 
reporter responses [153, 154]. 
We have developed M2H assays to interrogate the ability of hit compounds identified in 
the AR-TIF2 PPI HCS campaign to inhibit the PPI’s between the AF-2 surface formed by DHT 
ligand binding to the AR-LBD and two of its coactivators, either transcriptional intermediary 
factor 2 (TIF2/SRC2) or SRC1. The M2H assays were developed using either full-length TIF2 or 
SRC1 protein, cloned into the VP16 transcriptional activation domain. SRC1 is another member 
of the steroid nuclear receptor p160 coactivator family and is a homologue of TIF2 [58, 59]. By 
developing the M2H assay with both TIF2 and SRC1, we will be able to determine if our hit AR-
TIF2 PPI inhibitors and disruptors exhibit selectivity for TIF2 relative to SRC1. During assay 
development and optimization, the DNA concentrations of the 3 plasmid constructs were cross-
titrated to select the optimal amounts of coactivator-VP16, AR-LBD-Gal4 and 5xGal4-TATA-Luc 
reporter DNA for the assays, which were then used to prioritize the hits identified from the 143K 
AR-TIF2 PPIB screen. The AR-LBD::TIF2 M2H assay allowed us to confirm that hits identified 
in the AR-TIF2 PPIB campaign inhibited the direct interactions between the DHT-induced AF-2 
binding surface of the AR-LBD and TIF2, and whether they exhibited selectivity towards the 
related SRC1 p160 coactivator family member.  
3.3.1.2 Materials and Methods 
Plasmid DNAs. The 5xGAL4-TATA-luciferase reporter plasmid was a gift from Dr. 
Richard Maurer from the Oregon Health and Science University [155], and constructs pGAL4-
hAR-658-919 (AR-LBD amino acids 658-919 expressed as a fusion protein with Gal4-DBD) 
[156], pVP16-SRC1 (full-length SRC1 expressed as a fusion with VP16 activation domain) [157] 
and pVP16-Empty vector were kindly provided to us by Dr. Elizabeth Wilson, from UNC Chapel 
 64 
Hill. pVP16-TIF2 was generated by ligating TIF2, PCR amplified from pCR-BluntII-TOPO-
NCoA2 (TIF2) cDNA (purchased from Dharmacon), into the empty pVP16 vector.  
Cloning of TIF2 into a mammalian 2-hybrid pVP16 vector. The full-length TIF2 insert was 
amplified by polymerase chain reaction (PCR) from the pCR-BluntII-TOPO-NCoA2 (TIF2) 
cDNA using Phusion High-Fidelity DNA Polymerase (NEB). The primers for PCR were designed 
for the addition of EcoRI and BamHI cloning sites at the 5’ and 3’ flanking regions, respectively 
(ThermoFisher Scientific) (Table 3, on pg. 92). After PCR and the purification step, the insert was 
digested with EcoRI and BamHI. The VP16 vector was also double digested with EcoRI and 
BamHI enzymes. After overnight ligation, using T4 DNA ligase (New England Biolabs) at 16°C 
the insert was cloned into the pVP16 vector. Following the ligation, a small amount of the ligation 
mixture was transformed into DH5α competent cells and plated on ampicillin containing LB agar 
to select bacteria containing the pVP16-TIF2 plasmid DNA. Following overnight incubation at 
37°C, colonies were selected and expanded in ampicillin containing LB media. Next, DNA was 
isolated from cells expanded from an individual clone, and clones were analyzed via restriction 
analysis. Clones with bands at the correct molecular size were sent for sequencing. Sequencing 
analysis confirmed the correct cloned TIF2 construct, and plasmid DNA was isolated from DH5α 
cells (Table 4, on pg. 93).  
SDS-PAGE and Western Blot Confirmation of VP16-Coactivator Constructs.      Coactivator 
containing pVP16 vectors were then confirmed through western blot analysis. pVP16-TIF2 and 
pVP16-SRC1 were transfected into HEK 293 cells and allowed to express for 48 hrs. Forty-eight 
hours post transfection, cells were lysed, and the BCA reagent was used to determine protein 
concentrations of transfected cell lysates. An SDS-PAGE gel was then run to separate 25 µg of 
protein of each transfected cell lysate per well and compared to non-transfected HEK 293 cells. 
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Protein was then transferred to a nitrocellulose membrane and probed with either α-TIF2 or α-
SRC1 antibodies (Figure 14, on pg. 94). HEK 293 cell endogenously express coactivators TIF2 
and SRC1, which is evident in non-transfected HEK 293 lysates. A second immuno-positive band 
was detected in lanes loaded with protein from pVP16-TIF2 and pVP16-SRC1 transfected HEK 
293 cells, consistent with a higher molecular weight due to the fusion with VP16 (Figure 14).  
Mammalian-2-Hybrid Assay. HEK 293 cells were co-transfected with 5 ng of pGal4-AR-LBD, 
10 ng of either pVP16-TIF2 or pVP16-SRC1, and 20 ng of the 5xGal4-TATA-Luc reporter. Cells 
were transiently bulk co-transfected with the three plasmids using the Fugene6 transfection 
reagent. Prior to the transfection of cells each of the pGAL4-hAR-658-919, 5xGAL4-TATA-
luciferase reporter, and either pVP16-TIF2 or pVP16-SRC1 plasmid DNAs were individually 
incubated with Fugene6 at a 3:1 ratio for 25 min at room temperature (RT). Each Fugene6:plasmid 
DNA mixture was then added to HEK 293 cells that were suspended in DMEM (Cellgro10013CV) 
with 2 mM L-glutamine (Invitrogen) that was supplemented with 10% fetal bovine serum, and 
5,000 cells in a volume of 40 µL were seeded into the wells of 384-well assay plates and cultured 
overnight at 37°C, 5% CO2, and 95% humidity. After 24 h control wells were exposed to ± 25 nM 
DHT and the assay plate was returned to the incubator for an additional 24 h before BrightGlo® 
reagent was added to the plate and the relative luminescence units (RLUs) were captured on a 
SpectraMax M5e microtiter plate reader. Test compounds were run in the M2H assay in a 10-point 
2-fold dilution series spanning a concentration range between 0.0977 to 50 μM. 24 h post cell 
seeding into assay plates, 5 µL of the serially diluted test compounds was transferred to the wells 
using a Janus MDT automated liquid handling platform outfitted with a 384- well transfer head 
before 5 µL of 0.25 µM DHT (25 nM final) was transferred into each well, and the assay plates 
were returned to the incubator for an additional 24 h. 
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3.3.1.3 Assay Development and Optimization 
Determining the optimal cell background for the AR-LBD Mammalian 2-Hybrid TIF2 and 
SRC1 Coactivator assays. We began by conducting the mammalian 2-hybrid assay in 3 different 
cell lines (Figure 15, on pg. 95). We selected PC3 cells because they provided an AR-null PCa cell 
line background, and we selected HeLa cells and HEK 293 cells because they have frequently been 
used in mammalian 2-hybrid assays [88, 92, 157-159].  In cells co-transfected with 5 ng of pGal4-
AR-LBD, 10 ng of pVP16-TIF2, and 20 ng of the 5xGal4-TATA-Luc reporter construct only cells 
that were treated with DHT exhibited a luciferase response substantially greater than untreated 
background levels. Surprisingly PC3 cells produced very little response with or without DHT 
treatment, and the DHT-induced response in HeLa cells was ~60-fold lower than in HEK 293 cells.  
Based on our experience with other transient transfection assays, we attribute the much higher 
responses observed in HEK 293 cells to their much higher transfection efficiencies. We therefore 
selected the HEK 293 cell background to conduct our remaining mammalian 2-hybrid assays 
(Figure 15).  
Determining the optimal amounts of DNA plasmid constructs to use in the M2H 
Assays. To determine the optimal amount of pGal4-AR-LBD, pVP16-TIF2, or pVP16-SRC1 
plasmid DNA to use in the M2H assays conducted in HEK 293 cells we performed cross-titration 
transient transfection experiments with increasing amounts of the AR and coactivator plasmid 
DNAs (Figure 16, on pg. 96). The amount of 5xGal4-TATA-Luc reporter construct in the assays 
was kept constant at 20 ng, which had been previously been determined to be optimal in transient 
transfection experiments conducted in our lab. The cross-titration experiments were performed in 
384-well, white opaque plates. pGal4-AR-LBD plasmid DNA was added to cells at increasing 
amounts (0, 2.5, 5, 10 ng/well)  and cross-titrated with increasing amounts (0, 5, and 10 ng/well) 
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of pVP16-TIF2 or pVP16-SRC1 plasmid DNA. Only cells that were treated with DHT exhibited 
a luciferase response substantially greater than untreated background levels (Figure 16). In both 
the TIF2 and SRC1 M2H assays, the DHT-induced luciferase response increased in a linear fashion 
as the amount of pGal4-AR-LBD transfected into the HEK 293 cells was increased. Similarly, the 
DHT-induced M2H luciferase response increased in a roughly linear fashion as the amounts of the 
pVP16-coactivator constructs transfected into the HEK 293 cells was increased. The magnitude of 
the TIF2 M2H response was ~ 30-fold higher than the signal in the SRC1 M2H assay (Figure 16A 
versus 16B). The final amounts of plasmid DNAs selected for the optimized the M2H assays were 
5 ng for pGal-AR-LBD, and 10 ng each of the pVP16-Coactivator constructs (Figure 16).  
Determining the optimal DHT concentration for the M2H assays. A DHT-
concentration response was performed to determine the optimal concentration of DHT to use in 
subsequent M2H experiments.  HEK 293 cells were co-transfected with the 5xGal4-TATA-Luc 
reporter construct and the pGal4-AR-LBD plasmid with either the pVP16-TIF2 or pVP16-SRC1 
coactivator constructs and exposed to the indicated concentrations of DHT. DHT exhibited EC50s 
of 0.619 nM and 2.23 nM for the TIF2 and SRC1 M2H formats respectively (Figure 17, on pg. 
97). We therefore selected 25 nM of DHT as a suitable agonist concentration for activating both 
M2H assay formats as it was the second lowest concentration that gave us the highest signal when 
we ran DHT-concentration curves.  
Determining the DMSO tolerance for the M2H assays. A DMSO-concentration 
response was performed to determine the optimal concentration of DMSO to use in subsequent 
M2H experiments (Figure 18, on pg. 98).  DMSO exhibited IC50s of 1.97% and 1.16% for the TIF2 
and SRC1 M2H formats respectively. Therefore, we were able to determine that 0.5% DMSO 
would not interfere either TIF2 or SRC1 M2H assay formats (Figure 18).  
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3.3.1.4 Inhibition of the AR-TIF2 Biosensor assay to Measure DHT-induced AR-LBD Interactions 
with the TIF2 by Test Compounds 
All seven compounds in the test set inhibited DHT-induced AR-LBD interactions with the 
TIF2 and SRC1 coactivators in a concentration dependent manner (Figure 19, on pg. 99). In TIF2 
M2H assays, the anti-androgens flutamide, bicalutamide, and enzalutamide exhibited IC50s of 3.01 
± 0.75, 2.01 ± 0.99, and 2.36 ± 1.44 µM respectively, and the Hsp 90 inhibitor 17-AAG produced 
an IC50 of 0.33 ± 0.02 µM (Figure 19B-D, H and Table 5, on pg. 100). In SRC1 M2H assays  
flutamide, bicalutamide, and enzalutamide exhibited IC50s of 2.53 ± 0.66, 1.49 ± 0.69, and 1.37 ± 
0.91 µM respectively, and 17-AAG produced an IC50 of 0.45 +/- 0.08 µM (Figure 19B-D, H and 
Table 15). Compound #10, EPI-001, and Abiraterone acetate also exhibited concentration-
dependent inhibition in both the TIF2 and SRC1 M2H assay formats, however, they also displayed 
substantial concentration-dependent cytotoxicity in HEK 293 cells that complicates the 
interpretation of the data (Figure 19E, F, G and Table 5). Overall, there was no apparent selectivity 
for any of the validation compounds for their ability to disrupt DHT-induced AR-LBD interactions 
with either TIF2 or SRC1. The antiandrogens were likely active in both formats of the M2H assay 
because they block DHT binding to the AR-LBD, thereby inhibiting PPI’s from forming with 
either of the p160 coactivators. Similarly, the Hsp 90 inhibitor 17-AAG blocks the folding and 
stabilization of the AR-LBD into a high affinity ligand binding conformation, thereby inhibiting 
DHT from inducing PPI’s formation with the p160 coactivators. Compound #10, EPI-001, and 
abiraterone acetate all exhibited IC50s in both p160 M2H assay formats, however, viability assays 
run simultaneously with the M2H assay suggest that compound-mediated cytotoxicity may be the 
primary mechanism for decreasing the M2H reporter signal.   
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3.3.2  PSA6.1-Luc Reporter-Based Assay Developed in PC3-GFP-AR-FL Cells 
3.3.2.1 Assay Principle 
The PSA6.1-Luc reporter-based assay measures DHT-induced transcriptional activity of the AR, 
in PCa cells. The PSA-6.1 LUC plasmid luciferase reporter activity is controlled by a fragment of 
the PSA promoter that contains three androgen response elements (AREs), fused to a luciferase 
reporter gene (Figure 20, on pg. 101). When AR is transcriptionally active, it leads to the 
transcription of luciferase, and in the presence of the CellTiterGlo reagent, luciferase will convert 
the ATP substrate into light output, a quantifiable measurement of transcription. Any compound 
that can disrupt AR’s interaction with coactivator, TIF2, should prevent the further recruitment of 
the transcriptional machinery of the cell. Therefore, an AR AF-2-TIF2 inhibitor/disruptor should 
decrease the transcriptional activity of full-length AR (AR-FL) target genes, such as PSA. During 
assay development and optimization, we obtained and generated reagents that were necessary for 
conducting our reporter assay. We developed a PC3 cell line, stably transfected with AR-FL-GFP. 
We transiently transfected this cell line with our reporter construct, and we determined which DHT 
concentrations were optimal for AR’s subcellular localization in the nucleus, and those that were 
optimal for AR’s transcriptional activity. The appropriate conditions were then chosen to be used 
when prioritizing hits identified from the 143K AR-TIF2 PPIB screen. The PSA6.1-Luc reporter 
assay allowed us to interrogate the ability of hit compounds to modulate AR’s transcriptional 
activity in PC3 cells. Any compound that could decrease reporter activity was further prioritized 
along our screening paradigm.  
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3.3.2.2 Materials and Methods 
We developed the PSA6.1-LUC reporter-based assay in a PC3 cell line stably transfected with 
pEGFP-C1-AR-FL. PC3 cells are an AR-null PCa cell background into which we could stably 
transfect either pEGFP-C1-AR-FL or pEGFP-C1-AR-V7 (splice variant) constructs in order to 
compare AR-FL and AR-NTD related transcriptional events. The development of reporter assays 
using PC3 cells stably transfected with the pEGFP-C1-AR-V7 construct is described in chapter 4.  
The pPSA-6.1 LUC luciferase reporter plasmid was kindly provided by Dr. Zhou Wang in the 
Urology department of the University of Pittsburgh Cancer Institute. We developed the PC3 cell 
line stably transfected with full-length AR, using the pEGFP-C1-AR construct that was kindly 
gifted to us from Dr. Michael Mancini, Baylor College of Medicine. The PC3 cell line was 
purchased from the American Type Culture Collection.  
Developing the PC3 Cell Line Stably Transfected with pEGFP-C1-AR-FL. In order to 
generate a stable cell line, we transfected PC3 cells with the pEGFP-C1-AR-FL plasmid and then 
sorted these cells based on the presence of GFP. On day 1, PC3 cells were plated at a seeding 
density of 1.0 x 10^6 cells in a 100 mm TC dish.  On day 2, at 70% confluency, PC3 cells were 
transfected with 19 µg of pEGFP-C1-AR-FL, at a 3:1 Ratio of FuGENE6: plasmid DNA. 
Transfection conditions were based on those that were previously optimized in our lab that 
generated the highest transfection efficiency in PC3 cells. 48 h post transfection, the cells were 
initially sorted with the help of Dr. Hongmei Shen, University of Pittsburgh School of Medicine. 
They were then placed under selection with 600 µg/mL of G418. Prior to transfection, we ran kill 
curves in PC3 cells by exposing cells to increasing concentrations of antibiotic (G418) and 
determining the amount that was necessary to kill all of the cells over a 7-day period of time. 600 
µg/mL of G418 was chosen for selection and maintenance of the antibiotic resistance plasmid 
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DNA in PC3 cells. Two weeks after the first sort, the cells were harvested, counted, and sorted a 
second time. Again, they were placed under selection with 600 µg/mL of G418. A third and final 
sort was performed 2 weeks after the second. Cells were sorted into two groups: those that 
expressed high levels of pEGFP-C1-AR-FL, and those that expressed low levels of pEGFP-C1-
AR-FL. The population of cells expressing lower levels of pEGFP-C1-AR-FL performed better in 
both the DHT-induced AR-FL-EGFP nuclear translocation, and PSA6.1-reporter assays (data not 
shown), and therefore we selected this population for use in subsequent experiments.  
PSA6.1-LUC Reporter Assay.  Fugene HD and PSA-6.1 LUC were combined at a 3:1 (µL:µg) 
ratio, respectively, in Opti-MEM and incubated for 25 min at room temperature (RT) before being 
combined with AR-FL-EGFP-PC3 cells that were suspended in RPMI 1640 media containing 1% 
L-glutamine, and 10% fetal bovine serum. Transfected cells were then seeded into white opaque 
384-well assay plates (#781080; Greiner Bio-one) at a seeding density of 3,000 cells per well in a 
volume of 40 uL and incubated at 5% CO2, 37C, and 95% humidity for 24 h. Each well received 
20 ng of PSA-6.1 LUC plasmid DNA. After 24 h, 5 uL of serially diluted compounds was 
transferred to the wells by using a Janus MDT automated liquid handling platform outfitted with 
a 384- well transfer head; then, 5 uL of 0.25 μM DHT (25 nM final in well) in SFM was transferred 
to each well; and the assay plates were returned to the incubator for an additional 24 h before 25 
μL of BrightGlo luciferase reagent (Promega) was added to the wells and the relative light units 
(RLUs) were captured on a SpectraMax M5e plate reader (Molecular Devices LLC). 
3.3.2.3 Assay Development and Optimization 
Determining which cell background to develop reporter assays in. To determine which PCa 
cell line to use for developing a stably transfected AR-FL EGFP line, we characterized the 
endogenous expression levels of coactivator TIF2, and the AR in the 5 PCa cell lines: PC3, DU-
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145, 22Rv1, and C4-2 (Figure 21, on pg. 102). Cells were cultured in a 100 mm tissue culture dish, 
and once they were 60-70% confluent, they were washed by adding cold PBS to the culture dish 
which was placed on ice. PBS was then aspirated and a second wash was performed. Next, 800 
µL of chilled RIPA buffer with protease inhibitors was added to the plate as a lysis buffer. Cells 
were removed from the surface of the plate using a cell scraper. Cells were transferred to a 
microcentrifuge tube and sonicated on ice 3x; 5s each at 20% amplitude. Next, cells were incubated 
on ice for 30 min. Finally, cells were centrifuged for 25 minutes at 14,000 rpm at 4°C. Supernatant 
was transferred to a fresh tube and BCA reagent was used to determine protein concentrations of 
each lysate. Then an SDS-PAGE was performed and 20 µg of protein was added to each lane of 
the gel from each cell lysate. After the gel was run for protein separation, it was transferred to a 
nitrocellulose membrane. The membrane was then probed with TIF2 (Bethyl Labs #A300-356A), 
and AR (Cell Signaling #5153), rabbit antibodies at a 1:1000 dilution for 1 hr at RT. Next the 
membrane was washed 3x with Tris buffered saline and 0.01% Tween20 (TBS-T) and secondary 
goat anti-rabbit IgG (Santa Crus #2004), was added to the membrane at a 1:2000 dilution for 1 hr 
at RT. Next, the membrane was probed with a GAPDH antibody (Pierce #MA1-16757), added at 
a 1:1000 dilution, for 1 hr at RT. The membrane was washed 3x with Tris buffered saline and 
0.01% Tween20 (TBS-T) and secondary goat anti-mouse antibody, at a dilution of 1:10,000, for 1 
hr at RT (Figure 21).  We chose PC3 cells as our cell background because it is an AR-null cell 
line, and it expresses the TIF2 coactivator. 
DHT concentration response in AR-FL-EGFP Nuclear Translocation assay. The DHT 
concentration response was conducted in the pEGFP-C1-AR-FL-PC3 cell line (Figure 23, on pg. 
104). To quantify DHT-induced nuclear translocation  of AR-FL-EGFP in PC3 cells, cells were 
plated, and treated with increasing concentrations of DHT for 24 hrs, before being fixed, and 
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imaged on an IXM automated HCS platform (Molecular Devices LLC). Images were then 
analyzed with the TE image analysis module of the MetaXpress software (Molecular Devices 
LLC). Exposure of cells to increasing amounts of DHT, increased the inner/outer intensity ratio in 
the cells, which is a measure of the mean average fluorescence intensity of AR-FL-GFP in the 
nucleus, divided by the mean average fluorescence intensity of AR-FL-GFP in the cytoplasm. 
Exposure of the PC3-AR-FL-EGFP cells to increasing amounts of DHT, resulted in a 
concentration-dependent increase in inner/outer intensity ratio with an EC50 of 1.23 +/- 0.131 nM 
(Figure 23). Representative images of subcellular localization of AR-FL-GFP in PC3 cells in the 
absence or presence of DHT are shown in Figure 22, on pg. 103.  
DHT concentration response in PSA6.1-LUC reporter assay. The DHT concentration response 
was conducted in pEGFP-C1-AR-FL containing PC3 cells transiently transfected with the PSA6.1-
LUC reporter construct (Figure 24, on pg. 105). Cells were transfected with the following 
conditions, 20 ng of PSA6.1-LUC reporter construct combined with FugeneHD at a 3:1 ratio, 
which had been previously determined in transient transfection assays run in our lab. Cells were 
treated with increasing amounts of DHT for 24 hrs, which increased reporter response in a 
concentration dependent manner, and produced an EC50 of 0.280 +/- 0.034 nM (Figure 24). We 
therefore selected 25 nM of DHT as a suitable agonist concentration for conducting the PSA6.1-
LUC reporter based assay. 
3.3.2.4 Test set performance in PSA6.1 Reporter Assay 
In PC3-AR-FL-GFP cells transfected with the PSA-6.1-LUC reporter, the anti-androgens 
flutamide, bicalutamide, and enzalutamide inhibited DHT-induced reporter activity in a 
concentration dependent manner, exhibiting IC50s of 17.4 ± 3.91, 21.9 ± 4.80, and 19.5 ± 3.45 µM, 
respectively (Figure 25B-D, on pg. 106 and Table 6, on pg. 107). This was expected, since these 
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compounds are FDA-approved compounds for the treatment of PCa, and act by antagonizing DHT 
binding to the AR-LBD, thereby preventing AR activation of transcription. The Hsp 90 inhibitor, 
17-AAG, also decreased AR-FL’s transcriptional activity in cells in a concentration dependent 
manner, producing an IC50 of 1.72 ± 0.48 μM (Figure 25H and Table 6). This is likely due to this 
compound’s ability to block the folding and stabilization of the AR in a high affinity ligand binding 
conformation, thereby inhibiting DHT binding, and therefore diminishing AR’s transcriptional 
activity in the cell. Surprisingly, investigational drugs, compound #10, and EPI-001, which target 
the AR-NTD, did not inhibit AR’s transcriptional activity in PC3-AR-FL-GFP cells at ≤50 µM 
(Figure 25E, F and Table 6). Finally, abiraterone acetate also didn’t inhibit reporter activity at ≤50 
µM (Figure 25G and Table 6). Abiraterone inhibits Cyp17a1’s ability to synthesize androgen, and 
since this assay is supplemented with 25 nM DHT, this compound does not affect AR’s ability to 
function in the cell. To control for the potential cytotoxicity of these compounds, growth inhibition 
assays were run for each compound, simultaneously, to determine whether a decrease in reporter 
based activity was due to a decrease in AR transcriptional activity or due to compound induced 
cell death. Under the conditions described above, validation compounds exhibited no apparent 
cytotoxicity in the PC3 cell line stably expressing pEGFP-AR-FL, indicating that any decrease in 
reporter signal was actually due to a compound’s ability to block DHT-induced AR transcriptional 
activity (Figure 25 and Table 6).   
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3.3.3  AR-LBD H3-DHT RadioligandBinding Assay 
3.3.3.1 Assay Principle 
 
The competitive radioligandbinding assay employs radiolabeled H3-DHT, a known ligand 
and agonist of AR. This assay specifically measures the displacement of H3-DHT from AR-LBD 
in the presence of increasing concentrations of each test compound. AR-LBD was cloned into a 
pET28a expression vector that bears a 6x histidine tag, and was further expressed and purified for 
use in the radioligand binding assay. Histidine tagged AR-LBD was added to the wells of 96-well 
copper coated plates (Pierce) overnight, where histidine chelates the Cu2+ coating of the plate’s 
surface. The next day, any unbound protein is washed away. Next, compound and 10 nM of the 
radiolabel, H3-DHT, is added to each well of the plate. If a compound can antagonize AR, it will 
compete with H3-DHT for binding. If a compound is not an AR-antagonist then H3-DHT will bind 
AR, unencumbered. After 1 hr of incubation, any unbound radiolabel and compound are washed 
away. If the compound was an antagonist, it will compete with and displace H3-DHT from binding 
AR, and result in low quantifiable β-emissions (counts per minute, CPMs) in the well. If the 
compound was not an antagonist, it will not have displaced H3-DHT from binding to AR, and there 
will be high CPMs in the well (Figure 26, on pg. 108). The H3-DHT radioligand binding assay was 
incorporated into our screening paradigm to identify and deprioritize hits from the HCS AR-TIF2 
biosensor assay that inhibited/disrupted AR-TIF2 PPIs through antagonism of the AR at its ligand 
binding domain (AR-LBD). Any compound with the ability to displace H3-DHT from binding to 
the AR-LBD was able to antagonize the receptor, and represented an undesirable compound 
profile. Any compound that did not antagonize the AR-LBD could be a direct PPI 
inhibitor/disruptor.  
 76 
3.3.3.2 Materials and Methods  
 
The pET28a expression vector containing a 6x Histidine-tagged AR-ligand binding domain 
(LBD) residues 622-919 (pET28a-His6-AR-LBD) was kindly provided by Dr. Fletterick and Dr. 
Nguyen of UCSF (Figure 27, on pg. 109). We purchased radioligand, H3-Dihydrotestosterone (H3-
DHT) from Perkin Elmer. Copper coated high capacity plates (96-well), were purchased from 
Pierce. We expressed and purified His6-AR-LBD for use in our assay development and validation 
experiments.  
Transformation and Expression of 6xHis-AR-LBD (622-919). OneShot BL21 (DE3) 
competent E. coli cells (Life Technology; C6060-10) were transformed with the pET28a-His6-AR-
LBD plasmid and streaked on kanamycin containing LB agar plates to select colonies for preparing 
bacterial glycerol stocks. The pET28a-His6-AR-LBD plasmid was isolated from transformed 
bacteria and sequenced to confirm the identity of the plasmid DNA. Bacteria transformed with 
pET28a-His6-AR-LBD were used to inoculate cultures that were incubated overnight at 37°C and 
then used to inoculate an expansion culture that was incubated at 37°C until it reached an OD of 
0.1 and was then supplemented with 50 μM DHT. Cultures were switched to 18°C and incubated 
until they reached an O.D. of 1.0–1.2, and then, His6-AR-LBD expression [118, 160] was induced 
by incubation with 200 μM IPTG for an additional 18–20 h at 16°C. Cells were pelleted by 
centrifugation for 20 min at 5,000 g at 4°C and stored frozen at −80°C.  
Purification Strategy for 6xHis-AR-LBD (622-919). Frozen cell pellets were thawed on ice, and 
they were suspended in “buffer A”: 50 mM HEPES pH of 7.65, 300 mM Li2SO4, 250 μM TCEP, 
10% glycerol, and 50 μM DHT containing protease inhibitors and lysozyme (0.1 mg/mL). After 
20–30 min of lysozyme treatment, cells were lysed by twelve, 30 s 30% amplitude bursts of a probe 
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sonicator (Fisher Scientific Model 505 Sonic Dismembrator), and they were then centrifuged at 
20,000 g for 30 min at 4°C; the supernatant was added to Ni2+-conjugated resin beads that had been 
pre-washed and equilibrated with “buffer A.” The resin was washed twice with approximately 
eight bed volumes of buffer A, then once with four bed volumes of buffer A supplemented with 
2 mM ATP and 10 mM MgCl2, and finally once again with four bed volumes of “buffer A.” The 
resin was then washed once with approximately four bed volumes of 20 mM imidazole in “buffer 
A,” and the His6-AR-LBD was eluted in four fractions of two bed volumes of 300 mM imidazole 
in “buffer A.” The protein concentrations in each elution fraction were determined in the BCA 
protein assay; the protein constituents were separated on 12% SDS-PAGE gels and transferred to 
nitrocellulose membranes; and western blots were probed with anti-AR and anti-His antibodies 
obtained from Santa Cruz Biotechnology (Figure 28, on pg. 110). The His6-AR-LBD containing 
fractions were pooled and then dialyzed in buffer containing 50 mM HEPES pH 7.65, 150 mM 
Li2SO4, 5% glycerol, 0.2 mM TCEP, and 20 μM DHT. The concentration of pooled, dialyzed 
protein concentration was determined in the BCA protein assay, and aliquots were stored at −80°C 
[118, 160]. 
H3-DHT Radioligand Binding Assay. The His6-AR-LBD H3-DHT competition binding assay 
was carried out in 96-well Cu2+-coated plates (ThermoFisher) that were incubated overnight at 4°C 
with 5 μg per well His6-AR-LBD in 100 μL of PBS. Unbound His6-AR-LBD was aspirated; the 
plate was washed 3 × with 100 μL of 0.05% Tween 20 in PBS and then blocked with 100 μL of 
1 mg/mL bovine serum albumin (BSA) in PBS for 1 h. After three more washes with 100 μL of 
PBS and 0.05% Tween 20, 40 μL of PBS were added to the wells, via a Matrix pipettor 
(ThermoFisher). Next 5 uL of compound was transferred to the wells also using the Matrix pipettor 
(ThermoFisher), followed by 5 μL of 100 nM H3-DHT. Compounds were tested in the assay 
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ranged from 0.0977 to 50 μM, at a 1:2 dilution for 10-assay points, in the presence of 10 nM H3-
DHT. After a 1 h co-incubation, compound and H3-DHT were aspirated and washed 3 × with 
0.05% Tween 20 in PBS; 100 μL of micro-scintillation cocktail buffer was added to each well; 
plates were sealed with adhesive plastic covers; and the counts per minute (CPMs) were captured 
in a TopCount NXT microtiter plate reader (Perkin Elmer). 
3.3.3.3 Assay Development and Optimization 
Determining the optimal amounts of His6-AR-LBD (622-919) protein to use in the 
RadioligandBinding Assay. To determine the optimal amount of protein to use in the 
radioligandbinding assay, we performed a protein titration with increasing amounts of His6-AR-
LBD (Figure 29A, on pg. 111). Increasing amounts of His6-AR-LBD (0-15 µg/well) were added 
to wells of 96-well Cu2+-coated plates, incubated overnight at 4°C, after which, unbound His6-AR-
LBD was aspirated. After blocking the plate with bovine serum albumin (BSA) and a series of 
washes, 10 nM H3-DHT was added to the wells. The protein amount selected for use in the H3-
DHT binding assay was 5 µg AR-LBD/well (Figure 29A).    
Determining the optimal amounts of H3-DHT to use in the radio-ligand binding assay. A H3-
DHT saturation binding assay was performed to measure total and non-specific binding of H3-
DHT to AR-LBD (622-919) protein (Figure 29B). Increasing concentrations (0-40 nM) of H3-
DHT were incubated in Cu2+-coated plates coated with 5 µg/well His6-AR-LBD. Signal (CPMs) 
increased with increasing concentrations of H3-DHT, until 5 nM, where it looked like the signal 
began to plateau. The maximal binding capacity (Bmax) was determined to be 3837, and 
dissociation constant (Kd) was 3.23 nM. 10 nM of H3-DHT was selected for use in the 
radioligandbinding assay (Figure 29B). This concentration was used for all subsequent radioligand 
binding experiments. 
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Competition Binding Assay. We then conducted competitive displacement binding experiments 
with unlabeled DHT, to confirm that this assay could identify drugs that can compete with and 
antagonize H3-DHT binding to the AR-LBD (Figure 29C). The displacement binding assay was 
run using a fixed amount of AR-LBD (5 ug/well) protein, and 10 nM of H3-DHT. Increasing 
concentrations of unlabeled DHT were added to the assay ranging from 0 µM to 10 µM, in a 10-
point 1:2 dilution series.  The assay signal (CPMs) decreased in a concentration dependent manner 
and exhibited an IC50 for displacement binding of 0.058 µM (Figure 29C).  
3.3.3.4 Test set performance in H3-DHT radioligandbinding assay 
When the AR-antagonists, flutamide, bicalutamide, and enzalutamide were run in the competitive 
radioligandbinding assay, all three of them were able to displace H3-DHT from binding to His6-
AR-LBD, as expected, exhibiting IC50 values of 48.6 ± 19.5, 5.53 ± 3.27, and 50.2 ± 14.4 µM, 
respectively (Figure 30B-D, on pg. 112 and Table 7, on pg. 113). Neither compound #10, nor EPI-
001 displaced H3-DHT binding to His6-AR-LBD at ≤ 50 µM (Figure 30E-H and Table 7).  Since 
these compounds target the amino-terminal domain of the receptor, they would not be expected to 
compete with H3-DHT binding to the AR-LBD. Similarly, neither 17-AAG nor abiraterone acetate 
displaced H3-DHT binding to His6-AR-LBD, likely because these compounds also do not bind the 
AR ligand binding pocket.  
3.3.1  ALPHAScreen AR-LBD::TIF2-LXXLL-Peptide Binding Assay 
3.3.1.1 Assay Principle 
The ALPHAScreen AR-LBD::LXXLL-peptide binding assay is a biochemical assay that measures 
the interaction of the AR AF-2 surface formed by His6-AR-LBD, and a peptide containing the 
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LXXLL motif located in box III of the TIF2  coactivator’s nuclear interaction domain (NID) 
(Figure 31, on pg. 114). A literature search indicated that LXXLL motifs from box III of the NID 
were most important for TIF2’s interaction with the AR AF-2 surface, and it was therefore selected 
for use in the development of the ALPHAScreen assay [91, 93, 161, 162]. The ALPHAScreen is 
a homogenous mix and read assay that uses coated acceptor and donor beads to bind tagged 
proteins. In our assay, histidine-tagged AR-LBD protein chelates to Ni2+ coated acceptor beads, 
and the TIF2 Box III LXXLL motif peptide conjugated to biotin binds to streptavidin donor beads. 
Binding between the two interacting partners leads to close proximity between the donor and 
acceptor beads. Upon laser excitation of the donor bead, a singlet oxygen species is released and 
reacts with thioxene derivatives found within the acceptor bead, located within a distance of 200 
nm relative to the donor bead, which creates energy that when transferred to fluorophores within 
the bead, can be quantified via light emission at a wavelength of 520-620 nm [163] (Figure 31). 
This assay is performed by incubating Ni2+ coated acceptor beads with AR-LBD and 10 µM of 
DHT prior to mixing them with compound plus streptavidin bound TIF2 peptide donor beads. The 
pre-incubation of the acceptor beads allows for the DHT-induced formation of the AF-2 coactivator 
binding surface. Development and optimization of the ALPHAScreen included cross-titrating both 
the His6-AR-LBD protein and biotinylated-TIF2-box-III peptide to select the optimal amounts to 
use in the assay. The ALPHAScreen AR-LBD::TIF2-LXXLL-peptide binding assay was validated 
in competitive displacement binding experiments with  increasing amounts of unlabeled TIF2-III-
LXXLL peptide, and used to prioritize the hits identified in the 143K AR-TIF2 PPIB screen. The 
ALPHAScreen assay allowed us to determine whether AR-TIF2 PPI inhibitor or disruptor hits 
were capable of blocking the direct binding interactions between the LXXLL motifs of the TIF2 
NR box III peptide and His6-AR-LBD.   
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3.3.1.2 Materials and Methods 
The pET28a-AR-LBD (622-919) construct was a gift from Dr. Fletterick and Dr. Nguyen of 
UCSF, and its expression and purification were described earlier in this chapter. Both biotinylated-
TIF2-box-III (738-756), and Non-biotinylated TIF2-box-III (738-756) were synthesized by the 
Peptide & Peptoid Synthesis Facility, at the University of Pittsburgh Health Sciences Core 
Research Facilities (Table 8, on pg. 115). The ALPHAScreen Kit, which consisted of streptavidin 
donor beads and nickel chelate (Ni-NTA) acceptor beads, was purchased from Perkin Elmer.  
ALPHAScreen Assay. Validation compounds were run in this assay at a 0.0977 to 50 µM 
concentration range, at a 1:2 dilution, to generate a 10-point response curve. The assay validation 
was carried out in 384-well, white opaque plates. 150 nM of biotinylated TIF2-box III was 
incubated with streptavidin donor beads for 30 min at room temperature, in the dark. 18 uL of the 
streptavidin immobilized biotinylated TIF2 peptide mixture was added to the plate. A fixed amount 
of His6-AR-LBD (400ng/well), was incubated with 10 µM DHT, and Ni2+ chelate acceptor beads 
for 30 min at room temperature in the dark. 27 µL of this mixture was added to the plate. 32 wells 
of 0.5% DMSO controls were used as a maximum control, and 32 wells of 500x excess unlabeled 
TIF2-box-III (75 µM) were used as a minimum control. The bead-protein mixtures were then 
combined and incubated for 1 h at room temperature, in the dark, and after, read on an Envision 
plate reader (Perkin Elmer). 
3.3.1.3 Assay Development and Optimization 
Determining the optimal amounts of His6-AR-LBD (622-919) protein to use in the 
ALPHAScreen assay. To determine the amount of protein to use in the ALPHAScreen assay, we 
performed a protein titration with His6-AR-LBD (Figure 32A, on pg. 116). The amount of biotin-
TIF2-LXXLL-peptide in the assay was fixed at 100 nM. Increasing amounts of His6-AR-LBD (0-
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2 µg/well) were incubated with DHT, and Ni2+ coated acceptor beads for 30 min, before being 
mixed with streptavidin bound TIF2 donor beads in the plate. The ALPHASignal (CPMs) 
increased with increasing amounts of His6-AR-LBD, up until 1 ug of protein/well was reached, 
after which the signal did not increase further (Figure 32A). The final amount of His6-AR-LBD 
protein selected for the optimized ALPHAScreen assay was 400 ng/well, as this was the lowest 
protein amount that we could use that produced the highest signal.  
Determining the optimal amounts of Biotinylated-TIF2-box-III (738-756) Peptide to use in 
the ALPHAScreen assay. Biotinylated-TIF2-box-III titration experiments were performed to 
select for the optimal concentration of peptide to use in the ALPHAScreen assay (Figure 32B). 
Increasing concentrations of biotinylated TIF2-box III (0-200 nM) were incubated with 
streptavidin donor beads for 30 min before being mixed with DHT bound His6x-AR-LBD (0.4 
μg/well) chelated by Ni2+ acceptor beads. The ALPHASignal (CPMs) increased with increasing 
concentrations of TIF2-LXXLL-peptide, up to around  100 nM, after which  it appeared to plateau. 
The apparent Kd for TIF2 peptide binding to His6-AR-LBD was 151.3 nM, and the Bmax was 
projected at 42880 (Figure 32B). The final concentration of TIF2 peptide selected for the optimized 
ALPHAScreen assay was 150 nM.  
Conducting Competition/Displacement Binding Assays using Non-biotinylated TIF2-box-III 
(738-756). We then conducted competitive displacement binding experiments with unlabeled 
TIF2-III-LXXLL to confirm that this assay would identify AR AF-2::TIF2-LXXLL inhibitors 
(Figure 32C). Using the optimized ALPHAScreen assay conditions of biotinylated-TIF2-box III 
(150 nM/well)  streptavidin donor beads plus  His6-AR-LBD (400 ng/well) Ni2+ chelate acceptor 
beads in the presence of DHT, the addition of non-biotinylated TIF2-LXXLL-peptide decreased  
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the ALPHASignal (CPMs) in a concentration dependent manner and exhibited an IC50 for 
displacement binding of 2.76 nM (Figure 32C).  
3.3.1.4 Test Set Performance in ALPHAScreen Assay 
Only the Hsp90 inhibitor 17-AAG, and to a small extent the anti-androgen flutamide, inhibited the AR AF-
2 interaction with TIF2 Box III LXXLL motif peptide (Figure 33B-H, on pg. 117 and Table 9, on pg. 
118). Pre-incubating Ni2+ coated acceptor beads with AR-LBD and DHT prior to mixing with 
compound plus streptavidin bound TIF2-LXXLL peptide, allows the AF-2 coactivator binding 
surface to form. Anti-androgens bind the ligand binding pocket of the AR, which is composed of 
polar amino acids that are able to establish hydrogen bonds with the polar substituents of these 
compounds [164], however they should have no effect on direct AF-2::coactivator interactions. 
Neither Compound #10 nor EPI-001 inhibited AR AF-2 interactions with TIF2, which is justifiable 
as both compounds target the amino-terminus of the AR (Figure 33E-F, and Table 9). Abiraterone 
Acetate, a compound that inhibits the enzyme Cyp17a1, was also inactive in the ALPHAScreen, 
which makes sense, because this compound doesn’t directly interact with the AR-LBD. 
Surprisingly, the Hsp 90 Inhibitor, 17-AAG exhibited an IC50 value of 29.8 ± 9.78 μM in this assay 
(Figure 33G and Table 9).  17-AAG is a compound that inhibits the ATPase activity of the 
chaperone protein Hsp90. Since, His6-AR-LBD is a protein expressed and purified from E. coli 
cells, it’s possible that 17-AAG may disrupt AR’s interaction with bacterial chaperone proteins, 
which may prevent the AF-2 coactivator binding surface from folding correctly and binding the 
TIF2-LXXLL-peptide.   
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3.3.2  Growth Inhibition Assays 
3.3.2.1 Assay Principle 
We would anticipate that AR-TIF2 PPI inhibitors/disruptors would be more effective at inhibiting 
the growth of PCa cell lines that express AR compared with those that do not express AR. To test 
this hypothesis, we implemented CTG growth inhibition assays in five PCa cell lines: the LNCaP, 
C4-2, and 22Rv1 PCa cell lines express AR, while the PC3 and DU-145 cell lines are AR null. 
The development of CTG based growth inhibition assays has been described in one our previous 
publications [118]. 
3.3.2.2 Materials/Reagents 
Growth Inhibition Assay. The PCa cell line growth inhibition assays were developed and 
optimized using methods that were previously applied in other tumor cell lines [118]. On day 1, 
each PCa cell line was harvested, counted, and seeded into 384-well assay plates: PC3, DU-145, 
LNCaP, C4-2, and 22Rv1 cells were seeded at 1,000 cells per well in 45 μL of tissue culture media 
into uncoated, white, clear-bottom 384-well assay plates (VWR Cat. No. 82050-076) by using a 
Matrix electronic multichannel pipette (ThermoFisher) and cultured overnight at 37°C, 5% CO2, 
and 95% humidity. On day 2, 5 μL of compounds diluted in SFM was transferred into the test wells 
of the 384-well assay plates on the Janus MDT automated liquid handler equipped with a 384-well 
transfer head and the compound-treated assay plates were cultured for an additional 72 h in an 
incubator at 37°C, 5% CO2, and 95% humidity. Control wells received DMSO alone. On day 5, 
25 μL of the CTG detection reagent was dispensed into the wells of the assay plates by using a 
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Matrix electronic multichannel pipette, and the luminescence signal was captured on the 
SpectraMax M5e microtiter plate reader platform. 
3.3.2.3 Test Set Performance in Growth Inhibition Assays 
We anticipated that the AR-antagonists might selectively inhibit the growth AR-positive PCa cell 
lines. However, flutamide was equipotent against all 5 cell lines with IC50s in the 10-20 µM range, 
bicalutamide only inhibited PCa cell growth at concentrations greater >100 µM, and enzalutamide 
only inhibited growth at concentrations greater than 200 µM (Figure 34B-D, on pg. 119 and Table 
10, on pg. 120).  Strangely enough, compound #10 and EPI-001, did appear to preferentially inhibit 
growth of cell lines that were AR-positive over cell lines that were AR-negative. Compound #10 
exhibited IC50s of 17.6 ± 7.8, 14.5 ± 0.58, and 19.4 ± 4.63 µM, for LNCaP, C4-2, and 22Rv1’s, 
respectively, and IC50s of 40.8 ± 0.60 and >50 for PC3 and DU-145’s, respectively. EPI-001 
exhibited IC50s of 33.0 ± 5.97, 38.6 ± 3.25, and 41.2 ± 1.30, for LNCaP, C4-2, and 22Rv1’s, 
respectively, and IC50s of >50 for both PC3 and DU-145’s (Figure 34 and Table 10). This may be 
due to the fact that AR-null, androgen-independent cells, PC3’s, and DU-145’s are more resistant 
to cell death than AR-containing, androgen-dependent lines, LNCaP, C4-2, and 22Rv1’s [165]. 
17-AAG, and Abiraterone acetate inhibited the growth of all PCa cell lines, but not in an AR-
selective manner (Figure 34G, H and Table 10).  
3.3.3  Conclusions 
We have successfully developed and tested 5 different characterization assays that will allow us 
to prioritize hit compounds that inhibit the formation of or disrupt pre-existing PPI’s between the 
AR AF-2 surface and TIF2.  The M2H assays provide an orthogonal assay that will allow us to 
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confirm that the AR-TIF2 PPIB hits block AR-coactivator interactions and to evaluate the 
selectivity for TIF2 versus the related SRC1 p160 family member. The PSA6.1 reporter assay in 
PC3 cells stably expressing AR-FL will allow us to confirm that our AR-TIF2 PPI 
inhibitor/disruptor hits block AR mediated transcriptional activity. The His6-AR-LBD H3-DHT 
ligand binding assay will help us to distinguish between compounds that are PPI inhibitors and 
those that are AR antagonists. The AR-LBD-TIF2-LXXLL-peptide binding assay will enable us 
to determine whether AR-TIF2 PPI hits are blocking the direct binding interactions between the 
LXXLL motifs of the TIF2 NR box III peptide and AF-2 surface of the AR-LBD.  Since we 
anticipate that AR-TIF2 PPI inhibitors/disruptors would be more effective at inhibiting the growth 
of PCa cell lines that express AR compared to those that do not, our PCa growth inhibition assays 
will allow us to identify and prioritize such compounds. We are looking for hit compounds with 
the following bioactivity profile: active in the primary AR-TIF2 biosensor assay, can disrupt AR-
TIF2 PPIs in the mammalian 2-hybrid and AR-LBD-TIF2-LXXLL peptide binding assays, inhibit 
AR transcriptional activation, do not antagonize AR ligand binding, and selectively inhibit the 
growth of AR-positive cell lines. Hit compounds that fit this profile will be prioritized for lead 
optimization and further development as a therapeutic candidate for CRPC.   
Of the 7 test compounds run in our characterization assays, only 4 of them were able to inhibit 
AR-TIF2 PPI’s in the biosensor. These were AR-antagonists flutamide, bicalutamide, and 
enzalutamide, and Hsp90 inhibitor, 17-AAG. Although all 4 compounds were able to inhibit both 
TIF2/SRC1 recruitment to the AR-LBD in M2H assays, and DHT-induced PSA6.1-Luc reporter 
activity in PC3-AR-FL-GFP cells, all 3 antagonists were active in the H3-DHT radioligandbinding 
assays, as expected. Furthermore, none of the AR-antagonists were able to inhibit PPI’s in the 
ALPHAScreen assay at <50 μM, and none of them were able to selectively inhibit AR-positive 
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cell lines. As they don’t fit the bioactivity profile of an AR-TIF2 PPI inhibitor, we wouldn’t 
prioritize them. 17-AAG on the other hand did fit the bioactivity profile we were looking for. 
However, based on this compound’s mechanism of action, we know that this compound may be 
acting to inhibit AR’s function in these assays by preventing Hsp90’s ability to maintain AR in a 
high-affinity conformation for ligand binding, thereby prevent ligand-induced AR nuclear 
translocation and AF-2 surface formation. Therefore we would not prioritize any of them for lead 
optimization and development.  
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Figure 11. Chemical structures of the test set for the hits characterization assays  
Presented here are the chemical structures of compounds in the test set that we used to run in our hit 
characterization assays. These compounds include FDA approved therapeutics and experimental drugs for 
the treatment of PCa. Flutamide, bicalutamide, and enzalutamide are AR-antagonists that are prescribed as 
components of an androgen deprivation therapy (ADT) strategy. Similarly, the Cyp17a1 inhibitor 
abiraterone acetate that prevents androgen synthesis is also used as a component of ADT. Compounds #10 
and EPI-001 target the amino-terminus of AR rather than the ligand binding site, and 17-AAG is an inhibitor 
of the Hsp90 chaperone involved in the folding, maturation and maintenance of AR in a high affinity ligand 
binding conformation. 
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Figure 12. Inhibition of the AR-TIF2 Biosensor assay to measure DHT-induced AR-LBD interactions with 
TIF2 by test compounds 
U2-OS cells were co-infected with AR-RFP and TIF2-GFP rAV biosensors, and 3,000 cells were seeded 
into the wells of 384-well assay plates, and cultured overnight at 37°C, 5% CO2, and 95% humidity. 
After 24 h test compound and DHT were added to cells in two different formats. In format 1 (C then D), 
AR-TIF2 co-infected U2-OS cells were exposed to 3 hr of compound before treatment with 25 nM DHT 
for 90 min. In format 2 (D then C), AR-TIF2 co-infected U-2 OS cells were exposed to 25 nM of DHT 
for 90 min before treatment with the indicated concentrations of compounds for 3 hr. The AR-TIF2 data 
for compound treated wells were normalized to maximum (25 nM DHT + 0.5% DMSO, n=32) and 
minimum (0.5% DMSO, n=32) plate controls, and the % inhibition was plotted as the mean +/- SD (n = 
3) values from triplicate wells for each compound concentration plotted on the left Y-axis. The 
corresponding cell viability data for compound treated wells were normalized to 25 nM DHT + 0.5% 
DMSO control wells (n=32), and the % cell viability () was plotted as the mean +/- SD (n = 3). A) 
Representative plate control data for C then D () and D then C () AR-TIF2 biosensor formats are 
plotted on the left and right Y axis respectively. The concentration dependent normalized % inhibition of 
the C then D and D then C biosensor formats (left Y-axis) and cell viability data (right Y-axis) for B) 
Flutamide, C) Bicalutamide, D) Enzalutamide, E) Compound #10, F) EPI-001, G) 17-AAG, and H) 
Abiraterone acetate are presented. Representative experimental data from one of two independent 
experiments are shown.  
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Table 2. IC50 results of the test set run in the AR-TIF2 Biosensor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay  
AR-TIF2 Biosensor 
C then D D then C 
Mean IC50 (µM) sdm Mean IC50 (µM) sdm 
Flutamide 8.77 1.59 20.6 4.46 
Bicalutamide 2.49 0.20 4.01 1.37 
Enzalutamide 1.44 0.16 2.71 0.27 
Compound #10 >50 N/A >50 N/A 
EPI-001 >50 N/A >50 N/A 
17-AAG 0.20 0.02 0.39 0.01 
Abiraterone Acetate >50 N/A >50 N/A 
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Figure 13. Mammalian 2-Hybrid assay principle 
The mammalian 2-hybrid assay we developed involves the transfection of three main components 
including Gal4-AR-LBD, VP16-coactivator, and the 5xGal4-TATA-Luc reporter. Ligand binding to the 
nuclear receptor-Gal4 fusion protein directs it to bind to the DNA-binding response sequences in the 
5xGal4-TATA-Luc reporter plasmid, while ligand-induced binding interactions between the nuclear 
receptor and the co-activator-VP16 fusion protein recruits the transcriptional machinery of the cell, 
leading to overall transcription of the luciferase gene. This reporter activity is an indirect measure of 
nuclear receptor::co-activator protein interactions in the cell. We have developed this assay in two 
different co-activator formats using the AR-LBD-Gal4 fusion protein; A) One involves the TIF2/SRC2 
p160 coactivator cloned into the VP16 mammalian construct, and B) involves homologous SRC1 p160 
coactivator cloned into VP16 vector.   
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Table 3. PCR primer sequence for amplification and cloning of full-length TIF2 into pVP16 vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pVP16-TIF2 construct was created via the traditional ligation-dependent method. The full-length 
TIF2 insert was amplified from pCR-BluntII-TOPO-NCoA2 (TIF2) containing the wild type cDNA of 
the human TIF2 coactivator. The primers for the PCR were designed with the addition of EcoRI and 
BamHI cloning sites at the 5’ and 3’ flaking regions, respectively (ThermoFisher Scientific). The TIF2 
insert, and the VP16 vector were double digested with EcoRI and BamHI enzymes, and then insert and 
vector were ligated.  
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Table 4. Primers for sequence confirmation of pVP16-TIF2 
 
 
 
 
 
 
 
 
 
 
 
 
After cloning TIF2 into the pVP16 vector, transforming ligation product into DH5α cells, and plating 
DH5α cells on ampicillin containing LB agar plates, colonies were selected and expanded. DNA from 
expanded colonies was isolated so that individual colonies could be analyzed via restriction analysis. 
Clones with bands at the correct molecular size were sent for sequencing to confirm the correct cloned 
construct, using the sequencing primers listed above.  
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Figure 14. Western blot confirmation of pVP16-coactivator constructs 
Coactivators, pVP16-TIF2 and pVP16-SRC1 were transfected into HEK 293 cells and allowed to express 
their respective fusion proteins for 48 hrs. Forty-eight hours post transfection, cells were lysed, and the 
BCA protein detection regent was used to determine protein amount and concentration in transfected cell 
lysates. An SDS-PAGE gel was then run for protein separation, where 25 μg of protein from each lysate 
was added to different lanes of the gel. Protein was transferred to nitrocellulose membranes, and the 
resulting western blots were then probed with either anti-TIF2 or anti-SRC1 antibodies. HEK 293 cells 
endogenously express TIF2 and SRC1 coactivators, which are evident in non-transfected HEK 293 
lysates. A second band in pVP16-TIF2 and pVP16-SRC1 transfected HEK 293 cells is evident in 
transfected cell lysates, at a higher molecular weight due to the fusion with VP16.  
 
 
 
 
 
 
 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Determining which cell background enables the most robust mammalian 2-hybrid assay 
The mammalian 2-hybrid assay was conducted in 3 different cell lines co-transfected with the 
pGal4-AR-LBD, pVP16-TIF2, and 5xGal4-TATA-Luc reporter, to see how the luciferase reporter 
luminescence signal behaved in each cell line. PC3 cells were chosen because they are an AR-null 
prostate cancer cell line, and both HeLa cells and HEK 293 cells were chosen because they have 
been historically used in mammalian 2-hybrid assays. Cell were transiently co-transfected with the 
three plasmids using the FuGene transfection reagent, and 5,000 cells were seeded into the wells 
of 384-well assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h 
cells were exposed to 100 nM DHT and the assay plate was returned to the incubator for an 
additional 24 h before BrightGlo reagent was added to the plate and the RLUs were captured on a 
SpectraMax M5e microtiter plate reader. Luminescence RLU’s were plotted in the presence or 
absence of DHT for the three cell lines. The data are presented as the mean ± SD of triplicate wells 
per cell line ± DHT treatment, and representative data from one of 2 independent experiments are 
shown. 
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Figure 16. Mammalian 2-Hybrid assay development and optimization 
To determine the appropriate amounts of pGal4-AR-LBD and pVP16-TIF2 or pVP16-SRC1 to use in the 
mammalian 2-hybrid assay, cross-titration co-transfection experiments were performed in HEK293 cells. 
Interacting partners, pGAL4-AR-LBD with pVP16-TIF2 or pVP16-SRC1, plus the reporter construct 
5xGal4-TATA-Luc, were transiently co-transfected into HEK293 cells using the FuGene6 transfection 
reagent, and 5,000 cells were seeded into the wells of 384-well assay plates and cultured overnight at 
37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to 100 nM DHT and the assay plate 
was returned to the incubator for an additional 24 h before BrightGlo reagent was added to the plate and 
the RLUs were captured on a SpectraMax M5e microtiter plate reader. Luminescence RLU’s were plotted 
in the presence or absence of DHT for varying amounts of pGAL4-AR-LBD with pVP16-TIF2 or pVP16-
SRC1. The data are presented as the mean ± SD of triplicate wells per plasmid DNA combination.  
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Figure 17. Concentration Responses of the mammalian 2-hybrid assays to measure DHT-induced AR-LBD 
interactions with the A) TIF2 or B) SRC1 Coactivators 
DHT concentration response assays were conducted in HEK293 cells co-transfected with the pGal4-AR-
LBD plasmid and either A) the pVP16-TIF2 or B) the pVP16-SRC1 coactivator constructs. HEK293 cells 
were transiently co-transfected with the appropriate plasmids using the FuGene transfection reagent, and 
5,000 cells were seeded into the wells of 384-well assay plates and cultured overnight at 37°C, 5% CO2, 
and 95% humidity. After 24 h cells were exposed to the indicated concentrations of DHT and the assay 
plate was returned to the incubator for an additional 24 h before BrightGlo reagent was added to the plate 
and the RLUs were captured on a SpectraMax M5e microtiter plate reader. The data are presented as the 
mean ± SD of triplicate wells per DHT concentration, and representative data from one of 3 independent 
experiments are shown. DHT exhibited EC50s of 1.45 +/- 1.29 nM and 1.12 +/- 0.845 nM for the TIF2 and 
SRC1 M2H formats, respectively. 
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Figure 18. Mammalian 2-hybrid assay development and optimization: DMSO tolerance for HEK 293 cells 
transfected with pGal4-AR-LBD/pVP16-TIF2 and pGal4-AR-LBD/pVP16-SRC1 
To determine the % DMSO that the M2H assay can tolerate, a DMSO concentration response was 
conducted in HEK293 cells. These cells were transiently co-transfected with the appropriate plasmids 
using the FuGene transfection reagent, and 5,000 cells were seeded into the wells of 384-well assay plates 
and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to the 
indicated concentrations of DMSO and the assay plate was returned to the incubator for an additional 24 h 
before BrightGlo reagent was added to the plate and the RLUs were captured on a SpectraMax M5e 
microtiter plate reader. The data are presented as the mean ± SD of duplicate wells per DMSO 
concentration. TIF2 () and SRC1 () M2H formats are plotted on the left and right Y axis respectively. 
DMSO exhibited IC50s of 1.97% and 1.16% for the TIF2 and SRC1 M2H formats respectively.  
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Figure 19. Inhibition of the mammalian 2-hybrid assays to measure DHT-induced AR-LBD interactions with 
TIF2 or SRC1 coactivators by test compounds 
HEK293 cells were transfected with three M2H plasmid constructs, pGAL4-AR-LBD plus 5xGal4-
TATA-Luc with either pVP16-TIF2 or pVP16-SRC1, and 5,000 cells were seeded into the wells of 384-
well assay plates, and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were 
exposed to test compounds at the indicated concentrations for 3 h before overnight exposure to 25 nM 
DHT. The assay plate was returned to the incubator for an additional 24 h before BrightGlo reagent was 
added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. The M2H 
RLU’s data for compound treated wells were normalized to maximum (25 nM DHT + 0.5% DMSO, 
n=32) and minimum (0.5% DMSO, n=32) plate controls, and the % inhibition was plotted as the mean +/- 
SD (n = 3) values from triplicate wells for each compound concentration plotted on the left Y-axis. The 
corresponding cell viability data for compound treated wells were normalized to 0.5% DMSO control 
wells (n=64), and the % cell viability () was plotted as the mean +/- SD (n = 3) values from triplicate 
wells for each compound concentration plotted on the right Y-axis. A) Representative plate control data 
for the TIF2 () and SRC1 () M2H formats are plotted on the left and right Y axis respectively. The 
concentration dependent normalized % inhibition of the TIF2 and SRC1 M2H formats (left Y-axis) and 
cell viability data (right Y-axis) for B) Flutamide, C) Bicalutamide, D) Enzalutamide, E) Compound #10, 
F) EPI-001, G) 17-AAG, and H) Abiraterone acetate are presented. Representative experimental data 
from one of two independent experiments are shown.  
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Table 5. IC50 results of test set run in mammalian 2-hybrid assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay  
Mammalian 2-Hybrid 
Gal4-AR-LBD::VP16-TIF2 Gal4-AR-LBD::VP16-SRC1 
HEK 293 Growth 
Inhibition 
Mean IC50 (µM) sdm Mean IC50 (µM) sdm Mean IC50 (µM) 
sdm 
Flutamide 3.01 0.75 2.53 0.66 >50 N/A 
Bicalutamide 2.01 0.99 1.49 0.69 >50 N/A 
Enzalutamide 2.36 1.44 1.37 0.91 >50 N/A 
Compound #10 2.32 0.91 1.99 0.19 26.5 10.9 
EPI-001 9.15 2.47 8.15 1.27 36.6 9.3 
17-AAG 0.33 0.02 0.45 0.08 >50 N/A 
Abiraterone Acetate 4.47 1.96 2.43 0.64 30.5 7.72 
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Figure 20. PSA6.1-luciferase reporter assay principle 
The PSA reporter assay uses a promoter region from the prostate specific antigen gene, which is a target 
gene of AR, and a biomarker of PCa progression. The PSA promoter region is fused to a gene that codes 
for luciferase. If AR and TIF2 are bound to responsive elements on the promoter region of the PSA gene, 
this will lead to recruitment of the cell’s transcriptional machinery, and ultimately, the transcription of 
luciferase enzyme, which will convert luciferin reagent into light output that can be quantified. If a 
compound run in this assay can disrupt the interaction between AR and TIF2, this should decrease 
reporter activity. 
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Figure 21. Endogenous expression of TIF2 and AR in 5 PCa cell lines  
To determine which of the 5 PCa cell lines to use for developing the stably transfected GFP-AR-FL line, 
we characterized the endogenous expression levels of AR and coactivator TIF2, in 5 PCa cell lines we had 
in-house. 20 µg of protein was added from each lysate, to each well of the SDS-PAGE gel. After the gel 
was run for protein separation, it was transferred to a nitrocellulose membrane. The membrane was then 
probed with α-TIF2 and α-AR rabbit polyclonal antibodies, as well as α-GAPDH antibody used as a loading 
control. 
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Figure 22. IXM images of PC3 cells stably transfected with pEGFP-C1-AR in the presence or absence of DHT 
DHT response assays were conducted in PC3 cells stably transfected with pEGFP-C1-AR-FL plasmid 
construct. PC3 cells were seeded at a density of 3,000 cells/well into 384-well assay plates and cultured 
overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to the indicated 
concentrations of DHT for 24 before being fixed, and imaged on an IXU automated HCS platform 
(Molecular Devices LLC).These are representative images of PC3 cells stably transfected with the 
pEGFP-C1-AR plasmid construct. In untreated cells, AR-FL’s distribution is predominantly in the 
cytoplasm. When these cells are treated with DHT, AR-FL is predominantly nuclear.  
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Figure 23. Nuclear Translocation of AR-FL-GFP in PC3 cells exposed to increasing concentrations of DHT 
DHT concentration response assays were conducted in PC3 cells stably transfected with pEGFP-C1-AR-
FL plasmid construct. PC3 cells were seeded at a density of 3,000 cells/well into 384-well assay plates and 
cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to the indicated 
concentrations of DHT for 24 before being fixed and imaged on an IXU automated HCS platform 
(Molecular Devices LLC). Images were then analyzed with the TE image analysis module of the 
MetaXpress software (Molecular Devices LLC).  The data are presented as the mean ± SD of triplicate 
wells per DHT concentration, and representative data from one of 2 independent experiments are shown. 
DHT exhibited EC50 of 1.23 +/- 0.131 nM. 
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Figure 24. Concentration responses of the PSA6.1-Luc reporter assay to measure DHT-induced transcriptional 
activity of AR-FL-GFP in PC3 cells 
DHT concentration response assays were conducted in PC3 cells stably transfected with pEGFP-
C1-AR-FL plasmid and transiently transfected with the PSA6.1-LUC reporter construct. PC3 cells 
were transiently transfected with the appropriate plasmids using the FuGeneHD transfection 
reagent, and 3,000 cells were seeded into the wells of 384-well assay plates and cultured overnight 
at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to the indicated concentrations 
of DHT and the assay plate was returned to the incubator for either 30 min, 90 min, or 24 h before 
BrightGlo reagent was added to the plate and the RLUs were captured on a SpectraMax M5e 
microtiter plate reader. The data are presented as the mean ± SD of triplicate wells per DHT 
concentration, and representative data from one of 2 independent experiments are shown. DHT 
exhibited EC50 of 0.280 +/- 0.033 nM at 24 hrs DHT exposure. 
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Figure 25. Test set performance in PSA6.1-Luc reporter assay 
A DHT-induced PSA6.1-LUC reporter based assay was conducted with 7 test compounds. PC3-AR-FL-
GFP cell lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC plasmid 
DNA (20 ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally incubated 
overnight at 5% CO2, 95% humidity, and 37°C. PC3-AR-FL-GFP cells transfected with the PSA-6.1-LUC 
plasmid were exposed to the indicated concentrations of compounds for 3 h and were then treated with 25 
nM DHT. The assay plate was returned to the incubator for an additional 24 h before BrightGlo reagent 
was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. The 
PSA6.1-LUC RLU’s data for compound treated wells were normalized to maximum (25 nM DHT + 0.5% 
DMSO, n=32) and minimum (0.5% DMSO, n=32) plate controls, and the % inhibition was plotted as the 
mean +/- SD (n=3) values from triplicate wells for each compound concentration plotted on the left Y-axis. 
The corresponding cell viability data for compound treated wells were normalized to 25 nM DHT + 0.5% 
DMSO control wells (n=32), and the % cell viability () was plotted as the mean +/- SD (n = 3) plotted 
on the right Y-axis. A) Representative plate control data for one run is plotted. The concentration dependent 
normalized % inhibition of the DHT-induced PSA6.1-LUC reporter activity for B) Flutamide, C) 
Bicalutamide, D) Enzalutamide, E) Compound #10, F) EPI-001, G) 17-AAG, and H) Abiraterone acetate 
are presented. Representative experimental data from one of two independent experiments are shown.  
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Table 6. IC50 results of test set run in the PSA6.1-Luc reporter based assay 
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Figure 26. Radio ligand binding assay principle 
The competitive radio ligand binding assay we developed employs histidine tagged AR-LBD, and 
radiolabel H3-DHT, a known ligand and agonist of our target. His6-AR-LBD chelates to the Cu2+ coated 
plate surface, and then any unbound AR protein is washed away, after which 10 nM of the radiolabel and 
compound, is added to each well. After an hour incubation, any displaced radiolabel or compound is 
washed away. Columns 1 and 12 represent maximum and minimum controls, containing either the 
addition of 5% DMSO, or cold DHT, respectively. This assay specifically measures the displacement of 
H3-DHT from AR-LBD in the presence of increasing concentrations of each test compound, thereby 
identifying any compound acting as an AR-antagonist.  
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Figure 27. pET28a-His6-AR-LBD construct 
The pET28a-His6-AR-LBD (622-919) construct was kindly provided by Dr. Fletterick and Dr. Ngyuen 
from the University of California, San Francisco. This construct was designed by cloning amino acids 
622-919 of the androgen receptor, which encodes the ligand binding domain of the receptor, into a pET28 
bacterial expression vector. The pET28 bacterial expression vector bears a 6x histidine tag, which allows 
for the fusion of this tag to the AR.  
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Figure 28. pET28a-His6-AR-LBD  
Fractions collected from the Ni2+ - based affinity column were eluted with 300 mM Imidazole and were 
separated on 12% SDS-PAGE gels. Coomassie blue stained bands with the correct AR-LBD protein 
molecular weight (37 kDa) were further confirmed on western blots probed with α-His and α-AR, 
antibodies.  
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Figure 29. H3-DHT radio ligand binding assay development 
To determine the appropriate amounts of His6-AR-LBD to use in the radio ligand binding assay, we 
performed a protein titration by adding increasing amounts of His6-AR-LBD to 96-well Cu2+-coated plates. 
Any unbound His6-AR-LBD was aspirated from wells before blocking the plates with BSA before the 
addition of H3-DHT. The amount of H3-DHT used in the assay remained fixed at 10 nM. After 10 nM of   
H3-DHT was incubated for 1 hr, it was removed via aspiration. Next, scintillation buffer was added, and 
plates were sealed and read in a beta plate counter. CPM’s were then plotted and representative 
experimental data from one of three independent experiments are shown. To determine the appropriate 
amounts of H3-DHT to use in the radio ligand binding assay, saturation binding experiments were 
performed. Increasing amounts of H3-DHT were bound to His6-AR-LBD (5ug/well), and incubated for 1 
hr before it was removed via aspiration. Once scintillation buffer was added, plates were sealed and read in 
a beta plate counter. CPM’s were then plotted and representative experimental data from one of three 
independent experiments are shown. Finally, a displacement binding experiment was run by incubating 10 
nM H3-DHT together with increasing concentration of cold-DHT to compete for binding at the His6-AR-
LBD. Again, scintillation buffer was added, plates were sealed and read in a beta plate counter. CPM’s 
were then plotted and representative experimental data from one of three independent experiments are 
shown. 
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Figure 30. Test set performance in H3-DHT radio ligand binding assay  
Competitive displacement binding of H3-DHT to His6-AR-LBD run with the seven compounds in our test 
set. Five micrograms of His6-AR-LBD protein was added to the wells of 96-well copper-coated plates and 
allowed to bind overnight at 4°C. Unbound protein was removed by aspiration; the plate was washed 3x 
with PBS-Tween 20 buffer and blocked for 1 h with 1 mg/mL BSA in PBS-Tween 20. After 3x washes 
with PBS-Tween 20 buffer, 10 nM H3-DHT was added to the wells of the plate in the presence or absence 
of the indicated concentrations of validation compounds and incubated at RT for 1 h. Unbound H3-DHT 
was removed by aspiration and washing, and micro-scintillation reagent was added to the wells, and the 
CPMs were captured on a TopCount NXT microtiter β-counter. β-emission RLU’s data for compound 
treated wells were normalized to maximum (0.5% DMSO, n=8) and minimum (10 µM cold DHT, n=8) 
plate controls, and the % inhibition was plotted as the mean +/- SD (n=3) values from duplicate wells for 
each compound concentration. A) Representative plate control data for Run 1 and Run 2 is plotted. The 
concentration dependent normalized % inhibition of the H3-DHT bound to His6-AR-LBD for B) Flutamide, 
C) Bicalutamide, D) Enzalutamide, E) Compound #10, F) EPI-001, G) 17-AAG, and H) Abiraterone 
acetate are presented. Representative experimental data from one of two independent experiments are 
shown.  
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Table 7. IC50 results of test set run in H3-DHT radio ligand binding assay 
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Figure 31. AR AF-2::LXXLL-TIF2 peptide binding ALPHAScreen assay principle 
Schematic of ALPHAScreen assay. Histidine-tagged AR-LBD protein expressed and purified in E. coli 
cells is chelated to Ni2+ coated acceptor beads. TIF2-Box-III LXXLL motif peptides conjugated to biotin 
are immobilized to streptavidin donor beads. When AR-LBD and TIF2 interact, the beads are brought into 
close proximity. Subsequent excitation of the donor bead results in a chemical reaction releasing a singlet 
oxygen species. When a reagent contained in the acceptor bead is excited by the oxygen, it emits light at a 
wavelength between 520-620 nm. Any compound that acts to inhibit this protein-protein interaction will 
result in an attenuation of the signal. 
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Table 8. TIF2-box-III (738-756) peptide sequence used in ALPHAScreen assay 
Biotinylated and Non-biotinylated TIF2-box-III peptide were synthesized by the Peptide & Peptoid 
Synthesis Facility at the University of Pittsburgh’s Health Sciences Core Research Facilities. TIF2-box-III 
amino acids 738-756 have been shown to be the most important for the interaction with the AR AF-2 
surface. Biotinylated and Non-biotinylated TIF2-box-III are used in the development, and implementation 
of the ALPHAScreen assay.  
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Figure 32. AR AF-2::LXXLL-TIF2 peptide binding ALPHAScreen assay development 
A His6-AR-LBD Protein Titration, biotinylated-TIF2-box-III titration, and displacement binding 
experiments were carried out in 384-well, white opaque plates. The protein titration was run using 
different amounts of His6-AR-LBD 622-919, ranging from 0-2 µg/well, incubated with 10 µM DHT, and 
Ni2+ chelate acceptor beads for 30 min at room temperature in the dark. This mixture was combined with 
Biotinylated TIF2-box III that had been previously incubated with streptavidin donor beads, and was 
allowed to incubate together for 1 hr at RT in the dark, before being read on an envision plate reader to 
measure protein interactions. The biotinylated-TIF2-box-III titration was run using different amounts of 
biotinylated TIF2 peptide, ranging from 0-200 nM of peptide, incubated with streptavidin donor beads for 
30 min at room temperature in the dark. This mixture was combined with His6-AR-LBD (0.4 μg/well), 10 
µM DHT, and Ni2+ chelate acceptor beads that had been previously incubated together, and was allowed 
interaction for 1 hr at RT in the dark. Finally, these were a read on an envision plate reader to measure 
protein interactions. Displacement binding assays were run with fixed amounts of biotinylated TIF2 
peptide that were incubated with streptavidin donor beads for 30 min at room temperature in the dark. 
Different amounts of unlabeled TIF2 were added to biotinylated TIF2 peptide bound by streptavidin 
donor beads. Next, His6-AR-LBD (0.4 μg/well),  10 uM DHT, and Ni2+ chelate acceptor beads that had 
been previously incubated together, was added to the previous mixture and allowed to mix for 1 hr at RT 
in the dark. Finally, these were a read on an envision plate reader to measure protein interactions.  
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Figure 33. Test set performance in AR AF-2::LXXLL-TIF2 peptide binding ALPHAScreen assay 
A competitive displacement binding of biotinylated-TIF2-box-III peptide to His6-AR-LBD was 
conducted with 7 test compounds to validate the ALPHAScreen assay. Biotinylated-TIF2 peptide was 
incubated with streptavidin donor beads for 30 min, in the dark, at RT, and then added to 384-well assay 
plates at a final concentration of 150 nM. Next, compound was added to the wells of the plate at the 
indicated concentrations, and incubated for 30 min, in the dark, at RT. Simultaneously, pET28a-His6-AR-
LBD (400ng/well) was incubated with DHT, and Ni2+ coated acceptor beads for 30 min. Finally, DHT 
bound pET28a-His6-AR-LBD, chelated to acceptor beads were mixed with streptavidin bound TIF2-
peptide in 384-well plates. After mixing the ALPHAScreen components, they were incubated for 1 hr at 
RT in the dark, and after, read on an envision plate reader. The ALPHASignal (CPMs) data for compound 
treated wells were normalized to maximum (0.5% DMSO, n=32) and minimum (0.5% DMSO and 75 µM 
unlabeled TIF2, n = 32) plate controls, and the % inhibition was plotted as the mean +/- SD (n=3) values 
from triplicate wells for each compound concentration. A) Representative plate control data for Run 1 and 
Run 2 are plotted. The concentration dependent normalized % inhibition of the AR-AF2::LXXLL-peptide 
binding for B) Flutamide, C) Bicalutamide, D) Enzalutamide, E) Compound #10, F) EPI-001, G) 17-
AAG, and H) Abiraterone acetate are presented. Representative experimental data from one of two 
independent experiments are shown.  
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Table 9. IC50 results of test set run in AR AF-2::LXXLL-TIF2 peptide binding ALPHAScreen assay 
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Figure 34. Test set performance in growth inhibition assays 
Concentration-dependent inhibition of PCa cell line growth by 72 h exposure to test compounds. The five 
PCa cell lines were seeded into 384-well assay plates at 1,000 cells per well and incubated at 37C in 5% 
CO2 and 95% humidity for 24 h. After 24 h, the indicated concentrations of test compounds were 
transferred into the test wells of the 384-well assay plates that were then incubated at 37°C in 5% CO2 and 
95% humidity for an additional 72 h. The growth inhibition data for compound treated wells were 
normalized to maximum (0.5% DMSO, n=32) and minimum (200 µM Dox and 0.5% DMSO, n=32) plate 
controls, and the % inhibition was plotted as the mean +/- SD (n = 3) values from triplicate wells for each 
compound concentration plotted. A) Representative plate control data for each of the 5 cell lines: () PC3, 
() DU-145, () 22Rv1, () LNCaP, and () C4-2 is plotted. The concentration dependent normalized 
% inhibition of each cell line for B) Flutamide, C) Bicalutamide, D) Enzalutamide, E) Compound #10, F) 
EPI-001, G) 17-AAG, and H) Abiraterone acetate are presented. Representative experimental data from 
one of two independent experiments are shown.  
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Table 10. IC50 results of test set run in growth inhibition assays 
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 Targeting the Transactivation potential of the AR amino-terminal domain 
4.1 Introduction: Development of a Panel of Assays to Interrogate the Ability of 
Compounds to Block the Transactivation Potential of the AR-NTD 
Resistance to androgen deprivation therapy is due to continued AR signaling in cells despite 
achieving serum testosterone levels of less than 50 ng/dL in PCa patients [166]. Continued AR 
signaling and AR transcriptional activity arises from the molecular mechanisms of resistance that 
occur in CRPC cells.  AR dependent mechanisms of resistance contributing to CRPC include AR 
over-expression, continued intra-tumoral androgen synthesis, and promiscuous AR activation by 
non-androgenic ligands. These mechanisms compensate for lower cellular levels of DHT [48], 
[49], [50]. Other mechanisms that enable AR to signal in androgen depleted conditions include the 
emergence of AR splice variants, such as AR-V7 and ARv567es, which lack a ligand-binding 
domain (LBD), making them unresponsive to antiandrogens, [167], [168]. AR-V7’s transcriptional 
activity which is both constitutively active and androgen independent,  leads to the expression of 
target genes implicated in biosynthesis, such as the PCa biomarker PSA, and those associated with 
driving the cell cycle, such as UBE2C [67, 76, 166, 167, 169], both of which lead to disease 
progression. Since existing CRPC therapeutics are ineffective against splice variants like AR-V7, 
we developed PSA6.1-LUC and UBE2C-LUC promoter-based reporter assays to examine AR-
V7’s (AR-NTD) transcriptional activity in cells. Both the transcriptional activation reporter assays 
were developed using an AR-null PC3 cell background stably transfected with GFP-tagged AR-
V7 and will allow us to determine if compounds can block AR-V7 mediated transcription. 
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Furthermore, it’s been shown that coactivators, such as TIF2 and SRC1 can also bind to 
the AF-1 region, located in the receptor’s amino terminal domain (NTD), which activates 
[79],[103, 170] AR splice variants like AR-V7, and are proposed to contribute to AR’s continued 
transcriptional activity in the cell [50, 79, 85, 105, 106]. Studies have used GST-pull down assays, 
yeast two-hybrid assays, and mammalian 2-hybrid (M2H) assays to demonstrate that AR AF-1 
interacts with both TIF2 and SRC1 [79-82, 171, 172]. Therefore, we set out to develop mammalian 
2-hybrid assays using the 5xGal4-TATA-Luc reporter, Gal4-AR-NTD, and VP16-TIF2 or VP16-
SRC1 transfected into HEK 293 cells. We had three amino-terminal constructs available to us of 
different amino acid lengths, and structures. pGal4-AR-V7 encodes the entirety of the AR-V7 
splice isoform, pGal4-AR-NTD 1-558 encodes the entirety of the amino terminus of the AR, and 
pGal4-AR-NTD codes for the AR AF-1 transactivation surface. As expected, Gal4-AR-NTD 
mediated transcriptional activity in cells was independent of DHT.  
Unexpectedly however, Gal4-AR-NTD induced transcription was not modulated by the 
co-expression of either the VP16-TIF2 or VP16-SRC1 coactivators, which contradicts previous 
reports [79-82, 171, 172].  In the AF-1 M2H format we developed, we substituted the AR-NTD 
for the AR-LBD in the Gal4 construct so that we could take advantage of the existing TIF2 and 
SRC1 VP16 constructs which worked in the AF-2 version of the M2H (Chapter 3). Differences 
between the AF-1 M2H format that we developed, and previously published assays might account 
for the observed lack of TIF2 or SRC1 coactivation (see below).  Therefore, instead of using this 
assay to measure the ability of compounds to block the protein interactions between the AR-NTD 
AF-1 surface and TIF2 or SRC1 coactivators, we used it to interrogate their ability to block the 
constitutive transactivation of AR-NTD (1-503) (AF-1).  
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The two promoter-driven reporter assays, and the pGal4-AR-NTD transactivation assay 
enable us to determine whether hit compounds from the AR-TIF2 PPIB HCS can also block AR 
AF-1 mediated transcriptional activity, and might therefore block the CRPC enabling activities of 
AR splice variants. The development and optimization of these three assays are described in this 
chapter together with the results of seven test compounds that are known modulators of AR 
activation. 
4.2 Assays Developed to Characterize AR-TIF2 PPIB Inhibitor/Disruptor Hits that Block 
the AR AF-1 Transactivation Domain 
4.2.1  AR-NTD (1-503) Transactivation Assay 
4.2.1.1 Assay Principle 
We initially set out to develop M2H assays by transfecting 5xGal4-TATA-Luc reporter, Gal4-AR-
NTD, and VP16-TIF2 or VP16-SRC1 in three different cell lines. We found that Gal4-AR-NTD 
mediated transcriptional activity was independent of both DHT or co-activation by either VP16-
TIF2 or VP16-SRC1. During assay development and optimization, Gal4-AR-NTD (1-503) was 
transfected into 3 different cell lines, to determine which cell background exhibited the most robust 
signal for the M2H assays. The HEK 293 cell line was selected, and different concentrations of 
Gal4-AR-NTD constructs and VP16-coactivators were then cross-titrated to select the optimal 
amounts for the assays. Finally, three different AR-NTD constructs were compared to determine 
which of the three produced the most robust signal. After it was determined that VP16-coactivator 
expression did not enhance the  transcriptional activity of any of the AR-NTD constructs, the assay 
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was instead developed to interrogate the ability of compounds to block the constitutive  
transactivation of AR-NTD(1-503) (AF-1) (Figure 35, on pg. 140).  
4.2.1.2 Materials and Methods 
Plasmid DNAs. The 5xGAL4-TATA-luciferase reporter plasmid was a gift from Dr. Richard 
Maurer from the Oregon Health and Science University [155], and constructs pGAL4-hAR-1-503, 
(AR-NTD amino acids 1-503 expressed as a fusion protein with Gal4-DBD) [156], pVP16-SRC1 
(full-length SRC1 expressed as a fusion with VP16 activation domain)[157] and pVP16-Empty 
vector were kindly provided to us by Dr. Elizabeth Wilson, from UNC Chapel Hill. The generation 
of the pVP16-TIF2 construct was described in the chapter 3. An empty pGALO vector was kindly 
gifted to us by Dr. Gordon Tomaselli (Albert Einstein College of Medicine) and pGAL-hAR-1-
558, and pGAL4-AR3 (AR-V7), were generated by ligating PCR amplified inserts into the 
pGALO mammalian 2-hybrid vector. Enzymes BamHI and XbaI were purchased from New 
England Biolabs (NEB), and all primers were synthesized and purchased from ThermoFisher 
Scientific. 
Cloning of AR-NTD (1-558) into a mammalian 2-hybrid pGAL4 vector. The pGAL4 vector 
containing the AR-NTD 1-558 construct was created via the traditional ligation-dependent 
method. The AR-NTD 1-558 insert was PCR amplified from pEGFP-C1-AR full-length cDNA 
construct containing the wild type cDNA of the full-length androgen receptor. The primers for 
PCR were designed with the addition of BamHI and XbaI cloning sites at the 5’ and 3’ prime 
flanking regions, respectively (Table 11, on pg. 141). The AR-NTD 1-558 insert as well as the 
pGALO vector were double digested with BamHI and XbaI enzymes. After overnight ligation, 
using T4 DNA ligase (New England Biolabs) at 16°C the insert was cloned into the GAL4 vector. 
After ligation, a small amount of ligation mixture was transformed into DH5α competent cells and 
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plated on ampicillin containing LB agar to select for bacteria containing the GAL4-AR-NTD 1-
558 plasmid DNA. After overnight incubation at 37°C colonies were selected and expanded in 
ampicillin containing LB media, and clones were analyzed via restriction analysis to identify 
clones with bands at the correct molecular size.  
Cloning of AR3 (AR-V7) into a mammalian 2-hybrid pGAL4 vector. The AR3 insert was 
amplified by polymerase chain reaction (PCR) from the pEGFP-C1-AR-V7 cDNA using Phusion 
High-Fidelity DNA Polymerase (NEB). The PCR primers were designed with the addition of 
BamHI and XbaI cloning sites at the 5’ and 3’ prime flanking regions, respectively (Table 12, on 
pg. 142). After PCR and the purification step, the insert, and pGALO vector were double digested 
with BamHI and XbaI. After overnight ligation, using T4 DNA ligase (New England Biolabs) at 
16°C the insert was cloned into the pGAL4 vector. After ligation, a small amount of ligation 
mixture was transformed into DH5α competent cells and plated on ampicillin containing LB agar 
to select for bacteria containing the pGAL4-AR3 plasmid DNA. After overnight incubation at 
37°C colonies were selected and expanded in ampicillin containing LB media overnight and clones 
were analyzed via restriction analysis to identify clones with bands at the correct molecular size.  
SDS-PAGE and Western Blot Confirmation of GAL4-AR-NTD Constructs. AR-NTD 
containing pGAL4 vectors were then confirmed through western blot analysis. pGAL4-AR-NTD 
(1-503), pGAL4-AR-NTD (1-558), and pGAL4-AR3 (AR-V7) were transfected into HEK 293 
cells and allowed to express for 48 hrs. Forty-eight hours post transfection, cells were lysed, and 
the BCA reagent was used to determine protein concentrations of transfected cell lysates. An SDS-
PAGE gel was then run to separate 25 µg of transfected cell lysates per well and compared to non-
transfected HEK 293 cells. Protein was then transferred to a nitrocellulose membrane and probed 
with an α-AR antibody (Cell Signaling; #D6FI1) specific for the amino terminal domain of the 
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receptor (Figure 36, on pg. 143). Immuno-positive bands of increasing size are seen in transfected 
HEK 293 cells, corresponding to GAL4-AR-NTD 1-503, GAL4-AR-NTD 1-558, and GAL4-AR3 
(AR-V7), respectively. Bands at the correct molecular size are evident in transfected cell lysates 
(Figure 36).  
AR N-terminal Domain (AR-NTD) Transactivation Assay. HEK 293 cells were co-transfected 
with 5 ng of pGal4-AR-NTD (1-503), and 20 ng of the 5xGal4-TATA-Luc reporter. Cells were 
transiently bulk co-transfected with these plasmids using the Fugene6 transfection reagent. Prior 
to the transfection of cells each of the pGAL4-hAR-1-503, and 5xGAL4-TATA-luciferase 
reporter, were individually incubated with Fugene6 at a 3:1 ratio for 25 min at room temperature 
(RT). Each Fugene6:plasmid DNA mixture was then added to HEK 293 cells that were suspended 
in DMEM (Cellgro10013CV) with 2 mM L-glutamine (Invitrogen) that was supplemented with 
10% fetal bovine serum, and 5,000 cells in a volume of 40 µL were seeded into the wells of 384-
well assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. 24 h post cell 
seeding into assay plates, 5 µL of the serially diluted test compounds was transferred to the wells 
using a Janus MDT automated liquid handling platform outfitted with a 384-well transfer head, 
and assay plates were returned to the incubator for an additional 24 h before BrightGlo® reagent 
was added to the plate and the relative luminescence units (RLUs) were captured on a SpectraMax 
M5e microtiter plate reader. Test compounds were run in the M2H assay in a 10-point 2-fold 
dilution series spanning a concentration range between 0.0977 to 50 μM.  
4.2.1.3 Assay Development and Optimization 
Determining the optimal cell background for the AR-NTD Mammalian 2-Hybrid TIF2 and 
SRC1 Coactivator assays. We began by conducting the M2H assay in 3 different cell lines (Figure 
37, on pg. 144). We selected PC3 cells because they provided an AR-null prostate cancer cell line 
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background, and we selected HeLa cells and HEK 293 cells because they have frequently been 
used in mammalian 2-hybrid assays [88, 92, 157-159].  In cells co-transfected with 5 ng of pGal4-
AR-NTD (1-503), 10 ng of pVP16-TIF2 or pVP16-SRC1, and 20 ng of the 5xGal4-TATA-Luc 
reporter, both DHT treated and untreated cells exhibited a comparable luciferase response, which 
is consistent with AR-NTD’s constitutive transcriptional activity [76, 80, 81, 169].  The reporter 
response in all three cell lines was equivalent in the presence or absence of DHT but the activity 
in HeLa and PC3 cells  was ~ 400-fold and ~300-fold lower than in HEK 293 cells respectively.  
Based on our previous experience with other transient transfection assays, we attribute the much 
higher responses observed in HEK 293 cells to their much higher transfection efficiencies. We 
therefore selected the HEK 293 cell background to conduct further assay development experiments 
(Figure 37).  
 
Determining the optimal amounts of DNA plasmid constructs to use in the M2H Assays.  
The optimal amounts of GAL4-AR-NTD 1-503, VP16-Coactivator, and 5xGal4-TATA-Luc 
reporter construct to use in the HEK 293 M2H assay were determined to be 5 ng, 10 ng, and  20 
ng, respectively, consistent with the amount of  DNA  previously determined to be optimal  in 
HeLa cells (data not shown). To determine the optimal amounts of pGal4-AR-NTD (1-558), 
pGal4-AR3 (AR-V7), pVP16-TIF2, or pVP16-SRC1 plasmid DNA to use in the HEK 293 M2H 
assays cells we performed cross-titration transient transfection experiments with increasing 
amounts of the AR-NTD constructs and coactivator plasmid DNAs (Figures 37 & 38, on pgs. 144 
& 145). We selected three different pGal4-AR-NTD plasmids to conduct experiments with: pGal4-
AR-NTD (1-503), pGal4-AR-NTD (1-558), and pGal4-AR3 (AR-V7). The pGal4-AR-NTD (1-
503) construct was chosen because it contains the entire AF-1 binding region and has been used 
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previously in reporter based assays [115, 173]. We selected the pGal4-AR-NTD (1-558) construct 
because it encodes the entire AR-NTD. The pGal4-AR3 construct encodes the entire the AR-V7 
splice isoform (Figure 36). The amount of 5xGal4-TATA-Luc reporter construct in the assays was 
kept constant at 20 ng, which had been previously determined in transient transfection experiments 
conducted in our lab. The cross-titration experiments were performed in 384-well, white opaque 
plates. pGal4-AR-NTD was added to cells at increasing amounts (0, 5, 10 ng/well) of plasmid 
DNA, and cross-titrated with increasing amounts (0, 5, and 10 ng/well) of pVP16-TIF2 or pVP16-
SRC1 plasmid DNA. Cells were either treated with DHT, or not treated (NT) for each transfection 
condition. In each of the M2H titration experiments, the luciferase response increased in a linear 
fashion independent of DHT treatment as the amount of pGal4-AR-NTD transfected into the HEK 
293 cells was increased. However, there was no substantial increase in M2H luciferase reporter 
response as the amounts of the pVP16-coactivator constructs transfected into the HEK 293 cells 
were increased (Figures 38-39 on pgs. 145-146).Therefore, we selected 5 ng for pGal4-AR-NTD 
construct, and 10 ng each of the pVP16-Coactivator plasmid constructs to use for comparing the 
differences between reporter activity mediated by each pGal4-AR-NTD construct in the presence 
or absence of VP16-coactivators (Figure 40 on pg. 147). 
Determining if each of the pGal4-AR-NTD plasmid constructs requires VP16-
Coactivator to produce 5xGal4-TATA-Luc reporter based assay signal. In cells co-transfected 
with 20 ng of the 5xGal4-TATA-Luc reporter, 5 ng of either of the three pGal4-AR-NTD 
constructs, and either 0 ng or 10 ng of pVP16-TIF2 or pVP16-SRC1, both DHT treated and 
untreated cells exhibited comparable luciferase reporter responses, which is consistent to AR-
NTD’s constitutive activity. HEK 293 cells transfected with pGal4-AR-NTD (1-558) or pGal4-
AR3 (AR-V7) produced a reporter response that was ~2-fold, and ~60-fold lower, respectively, 
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than HEK 293 cells transfected with pGal4-AR-NTD (1-503) (Figure 41 on pg. 148). We attribute 
the much lower responses observed in HEK 293 cells transfected with the pGal4-AR3 (AR-V7) 
due to the presence of an AR DNA-binding domain (AR-DBD) present in the AR-V7 construct. 
Since the pGal4 construct contains a DBD specific for the Gal4 binding sites on the reporter DNA, 
the presence of the AR-DBD sequence in the AR-V7 construct may lead to competitive DNA 
binding at ARE sites that are not in the reporter construct, thereby decreasing the 5xGal4-TATA-
Luc reporter response. Although both pGal4-AR-NTD (1-503) and pGal4-AR-NTD (1-558) 
produced a robust signal, we selected pGal4-AR-NTD (1-503) for further assay development 
experiments.  
Unexpectedly, we observed that none of the three AR-NTD constructs responded to SRC1 or 
TIF2 coactivation (Figure 41). This contradicts the published literature [79-82, 171, 172]. The 
differences that we have observed may be due to differences in the assay formats. For example, 
the other groups used CV-1 cells to conduct their assays, while we used the HEK 293 cell line. 
Furthermore, our assays were developed with the AR-NTD inserted into the Gal4-DBD construct 
and the coactivators inserted into the VP16 construct, whereas the other studies flipped the bait 
and prey protein constructs; TIF2 and SRC1 coactivators were inserted into Gal4-DBD vectors 
and AR-NTD inserted into the VP16 vector. Therefore, we could not use this assay to measure 
AR-NTD coactivator protein-protein interactions, but rather we used it to measure constitutive 
AR-NTD transactivation.  
4.2.1.4 Test set performance in pGal4-AR-NTD based Transactivation assays 
Testing Known AR Modulator Compounds in the Constitutive AR-NTD Transactivation 
Assay. We first ran our test set of compounds in HEK 293 cells co-transfected with 20 ng 5xGal4-
TATA-Luc, 5ng of pGal4-AR-NTD (1-503), and either 0 ng or 10 ng of VP16-SRC1 or VP16-
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TIF2. The test set of compounds included FDA approved therapeutics and experimental drugs for 
the treatment of PCa.  
In AR-NTD assays conducted without coactivators, flutamide, bicalutamide, and 
enzalutamide exhibited IC50s of 4.83 +/- 0.14, 18.83 +/- 2.46, and 31.50 +/- 2.63 µM, respectively. 
In assays conducted with the pVP16-TIF2 coactivator, anti-androgens flutamide, bicalutamide, 
and enzalutamide exhibited IC50s of 4.65 +/- 0.74, 33.3 +/- 13.3, and 52.84 +/- 2.25 µM, 
respectively (Figure 41B-D and Table 13, on pg. 150). In assays conducted with pVP16-SRC1, 
flutamide, bicalutamide, and enzalutamide exhibited IC50s of 3.57 +/- 0.12, 29.4 +/- 14.0, and 
39.88 µM, respectively (Figure 42B-D, on pg. 149 and Table 13). It’s important to note that the 
three AR antagonists behaved very similarly in all three assay formats, suggesting their AR-NTD 
transactivation assay compound responses were not altered in the presence of the TIF2 or SRC1 
coactivators. We would anticipate that antiandrogens would not be as efficient at inhibiting AR-
NTD transcription activity as they would be in assays that employ a ligand binding domain.  As 
expected, two of the three antiandrogens exhibited less potent IC50s in AR-NTD assays relative to 
those in assays using AR-LBDs; enzalutamide’s AR-NTD IC50 was nearly ~22-fold higher than in 
the pGal4-AR-LBD TIF2 or SRC1 M2H assays, and bicalutamide’s IC50 was nearly 15-fold 
higher. Surprisingly, flutamide performed similarly in the AR-NTD assay and in the pGal4-AR-
LBD TIF2 or SRC1 M2H assays.  
The CYP17A1 inhibitor abiraterone acetate produced IC50s of 6.43 +/- 0.28 µM, 14.7 +/- 
3.02 µM, and 12.5 +/- 2.75 µM in the AR-NTD transactivation assays conducted alone or in the 
presence of the TIF2 or SRC1 coactivators, respectively (Figure 41H and Table 13). 
The Hsp 90 inhibitor, 17-AAG, produced IC50s of 3.54 +/- 0.54 µM, 4.31 +/- 1.8 µM, and 
2.05 +/- 0.85 µM in the AR-NTD transactivation assay conducted alone or in the presence of the 
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TIF2 or SRC1 coactivators, respectively (Figure 42G and Table 13). Since Hsp90 is involved with 
the maturation and folding processes of nearly 200 client proteins in mammalian cells, including 
AR-FL [174], it’s plausible that inhibiting Hsp90 may also affect the maturation and folding of 
AR-NTD thereby inhibiting it’s transactivation response. 17-AAG produced an AR-NTD IC50 that 
was ~9-fold higher than in the pGal4-AR-LBD TIF2 or SRC1 M2H assays.  
Compound #10 and EPI-001 both target the AR-NTD.  Compound #10 produced IC50s of 
1.55 +/- 0.04 µM, 4.64 +/- 0.39 µM, and 3.56 +/- 0.03 in the AR-NTD transactivation assay 
conducted alone or in the presence of the TIF2 or SRC1 coactivators, respectively (Figure 42E,F 
and Table 13).  EPI-001 produced IC50s of 9.92 +/- 1.24 µM, 19.5 +/- 2.82 µM, and 15.3 +/- 3.27 
µM in the AR-NTD transactivation assay conducted alone or in the presence of the TIF2 or SRC1 
coactivators, respectively (Figure. 42E, F and Table 13).  
Compound #10, EPI-001, and Abiraterone acetate produced IC50s in the associated 
viability counter assays run simultaneously with the AR-NTD transactivation assays, suggesting 
that compound-mediated cytotoxicity may be contributing significantly to the decreased reporter 
signals.  Overall however, it was evident that all compounds behaved similarly in all three assay 
formats, AR-NTD alone or in the presence of TIF2 or SRC1 coactivators.  
4.2.2  PSA6.1-Luc and UBE2C-Luc Reporter based assays developed in PC3-GFP-AR-V7 
Cells 
4.2.2.1 Assay Principle 
The PSA6.1-Luc and UBE2C-Luc reporter-based assays measure the transcriptional activity of the 
AR-V7 splice-variant in PCa cells. As described previously, the PSA-6.1 LUC plasmid luciferase 
reporter activity is controlled by a fragment of the PSA promoter that contains three androgen 
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response elements (AREs), fused to a luciferase reporter gene. The UBE2C reporter is a luciferase 
construct driven by three repeats of an AR-V7-specific promoter element of the ubiquitin-
conjugating enzyme E2C (UBE2C) gene (Figure 43, on pg. 151) [76]. AR-V7’s binding to the 
promoter region of PSA or UBE2C leads to the transcription of the luciferase reporter gene, and 
in the presence of CellTiter GloTM, luciferase will convert the luciferin substrate into light output, 
a quantifiable measurement of this transcription. Any compound that has the ability to modulate 
AR-NTD (AF-1)’s transcriptional activity in the cell should inhibit reporter activity in these 
assays. During assay development and optimization, the DNA concentrations of PSA6.1-Luc 
reporter, and UBE2C-Luc reporter, as well as the ratios of FuGeneHD to DNA were titrated to 
select the optimal amounts to use in the assays.  Next, we transiently transfected our reporter 
constructs, into 3 different cell lines: PC3’s, PC3-AR-FL, and PC3-AR-V7, and compared reporter 
responses in the presence or absence of DHT, to determine their constitutive and DHT-induced 
reporter responses. Using the optimized conditions the PSA6.1-Luc and UBE2C-Luc reporter 
assays were used to characterize the hits from the 143K AR-TIF2 PPIB screen. The PSA6.1-Luc 
and UBE2C-Luc reporter assays allowed us to interrogate the ability of hit compounds to modulate 
AR-V7’s transcriptional activity in PC3 cells. Any hit compound that could decrease reporter 
activity driven by the AR-splice variant AR-V7, would be prioritized for consideration as hits 
potentially suitable for lead optimization.   
4.2.2.2 Materials and Methods 
Reporter Constructs and Cell Lines. As described previously, the pPSA-6.1 LUC luciferase 
reporter plasmid was kindly provided by Dr. Zhou Wang in the Urology department of the 
University of Pittsburgh Cancer Institute. The pGL4.28-UBE2C 20bpX3 luciferase reporter 
plasmid was kindly provided by Dr. Yan Dong from Tulane University. We obtained the PC3 cell 
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line stably transfected with AR-splice variant, AR-V7, from Dr. Michael Mancini, Baylor College 
of Medicine. The PC3 cell line was purchased from the American Type Culture Collection. 
PSA6.1-LUC Reporter Assay. Prior to the transfection of AR-V7-GFP containing PC3 cells, 
Fugene HD and PSA-6.1 LUC were combined at a 3:1 (µL:µg) ratio, respectively, in Opti-MEM 
and incubated for 25 min at room temperature (RT) before being added to cells that were suspended 
in RPMI 1640 media containing 1% L-glutamine, and 10% fetal bovine serum. Bulk transfected 
cells were then seeded into white opaque 384-well assay plates (#781080; Greiner Bio-one) at a 
seeding density of 3,000 cell per well in a volume of 40 uL and incubated at 5% CO2, 37C, and 
95% humidity for 24 h. Each well received 20 ng of PSA-6.1 LUC plasmid DNA. After 24 h, 5 
uL of serially diluted compounds was transferred to the wells using a Janus MDT automated liquid 
handling platform outfitted with a 384- well transfer head; then, 5 uL of SFM was transferred to 
each well; and the assay plates were returned to the incubator for an additional 24 h before 25 μL 
of BrightGlo luciferase reagent (Promega) was added to the wells and the relative light units 
(RLUs) were captured on a SpectraMax M5e plate reader (Molecular Devices LLC). 
UBE2C-LUC Reporter Assay. Prior to the transfection of AR-V7-GFP containing PC3 cells, 
Fugene HD and UBE2C-LUC were combined at a 3:1 (µL:µg) ratio, respectively, in Opti-MEM 
and incubated for 25 min at room temperature (RT) before being added to cells that were suspended 
in RPMI 1640 media containing 1% L-glutamine, and 10% fetal bovine serum. Bulk transfected 
cells were then seeded into white opaque 384-well assay plates (#781080; Greiner Bio-one) at a 
seeding density of 3,000 cell per well in a volume of 40 uL and incubated at 5% CO2, 37C, and 
95% humidity for 24 h. Each well received 10 ng of UBE2C LUC plasmid DNA. After 24 h, 5 uL 
of serially diluted compounds was transferred to the wells using a Janus MDT automated liquid 
handling platform outfitted with a 384- well transfer head; then, 5 uL of SFM was transferred to 
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each well; and the assay plates were returned to the incubator for an additional 24 h before 25 μL 
of BrightGlo luciferase reagent (Promega) was added to the wells and the relative light units 
(RLUs) were captured on a SpectraMax M5e plate reader (Molecular Devices LLC). 
4.2.2.3 Assay Development and Optimization 
Optimizing Transfection Conditions: Determining the optimal amounts of DNA plasmid 
reporter construct and FuGeneHD:DNA ratio to use in the PSA6.1-LUC reporter assay. 
We conducted our assays in PC3 cells stably transfected with PC3-AR-V7-GFP. Images taken of 
this cell line show that the GFP-tagged AR-V7 construct is constitutively nuclear in the presence 
or absence of DHT (Figure 44, on pg. 152). To determine the optimal amount of PSA6.1-Luc 
reporter plasmid DNA to use in the PSA6.1-Luc reporter assay conducted in PC3-AR-V7-GFP 
cells we performed titration experiments with increasing amounts of the PSA6.1-Luc plasmid 
DNAs. At the same time, we increased the ratio of FuGeneHD:DNA (Figure 45, on pg. 153). These 
experiments were performed in 384-well, white opaque plates. PSA6.1-Luc was added to cells at 
increasing amounts (0, 10, 15, 20 ng/well) of plasmid DNA, and transfected with increasing ratios 
of the FuGeneHD transfection reagent (2:1, 3:1, 4:1). These experiments were run in ligand-
independent conditions, as AR-V7 does not require androgen stimulation for its transcriptional 
activation. The luciferase response increased in a linear fashion as the amount of pPSA6.1-Luc 
DNA transfected into PC3-AR-V7 cells was increased.  However, there was only a slight 
difference in reporter response when the FugeneHD:DNA ratio was increased. The final amounts 
of plasmid DNAs selected for the optimized the PSA6.1-Luc assays conducted in PC3-AR-V7 
cells were 20 ng for the pPSA6.1 construct, at a 3:1 FuGeneHD:DNA ratio. These are the same 
conditions that were used to conduct the PSA6.1-Luc reporter assay in PC3-AR-FL-GFP cells.  
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Optimizing Transfection Conditions: Determining the optimal amounts of DNA plasmid 
reporter construct and FuGeneHD:DNA ratio to use in the UBE2C-LUC reporter assay. 
To determine the optimal amount of UBE2C-Luc reporter plasmid DNA to use in the UBE2C-Luc 
reporter assays conducted in PC3-AR-V7-GFP cells we performed titration experiments with 
increasing amounts of the UBE2C-Luc plasmid DNAs. At the same time, we increased the ratio 
of FuGeneHD:DNA (Figure 46, on pg. 154). These experiments were performed in 384-well, 
white opaque plates. UBE2C-Luc was added to cells at increasing amounts (0, 10, 20, 40 ng/well) 
of plasmid DNA, and transfected with increasing ratios of the FuGeneHD transfection reagent 
(2:1, 3:1, 4:1). These experiments were run in ligand-independent conditions, as AR-V7 does not 
require androgen stimulation for its transcriptional activity. The luciferase response increased in a 
linear fashion as the amount of UBE2C-Luc transfected into PC3-AR-V7 cells was increased. 
There was an increase in reporter response when the FugeneHD:DNA ratio was increased from 
2:1 to 3:1, but the difference between 3:1 and 4:1 ratio was smaller. The final amounts of plasmid 
DNAs selected for the optimized the PSA6.1-Luc assays conducted in PC3-AR-V7 cells were 10 
ng for the PSA6.1 construct, at a 3:1 FuGeneHD:DNA ratio.  
Demonstrating Reporter Response in PSA6.1-Luc and UBE2C-Luc transfected cell lines: 
PC3, PC3-AR-FL-GFP, and PC3-AR-V7-GFP, in the presence or absence of DHT 
To compare promoter-driven reporter responses in each cell line, in the presence or absence of 
DHT, PC3’s, PC3-AR-FL-GFP, or PC3-AR-V7-GFP cells were transiently transfected with either 
PSA6.1-Luc or UBE2C-Luc reporter constructs before being seeded in 384-well, white, opaque 
plates and incubated at 5% CO2, 37°C, and 95% humidity for 24 h. The next day either DHT 
(100nM) or SFM was added to each well and again incubated at 5% CO2, 37°C, and 95% humidity 
for 24 h   (Figure 47, on pg. 155). In PC3 cells transfected with either the PSA6.1-LUC or UBE2C-
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LUC reporter plasmid, there was no reporter response, which was expected as these cells do not 
contain AR (Figure 47). When PC3-AR-FL-GFP cells were transfected with the PSA6.1-Luc 
reporter plasmid, reporter based response was only observed upon the addition of DHT to cells. 
When PC3-AR-FL-GFP cells were transfected with the UBE2C-LUC reporter plasmid, reporter 
based response was minimal, with response levels similar to those observed in PC3 cells (Figure 
47).  Finally, when the PSA6.1-LUC reporter plasmid was transfected into PC3-AR-V7-GFP cells, 
reporter activity was observed to the same degree both in the presence or absence of DHT (Figure 
47). We attribute this to AR-V7’s predominant nuclear subcellular localization in both untreated 
and treated cells (Figure 44). Similarly, when the UBE2C-LUC reporter plasmid was transfected 
into PC3-AR-V7-GFP cells, reporter activity was observed both in the presence or absence of 
DHT, indicating that AR-V7’s transcriptional activity in the cell of the UBE2C-promoter is DHT-
independent (Figure 47). 
4.2.2.4 Test set performance in PSA6.1-Luc and UBE2C-Luc reporter assays  
Testing the PSA6.1-LUC and UBE2C-LUC Reporter Assays with Known AR Modulator 
Compounds 
In PC3-AR-V7-GFP cells transfected with PSA-6.1-LUC, anti-androgen flutamide, was able to 
inhibit reporter activity, exhibiting an IC50 value of 11.5 +/- 1.22 µM, while bicalutamide, and 
enzalutamide failed to achieve an IC50 at ≤50 µM (Figure 48B-D, on pg. 156 and Table 14, on pg. 
157). Since these compounds act by preventing DHT’s binding to the AR-LBD, we predicted that 
none of these compounds would be able to prevent AR-V7’s transcriptional activity in the cell. 
Unexpectedly, just as flutamide was able to inhibit reporter activity in the pGal4-AR-NTD 
transactivation assay, it was also able to inhibit AR-V7 driven PSA6.1-promoter based reporter 
activity. The Hsp 90 inhibitor 17-AAG produced an IC50 of 0.68 +/- 0.37 μM in the AR-V7-
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PSA6.1-LUC reporter assay (Figure 48G and Table 14), likely due to its ability to prevent protein 
maturation and folding. Compound #10, and EPI-001 exhibited IC50s of 50.3 +/- 11.3, and 25.3 
+/- 4.05 μM, respectively (Figure 48E, F and Table 14).  This was expected as these compounds 
had been previously identified with the ability to target the AR-NTD [124, 147, 149, 175]. 
Abiraterone acetate also failed to achieve an IC50 at ≤50 µM in the PSA-6.1-LUC reporter assay 
performed in PC3-AR-V7-GFP cells (Figure 48H and Table 14). This compound targets 
Cyp17a1’s ability to synthesize androgen, and since the AR-NTD does not require DHT to be 
transcriptionally active, this compound does not affect AR-V7’s ability to function in the cell.  
In PC3-AR-V7-GFP cells transfected with UBE2C-Luc, the anti-androgen flutamide, was able to 
inhibit reporter activity, exhibiting an IC50 value of 28.6 +/- 2.71 µM, while bicalutamide, and 
enzalutamide failed to achieve an IC50 at ≤50 µM (Figure 49B-D, on pg. 158 and Table 15, on pg. 
159). As expected, both bicalutamide, and enzalutamide were unable to inhibit AR-V7 based 
transcriptional activity in these cells. Again, flutamide was able to inhibit AR-V7 based 
transcriptional activity in a concentration dependent manner. 17-AAG produced an IC50 of 0.75 
+/- 0.50 μM (Figure 49G and Table 15). Compound #10 and EPI-001 exhibited IC50s of 58.6 +/- 
0.79, and 49.2 +/- 0.76 μM, respectively (Figure 49E, F and Table 15). However, they were only 
able to inhibit reporter activity at the highest concentration used in the assay. Abiraterone acetate 
did not inhibit UBE2C-LUC reporter activity in PC3-AR-V7-GFP cells at ≤ 50 µM (Figure 49H 
and Table 15).  
To control for the potential cytotoxicity of these compounds, growth inhibition assays were 
run for each compound, simultaneously, to determine whether any decrease in AR-V7 
transcriptional activity was due to compound induced cell death. Under the conditions described 
above, none of the compounds from the test set exhibited any apparent cytotoxicity in the PC3 cell 
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line stably expressing pEGFP-AR-V7, indicating that any decrease in reporter signal was actually 
due to a compound’s ability to block AR-V7 induced transcriptional activity (Figures 48 & 49 and 
Tables 14 & 15).  
4.2.3  Conclusions 
Given the emergence of splice variants that code for the AR-NTD, and whose expression has led 
to relapse in CRPC patients, we have developed three different characterization that will allow us 
to identify compounds that can target AR-NTD’s transcriptional activity in CRPC cells. We are 
looking for a compound that can disrupt pGal4-AR-NTD response in the transactivation assay, 
and is able to inhibit AR-V7’s transcriptional activation in both promoter-driven reporter assays. 
A compound with a desirable biological profile is that which could disrupt transcription due to 
both the AR AF-1 and AR AF-2 transactivation domains. Flutamide and 17-AAG both inhibited 
all three assays in a concentration dependent manner. However, based on their known mechanisms 
of action, we believe that their activity may be non-specific to the AR-NTD. On the other hand, 
Compound #10 and EPI-001 both inhibited the pGal4-AR-NTD transactivation and AR-V7-
PSA6.1-Luc reporter assays in a concentration dependent manner, and the AR-V7-UBE2C-Luc 
reporter assay at the highest concentrations tested. These two compounds are examples of those 
that might be prioritized, and possibly developed into therapeutics for CRPC.   
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Figure 35. Mammalian 2-hybrid assay. pGal4-AR-NTD transactivation assay principle 
The mammalian 2-hybrid assay we developed involves the transfection of three main components 
including Gal4-AR-NTD, VP16-coactivator, and the 5xGal4-TATA-Luc reporter. The nuclear receptor-
Gal4 fusion protein binds to the DNA-binding response sequences in the 5xGal4-TATA-Luc reporter 
plasmid, while binding interactions between the nuclear receptor and the co-activator-VP16 fusion protein 
recruits the transcriptional machinery of the cell, leading to overall transcription of the luciferase gene. 
This reporter activity is an indirect measure of nuclear receptor::co-activator protein interactions in the 
cell. We have developed this assay in two different co-activator formats using the AR-NTD-Gal4 fusion 
protein; A) One involves the TIF2/SRC2 p160 coactivator cloned into the VP16 mammalian construct,  
B) the second involves homologous SRC1 p160 coactivator cloned into the VP16 vector. C) Involves 
neither coactivator for AR-AF-1 mediated 5xGal4-TATA-Luc reporter transcriptional activity.  
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Table 11. PCR primer sequence for amplification and cloning of AR-NTD (1-558) into pGal4 vector 
 
 
 
The constructs for the GAL4 vector containing the AR-NTD (1-558) was created via the traditional ligation-
dependent method. The AR3 insert was amplified by polymerase chain reaction (PCR) from the pEGFP-
C1-AR full-length cDNA. The primers for the PCR were designed with the addition of BamHI and XbaI 
cloning sites at the 5’ and 3’ prime flanking regions, respectively (ThermoFisher Scientific). The AR-NTD 
insert, and the pGALO vector were double digested with BamHI and XbaI enzymes, and then insert and 
vector were ligated.  
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Table 12. PCR primer sequence for amplification and cloning of AR-V7 (AR3) into pGal4 vector 
 
The constructs for the GAL4 vector containing the AR-V7 (AR3) were created via the traditional ligation-
dependent method. The AR3 insert was amplified by polymerase chain reaction (PCR) from the pEGFP-
C1-AR full-length cDNA. The primers for the PCR were designed with the addition of BamHI and XbaI 
cloning sites at the 5’ and 3’ prime flanking regions, respectively (ThermoFisher Scientific). The AR-NTD 
insert, and the pGALO vector were double digested with BamHI and XbaI enzymes, and then insert and 
vector were ligated.  
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Figure 36. Western blot confirmation of pGal4-AR-NTD constructs 
AR-NTD containing GAL4 vectors were transfected into HEK293 cells and allowed to express their 
respective fusion proteins for 48 hrs. Forty-eight hours post transfection, cells were lysed, and the BCA 
protein detection reagent was used to determine protein amount and concentration in transfected cell 
lysates. An SDS-PAGE gel was then run for protein separation, where 25 μg of protein from each lysate 
was added to different lanes of the gel. Protein was transferred to nitrocellulose membranes, and the 
resulting western blots were then probed with an α-AR antibody (Cell Signaling; #D6FI1), that recognizes 
a region in the amino terminal domain of the receptor. Immuno-positive bands of increasing size are seen 
in transfected HEK 293 cells, corresponding to GAL4-AR-NTD 1-503, GAL4-AR-NTD 1-558, and 
GAL4-AR3 (AR-V7), respectively. Bands at the correct molecular size are evident in transfected cell 
lysates (Figure 4). 
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Figure 37. Determining which cell background enables the most robust mammalian 2-hybrid assays 
The mammalian 2-hybrid assay was conducted in 3 different cell lines co-transfected with the pGal4-AR-
NTD (1-503), pVP16-TIF2 or pVP16-SRC1 and the 5xGal4-TATA-Luc reporter, to see how the luciferase 
reporter luminescence signal behaved in each cell line. PC3 cells were chosen because they are an AR-null 
prostate cancer cell line, and both HeLa cells and HEK 293 cells were chosen because they have been 
historically used in mammalian 2-hybrid assays. Cells were transiently co-transfected with the three 
plasmids using the FuGene6 transfection reagent, and 5,000 cells were seeded into the wells of 384-well 
assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to 
100 nM DHT and the assay plate was returned to the incubator for an additional 24 h before BrightGlo 
reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
Luminescence RLU’s were plotted in the presence or absence of DHT for the three cell lines. The data are 
presented as the mean ± SD of triplicate wells per cell line ± DHT treatment. 
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Figure 38. Mammalian 2-Hybrid assay development and optimization: cross-titration of pGal4-AR-NTD (1-
558) with A) pVP16-TIF2 or B) pVP16-SRC1 
To determine the appropriate amounts of pGal4-AR-NTD (1-558) and pVP16-TIF2 or pVP16-SRC1 to 
use in the mammalian 2-hybrid assay, cross-titration co-transfection experiments were performed in 
HEK293 cells. Interacting partners, pGAL4-AR-NTD (1-558) with pVP16-TIF2 or pVP16-SRC1, plus 
the reporter construct 5xGal4-TATA-Luc, were transiently co-transfected into HEK293 cells using the 
FuGene6 transfection reagent, and 5,000 cells were seeded into the wells of 384-well assay plates and 
cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to 100 nM DHT 
and the assay plate was returned to the incubator for an additional 24 h before BrightGlo reagent was 
added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
Luminescence RLU’s were plotted in the presence or absence of DHT for varying amounts of pGAL4-
AR-NTD (1-558) with pVP16-TIF2 or pVP16-SRC1. The data are presented as the mean ± SD of 
triplicate wells per plasmid DNA combination.  
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Figure 39. Mammalian 2-hybrid assay development and optimization: cross-titration of pGal4-AR3 (AR-V7) 
with A) pVP16-TIF2 or B) pVP16-SRC1 
To determine the appropriate amounts of pGal4-AR3 (AR-V7) and pVP16-TIF2 or pVP16-SRC1 to use 
in the mammalian 2-hybrid assay, cross-titration co-transfection experiments were performed in HEK293 
cells. Interacting partners, pGAL4-AR3 (AR-V7) with pVP16-TIF2 or pVP16-SRC1, plus the reporter 
construct 5xGal4-TATA-Luc, were transiently co-transfected into HEK293 cells using the FuGene6 
transfection reagent, and 5,000 cells were seeded into the wells of 384-well assay plates and cultured 
overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were exposed to 100 nM DHT and the 
assay plate was returned to the incubator for an additional 24 h before BrightGlo reagent was added to the 
plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. Luminescence RLU’s 
were plotted in the presence or absence of DHT for varying amounts of pGAL4-AR3 (AR-V7) with 
pVP16-TIF2 or pVP16-SRC1. The data are presented as the mean ± SD of triplicate wells per plasmid 
DNA combination.  
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Figure 40. Determining which pGal4-AR-NTD plasmid construct enables the most robust mammalian 2-hybrid 
assays 
The mammalian 2-hybrid assay was conducted in HEK 293 cell lines co-transfected with either of 3 
different pGal4-AR-NTD constructs: pGal4-AR-NTD (1-503), pGal4-AR-NTD (1-558), or pGal4-AR3 
(AR-V7), pVP16-TIF2 or pVP16-SRC1 and the 5xGal4-TATA-Luc reporter, to see how the different 
pGal4-AR-NTD constructs had an effect on luciferase reporter luminescence signal. We selected the pGal4-
AR-NTD (1-503) construct because it encodes the entire AF-1 surface and had been used previously in 
reporter-based assays. We selected the pGal4-AR-NTD (1-558) construct because it encodes the entire AR-
NTD, and we selected the pGal4-AR3 construct because it encodes the entire AR-V7 splice variant, making 
it the most biologically relevant construct for use in the M2H assay. Cells were transiently co-transfected 
with three plasmids using the FuGene6 transfection reagent, and 5,000 cells were seeded into the wells of 
384-well assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were 
exposed to 100 nM DHT and the assay plate was returned to the incubator for an additional 24 h before 
BrightGlo reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter 
plate reader. Luminescence RLU’s were plotted in the presence or absence of DHT for the three cell lines. 
The data are presented as the mean ± SD of triplicate wells per cell line ± DHT treatment. Representative 
experimental data from one of two independent experiments are shown.  
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Figure 41. Determining if each of the pGal4-AR-NTD plasmid constructs requires pVP16-coactivator to 
produce 5xGal4-TATA-Luc reporter based assay signal 
This experiment was conducted in HEK 293 cell lines co-transfected with either of 3 different pGal4-AR-
NTD constructs: pGal4-AR-NTD (1-503), pGal4-AR-NTD (1-558), or pGal4-AR3 (AR-V7), either no 
coactivator, pVP16-TIF2 or pVP16-SRC1 and the 5xGal4-TATA-Luc reporter, to see if different pGal4-
AR-NTD constructs had different coactivator requirements. Cells were transiently co-transfected with the 
indicated plasmids using the FuGene6 transfection reagent, and 5,000 cells were seeded into the wells of 
384-well assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 48 h cells 
BrightGlo reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter 
plate reader. Luminescence RLU’s were plotted in the absence of DHT for the three cell lines. The data are 
presented as the mean ± SD of triplicate wells per cell line ± DHT treatment. Representative experimental 
data from one of two independent experiments are shown.  
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Figure 42. Test set performance in pGal4-AR-NTD based transactivation assays 
HEK293 cells were transfected with three M2H plasmid constructs, pGAL4-AR-NTD (1-503) plus 5xGal4-
TATA-Luc with either pVP16-TIF2 or pVP16-SRC1, and 5,000 cells were seeded into the wells of 384-
well assay plates, and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 24 h cells were 
exposed to test compounds at the indicated concentrations and incubated overnight. The assay plate was 
returned to the incubator for an additional 24 h before BrightGlo reagent was added to the plate and the 
RLUs were captured on a SpectraMax M5e microtiter plate reader. The M2H RLU’s data for compound 
treated wells were normalized to the 0.5% DMSO, n=32 plate controls, and the % inhibition was plotted as 
the mean +/- SD (n = 3) values from triplicate wells for each compound concentration plotted on the left 
Y-axis. The corresponding cell viability () data for compound treated wells were normalized to 0.5% 
DMSO control wells (n=64), and the % cell viability was plotted as the mean +/- SD (n = 3) values from 
triplicate wells for each compound concentration plotted on the right Y-axis. A) Representative plate control 
data for No coactivator () the SRC1 () and TIF2 () M2H formats are plotted on the left axis. The 
concentration dependent normalized % inhibition of No coactivator, TIF2 and SRC1 M2H formats (left Y-
axis) and cell viability data (right Y-axis) for B) Flutamide, C) Bicalutamide, D) Enzalutamide, E) 
Compound #10, F) EPI-001, G) 17-AAG, and H) Abiraterone acetate are presented. Representative 
experimental data from one of two independent experiments are shown.  
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Table 13. IC50 results of test set run in pGal4-AR-NTD based transactivation assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
 
 
Figure 43. UBE2C-Luc reporter assay principle 
The UBE2C reporter assay is a luciferase construct driven by three repeats of an AR-V7-specific promoter 
element of the ubiquitin-conjugating enzyme E2C (UBE2C) gene. The UBE2C promoter region is fused to 
a gene that codes for luciferase. If AR-V7 and one of its coactivators, such as TIF2 are bound to responsive 
elements on the promoter region of the UBE2C gene, this will lead to recruitment of the cell’s 
transcriptional machinery, and ultimately, the transcription of luciferase enzyme, which will convert 
luciferin reagent into light output that can be quantified. If a compound run in this assay can disrupt the 
interaction between AR and TIF2, this should decrease reporter activity. 
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Figure 44. IXM images of PC3 cells stably transfected with pEGFP-C1-AR-V7 in the presence or absence of 
DHT 
Subcellular localization assays were conducted in PC3 cells stably transfected with pEGFP-C1-AR-V7 
plasmid construct in the presence or absence of DHT. PC3 cells were seeded at a density of 3,000 
cells/well into 384-well assay plates and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 
24 h cells were exposed +/- 100 nM DHT for 24 before being fixed, and imaged on an IXU automated 
HCS platform (Molecular Devices LLC).These are representative images of PC3 cells stably transfected 
with the pEGFP-C1-V7 plasmid construct. In both untreated and treated cells, AR-V7 is predominantly in 
the nuclear.  
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Figure 45. Optimizing transfection conditions: Determining the optimal amounts of DNA plasmid reporter 
construct and FuGENEHD:DNA ratio to use in the PSA6.1-Luc reporter assay 
To determine the optimal amount of PSA6.1-Luc reporter plasmid DNA to use in the PSA6.1-Luc 
reporter assays we performed titration experiments by increasing amounts of the PSA6.1-Luc plasmid 
DNAs and the ratio of FuGene:DNA in PC3-AR-V7-GFP cells. After the reporter construct was 
transiently transfected into PC3-AR-V7-GFP cells, 3,000 cells were seeded into the wells of 384-well 
assay plates, and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 48 h BrightGlo reagent 
was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
Luminescence RLU’s were plotted for the different conditions, and the data are presented as the mean ± 
SD of triplicate wells per plasmid DNA combination.  
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Figure 46. Optimizing transfection conditions: Determining the optimal amounts of DNA plasmid reporter 
construct and FuGENEHD:DNA ratio used in the UBE2C-Luc reporter assay 
To determine the optimal amount of UBE2C-Luc reporter plasmid DNA to use in the UBE2C-Luc 
reporter assays we performed titration experiments by increasing amounts of the UBE2C-Luc plasmid 
DNAs and the ratio of FuGene:DNA in PC3-AR-V7-GFP cells. After the reporter construct was 
transiently transfected into PC3-AR-V7-GFP cells, 3,000 cells were seeded into the wells of 384-well 
assay plates, and cultured overnight at 37°C, 5% CO2, and 95% humidity. After 48 h BrightGlo reagent 
was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
Luminescence RLU’s were plotted for the different conditions, and the data are presented as the mean ± 
SD of triplicate wells per plasmid DNA combination.  
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Figure 47. Demonstrating PSA6.1-Luc and UBE2C-Luc reporter response in different cell lines: PC3, PC3-AR-
FL-GFP, and PC3-AR-V7-GFP 
To compare the promoter-driven reporter response and its dependence on DHT in each cell line, PC3’s, 
PC3-AR-FL-GFP, or PC3-AR-V7-GFP cells were transiently transfected with either pPSA6.1-Luc or 
pUBE2C-Luc reporter constructs before being seeded in 384-well, white, opaque plates (3,000 cells/well) 
and incubated at 5% CO2, 37°C, and 95% humidity for 24 h. The next day either DHT (100nM) or SFM 
was added to each well and again incubated at 5% CO2, 37°C, and 95% humidity for 24 h. The next day 
BrightGlo reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter 
plate reader. Luminescence RLU’s were plotted for the different conditions, and the data are presented as 
the mean ± SD of six wells per condition.  
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Figure 48. Test set performance in PSA6.1-Luc reporter assay 
A PSA6.1-LUC reporter based assay was conducted with 7 test compounds to validate this assay. PC3-AR-
V7-GFP cell lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC plasmid 
DNA (20 ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally incubated 
overnight at 5% CO2, 95% humidity, and 37°C. PC3-AR-V7-GFP cells transfected with the PSA6.1-LUC 
plasmid were exposed to the indicated concentrations of compounds before the assay plate was returned to 
the incubator for an additional 24 h before BrightGlo reagent was added to the plate and the RLUs were 
captured on a SpectraMax M5e microtiter plate reader. The PSA6.1-LUC RLU’s data for compound treated 
wells were normalized to plate controls (0.5% DMSO, n=32), and the % inhibition () was plotted on the 
left Y-axis as the mean +/- SD (n=3) values from triplicate wells for each compound concentration. The 
corresponding cell viability data for compound treated wells were normalized to 0.5% DMSO control wells 
(n=32), and the % cell viability () was plotted on the right Y-axis as the mean +/- SD (n = 3).  A) 
Representative plate control data for one run is plotted. The concentration dependent normalized % 
inhibition of the DHT-induced PSA6.1-LUC reporter activity for B) Flutamide, C) Bicalutamide, D) 
Enzalutamide, E) Compound #10, F) EPI-001, G) 17-AAG, and H) Abiraterone acetate are presented. 
Representative experimental data from one of two independent experiments are shown.  
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Table 14. IC50 results of test set run in PSA6.1-Luc reporter based 
Assay  
PSA6.1-LUC Reporter  Growth Inhibition  
PC3-AR-V7-GFP Cells PC3-AR-V7-GFP Cells 
Mean IC50 (µM) sdm Mean IC50 (µM) sdm 
Flutamide 11.5 1.22 >50 N/A 
Bicalutamide >50 N/A >50 N/A 
Enzalutamide >50 N/A >50 N/A 
Compound #10 50.3 11.3 >50 N/A 
EPI-001 25.3 4.05 >50 N/A 
17-AAG 0.68 0.37 >50 N/A 
Abiraterone Acetate >50 N/A >50 N/A 
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Figure 49. Test set performance in UBE2C-Luc reporter assay  
A UBE2C-LUC reporter based assay was conducted with 7 test compounds to validate this assay. PC3-AR-
V7-GFP cell lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC plasmid 
DNA (10 ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally incubated 
overnight at 5% CO2, 95% humidity, and 37°C. PC3-AR-V7-GFP cells transfected with the UBE2C-LUC 
plasmid were exposed to the indicated concentrations of compounds before the assay plate was returned to 
the incubator for an additional 24 h before BrightGlo reagent was added to the plate and the RLUs were 
captured on a SpectraMax M5e microtiter plate reader. The UBE2C-LUC RLU’s data for compound treated 
wells were normalized to plate controls (0.5% DMSO, n=32), and the % inhibition () was plotted on the 
left Y-axis as the mean +/- SD (n=3) values from triplicate wells for each compound concentration. The 
corresponding cell viability data for compound treated wells were normalized to 0.5% DMSO control wells 
(n=32), and the % cell viability () was plotted on the right Y-axis as the mean +/- SD (n = 3). A) 
Representative plate control data for one run is plotted. The concentration dependent normalized % 
inhibition of the DHT-induced UBE2C-LUC reporter activity for B) Flutamide, C) Bicalutamide, D) 
Enzalutamide, E) Compound #10, F) EPI-001, G) 17-AAG, and H) Abiraterone acetate are presented. 
Representative experimental data from one of two independent experiments are shown.  
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Table 15. IC50 results of test set run in UBE2C-Luc reporter based assay 
 
Assay  
UBE2C-LUC Reporter  Growth Inhibition  
PC3-AR-V7-GFP Cells PC3-AR-V7-GFP Cells 
Mean IC50 (µM) sdm Mean IC50 (µM) sdm 
Flutamide 28.6 2.71 >50 N/A 
Bicalutamide >50 N/A >50 N/A 
Enzalutamide >50 N/A >50 N/A 
Compound #10 58.6 0.79 >50 N/A 
EPI-001 49.2 0.76 >50 N/A 
17-AAG 0.75 0.50 >50 N/A 
Abiraterone Acetate >50 N/A >50 N/A 
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 Compound Performance in Assays Developed to Prioritize Hits from the AR-TIF2 
PPIB 
5.1 Introduction  
In this chapter I will describe how AR-TIF2 PPI inhibitor/disruptor hit compounds identified from 
the LOPAC set and three compound libraries run in the primary screen (detailed in chapter 2) were 
initially triaged, and then prioritized for testing in the AF-2 and AF-1 transactivation domain 
characterization assays developed and described in chapters 3 and 4. Compounds that produced 
calculable IC50’s  in the AR-TIF2 PPIB assay were initially tested in growth inhibition assays 
conducted in 5 different PCa cell lines, two AR null and three AR positive PCa cell lines, and a 
PSA6.1-Luc reporter assay conducted in C4-2 cells. The PCa growth inhibition assays were used 
to prioritize AR-TIF2 PPI inhibitor/disruptor hits that differentially inhibited the growth of AR 
positive cell lines, while the PSA6.1-Luc reporter assay was used to confirm that they inhibited 
AR-mediated transcriptional activation. Prioritized hits were then tested in a H3-DHT 
radioligandbinding assay using recombinantly expressed AR-LBD, and a TIF2 Box III LXXLL 
peptide ALPHAScreen AR-LBD binding assay.  
Hit compounds that passed our testing paradigm with the desired biological activity profile 
were also subjected to a cheminformatics assessment of their physical and chemical properties. 
The initial hit triage resulted in a small set of 27 compounds that were confirmed in our secondary 
assays. Two hit compounds came from the 10K library, 7 from the 50K library, and 18 from the 
83K library. These compounds were clustered manually, and both chem-informatically and bio-
informatically assessed via the combined output of the FAFDrugs4 and SwissADME servers. 
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Compounds were assessed for PAINS, lead likeness, reactive functionality, induction of 
phospholipidosis, probability of good bioavailability via the Veber and Egan rules, and other 
parameters. Compounds that failed bio/chem informatics filters were removed from further 
consideration.  The remaining compound clusters and singletons were queried in scifinder to 
ascertain if there is known literature around the general scaffold they belong to and if they have 
known biological activities that would be unwanted. Through this assessment several chemotypes 
were removed from further consideration. For example, several hits were chalcones, compounds 
known to have promiscuous activity that have been used as fluorescent probes [176-178]. Zeranol, 
a singleton hit, was deprioritized because it has potent estrogenic activity and is used as a growth 
promoter in cattle [179, 180]. Compounds with unknown biological activity and/or mention in 
patent and peer-reviewed literature were thought to be suitable candidates for further investigation. 
Hits that displayed favorable biological profiles in the secondary characterization assays and were 
not flagged in any of the cheminformatics filters were selected for further testing in our AF-2 and 
AF-1 transactivation domain characterization assays.  
5.2 Initial Hit Triage 
5.2.1  LOPAC Set 
The 17 confirmed actives from the LOPAC set were run in 3 different counter-screens. The first 
was the p53-hDM2 PPIB assay that utilizes the same assay format and biosensor design but 
different protein interacting partners as the AR-TIF2 PPIB assay and therefore served as an assay 
interference and PPI selectivity counter-screen. None of the 15 AR-TIF2 PPI LOPAC hits were 
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active in the p53-hDM2 PPIB assay, indicating that they are unlikely to interfere with either the 
biosensor assay format or to be non-selective PPI inhibitors [118]. In an HCS assay designed to 
identify compounds that altered the sub-cellular distribution and/or expression of AR-GFP, the 
AR-TIF2 PPI LOPAC hits either enhanced the nuclear localization of AR-GFP or were inactive. 
The AR-GFP data suggest that some of the AR-TIF2 PPI LOPAC hits may be partial AR agonists, 
and, therefore, would not be expected to inhibit or disrupt AR-TIF2 PPIs. To evaluate the nuclear 
receptor (NR) selectivity of the AR-TIF2 PPI LOPAC hits, we tested their activity in a 
dexamethasone (Dex)-induced glucocorticoid receptor (GR) nuclear translocation assay. Although 
none of the steroid NR AR-TIF2 LOPAC hits inhibited Dex-induced GR nuclear translocation, the 
five non-steroid hits inhibited GR trafficking in a concentration-dependent manner [118].  
We would expect that AR-TIF2 PPI inhibitor/disruptor hits would be able to inhibit AR 
transcriptional activity, and to test this notion we examined their ability to inhibit the DHT-induced 
luciferase reporter activity of the PSA-6.1-LUC plasmid transiently transfected into the C4-2 and 
22Rv1 CRPC cell lines. Pre-exposure to the 15 AR-TIF2 PPI LOPAC hits inhibited DHT-induced 
PSA-6.1-LUC luciferase reporter activity in C4-2 and 22Rv1 cell lines in a concentration-
dependent manner (Table 16, on pg. 176) [118]. 
We would also anticipate that AR-TIF2 PPI inhibitors/disruptors would be more effective 
at inhibiting the growth of PCa cell lines that express AR relative to those that do not express AR. 
To test this hypothesis, we developed and implemented CellTiter-GloTM (CTG) growth inhibition 
assays in five PCa cell lines: LnCaP, C4-2, and 22Rv1 cells express AR, while PC3 and DU-145 
are AR null. Four of the 10 steroid NR ligand AR-TIF2 PPI LOPAC hits failed to inhibit the 
growth of any of the PCa cells lines at ≤50 μM (estrone, cortexelone, 17-α-H-PG, and nilutamide) 
and of the 6 others, only 2-methoxyestradiol (2-MOED) inhibited the growth of all five PCa cell 
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lines. None of the steroid NR ligand AR-TIF2 PPI LOPAC hits differentially inhibited the growth 
of AR-positive PCa cell lines relative to AR-null PCa cell lines. Although the non-steroid AR-
TIF2 PPI LOPAC hits were more potent and inhibited the growth of all five PCa cell lines in a 
concentration-dependent manner, they were equally effective at inhibiting the growth of AR-
positive and AR-negative PCa cell lines (Table 16). Therefore, none of the AR-TIF2 PPI LOPAC 
hits exhibited evidence of differential/selective growth inhibitory activity for AR positive over AR 
negative CaP cell lines that might be expected [118]. 
Finally, since one potential mechanism of blocking the formation of DHT-induced AR-
TIF2 PPIs would be to prevent DHT binding to the AR-LBD, we developed a secondary assay to 
identify AR antagonists among the AR-TIF2 PPI hits. The ten steroid LOPAC hits exhibited AR-
antagonist activity in our H3-DHT radioligandbinding assay (Table 16), and this is likely the basis 
of their activity in the AR-TIF2 PPIB assay. Since several of the steroid LOPAC hits have activities 
against other steroid nuclear receptors, including the estrogen, progesterone, mineralocorticoid, 
and glucocorticoid receptors, they lack selectivity.  The five non-nuclear receptor ligand LOPAC 
hits, 4-P-3-FOCN, TPCK, ZPCK, Bay 11-7085, and parthenolide were inactive in the H3-DHT 
radioligandbinding assay with IC50s >50 µM (Table 16). However, based on the cytoplasmic AR-
RFP distribution phenotypes of the non-steroid hits and their inhibition of Dex-induced GR-GFP 
nuclear translocation, it is possible that these compounds interfere with a common component of 
NR activation and trafficking. Among the possibilities are the following: the Hsp 90 and Hsp 70 
chaperones maintain both NRs in high-affinity structural conformations in the cytoplasm ready for 
ligand binding; ligand-bound AR and GR are both cargos of dynein mediated retrograde trafficking 
on microtubules to the nucleus; and the importin-α/β adaptor system mediates entry through the 
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nuclear pore complex of both NRs. Since none of the LOPAC hits exhibit the biological profile of 
a selective AR-TIF2 inhibitor/disruptor, they were deprioritized and not pursued further. 
5.2.2  10K Library 
Of the fourteen compounds from the 10K library that were confirmed active in both formats of the 
AR-TIF2 PPIB HCS assay, none of them exhibited activity in the 3 counter screens, indicating 
that they did not interfere with the biosensor assay format, and were not either nonselective PPI 
inhibitors or promiscuously active against GR, another member of the steroid nuclear receptor 
family. In AR-TIF2 PPIB concentration response assays, 5 of the confirmed actives produced 
calculable IC50s for inhibition of DHT-induced AR-TIF2 PPI formation and two produced 
calculable IC50s for disruption of pre-existing AR-TIF2 complexes (Table 16). All 5 hit compounds 
inhibited DHT-induced PSA6.1-Luc reporter-based activity in 22Rv1 and C4-2 cells in a 
concentration dependent manner, indicating that they blocked AR-mediated transcriptional 
activation. However, only 2 of the hits selectively inhibited the growth of AR-positive PCa cell 
lines over AR-null cell lines (Table 16). However, neither of the 2 hits exhibited activity in either 
the H3-DHT radioligandor TIF2 Box III LXXLL peptide ALPHAScreen binding assays (Table 
16). Furthermore, our cheminformatics analysis of the two hit structures raised a couple of 
concerns; PPS-00052526 was predicted to exhibit low overall bioavailability, and PPS-000059998 
was predicted to exhibit low solubility. Based on these data and analysis neither of the two 10K 
hits were prioritized for further hit characterization. 
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5.2.3  50K Library 
When AR-TIF2 PPIB confirmed actives from the 50K library were run in the 3 counter screens, 
only one was active in the AR-GFP nuclear localization assay, perhaps indicating that this 
compound may be reducing the AR-RFP biosensor expression levels or restricting its sub-cellular 
localization to the cytoplasm. We performed a medicinal chemistry structural classification and 
clustering of the 124 confirmed actives in the AR-TIF2 PPIB HCS assay to identify and eliminate 
potential liabilities, reactive and/or promiscuous assay interference compounds, and compounds 
that were not considered chemically tractable. The 124 compounds were sub-divided into 24 
structurally related clusters and 19 singletons, but not all the compounds were ordered from 
clusters with multiple representatives. 74 compounds were chosen for repurchase but only 70 were 
available.  The purchased confirmed actives were tested in  the AR-TIF2 PPIB assay in 10-point 
2-fold serial dilution series in triplicate starting at a maximum concentration of 50 µM. Fifty-six 
compounds inhibited DHT-induced AR-TIF2 PPI formation with IC50s <50 µM, and 52 
compounds disrupted pre-existing DHT-induced AR-TIF2 PPI complexes with IC50s <50 µM 
(Table 16).  Twenty-four of the most potent AR-TIF2 PPIB hits that exhibited some degree of 
selectivity for AR-positive cell lines in the five PCa growth inhibition assays were then tested in 
the C4-2-PSA6.1-Luciferase reporter assay. Eighteen of the AR-TIF2 PPIB hits were shown to 
inhibit DHT-induced reporter activity in a concentration dependent manner, indicating that they 
also blocked AR-mediated transcriptional activation. The 18 hits were then run in the H3-DHT 
radioligand and TIF2 Box III LXXLL peptide binding assays. Eight compounds produced IC50s 
<50 µM in the H3-DHT radioligandbinding assay, and 7 produced IC50s <50 µM in the TIF2 Box 
III LXXLL peptide binding assay or displayed concentration dependent inhibition responses with 
an extrapolated IC50 <100 µM (Table 16).   
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A medicinal chemistry analysis of the physical chemical properties of the 7 prioritized hit 
compounds predicted that 5026223 would have low aqueous solubility and was flagged by a Pan 
Assay Interference and Nuisance (PAINS) filter. 87237916 was also predicted to have low aqueous 
solubility, was flagged by both PAINS and Lilly filters, and did not share many of the 
characteristics of published PPI inhibitors.  The remaining 5 hits were then used to perform a 
structural similarity based query of the ChemBridge 410K core library database, using a tanimoto 
score of above 0.7 as a threshold for compound similarity selection.  
5.2.4  83K Library 
Thirty-six of the confirmed AR-TIF2 PPI inhibitor/disruptor actives from the 83K library were 
also active in two of the three counter-screens. Twenty-eight of the compounds reduced AR-GFP 
nuclear localization by >50%, suggesting that they might be indirectly inhibiting the AR-TIF2 
PPIB assay by reducing the AR-RFP biosensor expression levels or restricting its sub-cellular 
localization to the cytoplasm. Eight confirmed actives in the AR-TIF2 PPIB assay also inhibited 
GR nuclear translocation by >50%, and therefore either lack AR specificity/selectivity or they 
inhibit a shared component of the AR and GR signaling pathways. We therefore deprioritized these 
36 confirmed AR-TIF2 PPIB actives. Two hundred four confirmed actives were then run in 
concentration response assays in the AR-TIF2 PPIB assay, the C4-2-PSA6.1-Luc reporter assay, 
and the 5 PCa growth inhibition assays. One hundred seventeen hit compounds exhibited 
calculable IC50’s in one or both of the AR-TIF2 PPIB formats (Table 16). Twenty one compounds 
were also able to inhibit DHT-induced PSA6.1-Luc reporter activity in a concentration manner, 
with IC50’s <40 µM (Table 16), and 20 compounds were either able to inhibit the growth all 5 PCa 
cell lines or were able to target AR-positive cell lines in a selective manner run in the PCa GI50 
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assays. Only 18 of the 117 AR-TIF2 PPIB hits were also able to block AR-mediated transcriptional 
activation and the growth of PCa cell lines. Four of the 18 hit compounds also inhibited H3-DHT 
radioligand binding in a concentration dependent manner, but couldn’t achieve >50% inhibition at 
≤40 µM. Similarly, 3 of the 18 hit compounds also inhibited TIF2 Box III LXXLL peptide binding 
in a concentration dependent manner but failed to register an IC50 at ≤40 µM. Our structural 
classification, clustering and cheminformatics analysis of the 18 hit compounds from the 83K 
library grouped the hits into 3 major clusters and 8 singletons. The three clusters include: 1) 
Phenyl-acryloyl-2-methoxybenzyl-thio-acetic acids, 2) Oxprop-en-yl benzoic acids, and 3) 
Nitrophenyl-acrylaldehydes. Cluster two contains alpha beta unsaturated ring structures which are 
highly reactive species, while cluster 3 contains highly reactive aldehyde species. Compounds 
assigned as singletons also contained problematic functional groups. Since all of the hits from the 
83K library were flagged as problematic/reactive compounds, we deprioritized them from further 
characterization.  
5.3 Prioritized Hit Characterization 
After the initial triage of the AR-TIF2 inhibitor/disruptor hits described in section I of this chapter 
only 5 compounds from the 50K library met our bioassay profile and chemical tractability criteria.  
Based on the chemical structures of the 5 hits, 20 structurally similar analogs were selected via a 
similarity search query of the ChemBridge 410K core library database. These 25 compounds were 
profiled in the AR-TIF2 PPIB, C4-2-PSA6.1-Luc reporter, and 5 PCa cell lines growth inhibition 
assays. Six of the purchased analogs were inactive in both formats of the AR-TIF2 PPIB assays.  
Four of the 6 inactive analogs were also inactive in the PSA6.1-Luc reporter assay and 3 of the 
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compounds were unable to inhibit the growth of any of the 5 PCa cell lines.  4 of the inactive 
compounds were analogs of the cluster 1 compound 55803561, the 1B series containing thiadiazol-
5-piperidine-carboxamides. The remaining 19 compounds that were active in one or both AR-TIF2 
PPIB formats were also active in the PSA6.1-Luc reporter assay, although one exhibited 
substantial cytotoxicity in both the biosensor and reporter assays. The 19 compounds were also 
able to inhibit the growth of at least 2/5 PCa cell lines (Tables 17 & 19, on pgs. 178 & 180). We 
then tested the 18 most potent hit compounds in the TIF2 and SRC1 mammalian 2-hybrid assays, 
the H3-DHT radioligand binding assay, and the TIF2 Box III LXXLL peptide binding assay. All 
18 compounds produced IC50’s in the TIF2 and SRC1 M2H assays confirming that they block 
DHT-induced AR-LBD interactions with both coactivators. However, 7 of the compounds 
displayed measurable cytotoxicity in the M2H assays (Table 18, on pg. 179). Ten of the 18 
compounds were active in the LXXLL binding assay, and 3 of these were also active in the H3-
DHT binding assay.  
Based on these data ten compounds were selected for testing in the panel of AF-1 and AF-2 
transactivation domain assays described in chapters 2 and 3 (Figure 50, on pg. 177). From cluster 
1, we selected the two hits 98648798 and 55803564 together with one analog 26996278. From 
cluster 2, we selected the two hits 14977726 and 36998335 together with three analogs 21302587, 
24843178 and 60134988. From cluster 3, we selected two analogs 63718298 and 72508471. In 
addition to the H3-DHT and LXXLL peptide binding assays the ten compounds were also tested 
in the PSA6.1-Luc reporter assay conducted in PC3-AR-FL-GFP cells to evaluate AF-2 
transactivation domain interactions. To evaluate AF-1 transactivation domain interactions the ten 
compounds were profiled in the  pGal4-AR-NTD assay, and in two reporter assays, the PSA6.1-
Luc and the UBE2C-Luc reporter assays both performed in PC3 cells stably transfected with 
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pEGFP-C1-AR-V7. The following section details how these ten AR-TIF2 PPI hits performed in 
each characterization assay.  
5.3.1  Implementation of Assays Developed for Characterizing hits from the AR-TIF2 PPIB 
5.3.1.1 PSA6.1-Luc Reporter Assay in PC3-AR-FL-GFP Cells 
It was our expectation that compounds which inhibit or disrupt AR-TIF2 PPI’s should also inhibit 
or disrupt AR transcriptional activity. Seven of 10 prioritized AR-TIF2 PPI inhibitor/disruptor hits 
inhibited the DHT-induced PSA6.1-Luc reporter activity in PC3-AR-FL-GFP cells in a 
concentration dependent manner and produced calculable IC50s <50 µM (Figure 51B-G, on pg. 
181 and Table 20, on pg. 184). Compounds 26996278 and 63718298 also exhibited substantial 
levels of cytotoxicity which potentially contributed to and complicated the interpretation of the 
reporter data (Figure 51C, J and Table. 20). For both compounds the reporter IC50s were lower 
than the corresponding GI50 for cell loss, indicating that the inhibition of transcription occurred at 
lower compound concentrations before the apparent cytotoxicity became a contributing factor. 
Two other hits, 24843178 and 72508471, showed evidence of concentration dependent inhibition 
of reporter activity but failed to achieve 50% inhibition even at 100 µM (Figure 51I, K and Table 
20). Compound 21302587 was inactive in the AR-FL driven PSA6.1-Luc reporter assay at ≤100 
µM (Figure 51H and Table 20).  In sum therefore, 9 of the 10 prioritized AR-TIF2 PPI 
inhibitor/disruptor hits showed evidence of inhibiting DHT-induced AR-FL-mediated activation 
of transcription. 
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5.3.1.2 AR-LBD H3-DHT Radioligand Binding Assay 
The radioligand binding assay specifically measures the competitive displacement of H3-DHT 
from AR-LBD in the presence of increasing concentrations of each compound, and it was used to 
determine if any of the AR-TIF2 PPI hits inhibited the PPIB assay because they were AR-
antagonists. Only 3 of the hit analogs inhibited H3-DHT binding to the AR-LBD in the radioligand 
binding assay in a concentration dependent manner that produced calculable IC50s (Figure 52, on 
pg. 182). 98648798, 36998335, and 63718298 exhibited IC50’s of 43.7 ± 0.03, 62.9 ± 12.9, and 
56.2 ± 8.65 µM, respectively (Figure 52C, F, K and Table 20). The IC50s for inhibiting DHT-
induced AR-TIF2 PPI formation were many folds lower than for inhibiting ligand binding. The 
AR-TIF2 PPI IC50s for 98648798, 36998335, and 63718298 were 7.7-fold, 29.5-fold and 13.7-
fold lower than their corresponding ligand binding IC50s respectively. Six more AR-TIF2 PPI 
inhibitor/disruptor hits showed evidence of concentration dependent inhibition of H3-DHT binding 
to the AR-LBD but failed to achieve 50% inhibition even at 100 µM; 55803564, 26996278, 
14977726, 21302587, 24843178 and 60134988. The corresponding IC50s for inhibiting DHT-
induced AR-TIF2 PPI formation for the 6 hits were in the 1.1 to 14.5 µM range, and in the 5.8 to 
51.8 µM range for disrupting pre-existing AR-TIF2 PPIs. Only 72508471 exhibited no inhibition 
of H3-DHT binding to the AR-LBD at ≤100 µM. Although 9 of the 10 prioritized AR-TIF2 PPI 
inhibitor/disruptor hits inhibited H3-DHT binding to the AR-LBD to some extent, the IC50s for 
inhibiting/disrupting AR-TIF2 PPIs were many folds lower than for disrupting ligand binding. It 
seems unlikely that the apparent weak AR antagonism of the hits is a major contributor to their 
ability to inhibit and/or disrupt AR-TIF2 PPIs. Another possibility is that 9 hits bind to allosteric 
sites on the AR-LBD to induce a conformation shift which negatively impacts ligand binding.   
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5.3.1.3 TIF2 Box III LXXLL peptide binding ALPHAScreen Assay 
The ALPHAScreen AR-LBD::LXXLL-peptide binding assay is a biochemical assay that measures 
the interaction of the AR AF-2 domain formed by the AR-LBD and a peptide containing the 
LXXLL motif located in box III of the TIF2 coactivator’s nuclear interaction domain (NID). Eight 
of the 10 prioritized AR-TIF2 PPI inhibitor/disruptor hits inhibited AR-LBD::LXXLL-peptide 
binding to produce calculable IC50s. Five of the hit compounds produced IC50s <50 µM: 98648798, 
36998335, 60134988, 14977726, and 63718298 (Figure 52C, F-H, K and Table 20).  Three more 
of the hits produced IC50s in the 50 to 100 µM range; 26996278, 55803564 and 24843178 (Figure 
52D, E, J and Table 20). Compound 21302587 showed evidence of concentration dependent 
inhibition of AR-LBD::LXXLL-peptide binding but failed to achieve 50% inhibition even at 100 
µM (Figure 52I and Table 20). 72508471 was inactive in the AR-LBD::LXXLL-peptide binding 
assay (Figure 52L and Table 20).  
5.3.1.4 Growth Inhibition Assays 
We anticipated that any compounds that were able to disrupt the interactions between AR and 
TIF2 might selectively inhibit the growth of AR-positive PCa cell lines. For example, hit 
compound 55803564 produced GI50s against all 3 AR-positive cell lines but not in the two AR-
null cell lines (Table 19 on pg. 180). In contrast, 26996278 and 63718298 were equipotent against 
all 5 PCa cell lines and therefore did not demonstrate any selectivity for AR expressing cell lines. 
The remaining 7 hits exhibited differential selectivity for growth inhibition in 2/3 AR-positive PCa 
cell lines relative to AR-null cell lines.  
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5.3.1.5 Transactivation Assay using pGal4-AR-NTD 
To determine if the prioritized AR-TIF2 PPI inhibitor/disruptor hit compounds could inhibit AR-
NTD constitutive transcription, we used a 5xGal4 based luciferase reporter assay. Nine out of the 
ten hits produced calculable IC50’s <100 uM (Figure 53B-I, K, on pg. 185 and Table 21, on pg. 
188). Compound 63718298 produced a strange biphasic concentration response curve in the 
pGal4-AR-NTD-luciferase reporter assay. Nine of the 10 hits also displayed concentration 
dependent cytotoxicity in HEK 293 cells, and 7 produced calculable IC50’s <100 uM (Figure 53B-
I, K and Table 21). In general, pGal4-AR-NTD-luciferase reporter IC50s were lower than the 
corresponding GI50s for cell loss, indicating that the inhibition of transcription occurred at lower 
compound concentrations before the apparent cytotoxicity became a contributing factor. 
Compounds that inhibit the constitutive activation of the pGal4-AR-NTD-luciferase reporter assay 
may be able to prevent the transcriptional activity mediated by the AR AF-1 domain of splice 
variants such as AR-V7 which are upregulated during the relapse of CRPC patients receiving ADT 
therapy.  
5.3.1.6 PSA6.1-Luc & UBE2C-Luc Reporter Based Assay Development in PC3-AR-V7-
GFP Cells 
To determine if the prioritized AR-TIF2 PPI inhibitor/disruptor hit compounds were able to inhibit 
the transcriptional activity of the AR-V7 splice variant, we ran them in two reporter assays which 
involved the transient transfection of the PSA6.1-Luc and UBE2C-Luc reporter constructs into 
PC3-AR-V7-GFP cells. Since the PSA6.1-Luc reporter can be activated by AR-FL and AR splice 
variants such as AR-V7, we incorporated the UBE2C-Luc reporter because it can only be activated 
by AR splice variants. Nine of 10 ten compounds inhibited the AR-V7 driven PSA-6.1-Luc 
reporter activity in a concentration dependent manner, producing IC50s <100 µM (Figure 54B-J, 
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on pg. 186 and Table 21).   Only 26996278 also displayed cytotoxicity in growth inhibition assays 
run simultaneously with the reporter assays (Figure 54C and Table 21).  The reporter IC50 for 
26996278 was much lower than the corresponding GI50 for cell loss, indicating that the inhibition 
of transcription occurred at lower compound concentrations before the apparent cytotoxicity 
became a contributing factor. Compound 72508471 was completely unable to inhibit AR-V7’s 
activation of the PSA6.1-Luc reporter (Figure 54K and Table 21).   
In PC3-AR-V7-GFP cells transiently transfected with the UBE2C-LUC reporter, 7 of 10 
prioritized AR-TIF2 PPI inhibitor/disruptor hits inhibited AR-V7 induced reporter activity in a 
concentration dependent manner, producing IC50s <100 µM (Figure 55B-H, on pg. 187 and Table 
21).  Again, only 26996278 also displayed cytotoxicity in growth inhibition assays run 
simultaneously with the reporter assays (Figure 55C and Table 21).  The UBE2C-Luc reporter IC50 
for 26996278 was much lower than the corresponding GI50 for cell loss, indicating that the 
inhibition of transcription occurred at lower compound concentrations before the apparent 
cytotoxicity became a contributing factor. 63718298 and 72508471 showed evidence of 
concentration dependent inhibition of UBE2C-Luc reporter activity but failed to achieve 50% 
inhibition even at 100 µM (Figure 55J, K and Table 21). Only 24843178 was unable to inhibit AR-
V7 driven UBE2C-LUC reporter activity (Figure 55I and Table 21). 
5.3.2  Conclusion: Which Compounds are Prioritized and Why? 
Cluster 1 hits – 98648798, 26996278, and 55803564. All three cluster 1 analogs produced 
calculable IC50s or demonstrated concentration dependent inhibition in our panel of AF-2 and AF-
1 domain transactivation assays.  While 26996278 was equipotent at inhibiting the growth of all 5 
PCa cell lines, 55803564 only produced GI50s against the 3 AR-positive cell lines. 98648798 also 
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exhibited differential selectivity for growth inhibition in 2/3 AR-positive PCa cell lines relative to 
AR-null cell lines. The cluster 1 series of AR-TIF2 PPI inhibitor/disruptor hit compounds exhibit 
the desired biological activity profile with acceptable physiochemical properties and have the 
potential to block both AF-1 and AF-2 domain mediated transactivation. This class of AR-TIF2 
PPI inhibitor/disruptor hits remains on the priority list for consideration as starting points for a 
medicinal chemistry hit to lead optimization effort. 
Cluster 2 hits – 14977726, 21302587, 24843178, 36998335 and 60134988. Three of the 5 
analogs produced calculable IC50s or showed concentration dependent inhibition in all 3 of the 
AF-2 domain transactivation assays.  In contrast, 21302587 and 24843178 only exhibited minimal 
or no activity in the AF-2 domain transactivation assays.  Four of the 5 analogs produced calculable 
IC50s in all 3 of the AF-1 domain transactivation assays, 24843178 was active in only 1 of the 3 
AF-1 assays. All five analogs exhibited differential selectivity for growth inhibition in either 3/3 
or 2/3 AR-positive PCa cell lines relative to AR-null cell lines. The less potent analogs of cluster 
2 might be considered evidence of an emerging structure activity relationship (SAR) but additional 
analogs would have to be purchased/synthesized and tested to confirm this.  The cluster 2 series 
of AR-TIF2 PPI inhibitor/disruptor hit compounds exhibit the desired biological activity profile 
with acceptable physiochemical properties and have the potential to block both AF-1 and AF-2 
domain mediated transactivation. This class of AR-TIF2 PPI inhibitor/disruptor hits remains on 
the priority list for consideration as starting points for a medicinal chemistry hit to lead 
optimization effort. 
Cluster 3 hits – 63718298 and 72508471. Compound 72508471 was not very active in any 
of the three AF-2 transactivation domain assays and was also not very active in two of the three 
AF-1 transactivation domain assays. The apparent lack of activity in the AF-2 domain assays was 
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surprising since it had produced calculable IC50’s in the DHT-induced AR-TIF2 PPI formation 
assay, the TIF2 and SRC1 M2H assays, the C4-2-PAS6.1 reporter assay and exhibited evidence 
of differential selectivity toward AR-positive cell lines in the PCa growth inhibition assays. 
72508471 also exhibited strange biphasic concentration response curves in three of the assays; the 
AR-FL PSA6.1 reporter assay, the constitutively active pGal4-AR-NTD-luciferase reporter assay, 
and the AR-V7 driven PSA6.1-Luc reporter assay.  Compound 63718298, the other member of 
cluster 3, was equipotent against all 5 PCa cell lines and therefore did not demonstrate any 
selectivity for AR expressing cell lines. Compound 63718298 also exhibited strange biphasic 
concentration response curves in two of the assays; the AR-FL PSA6.1 reporter assay and the 
constitutively active pGal4-AR-NTD-luciferase reporter assay.  Based on these data we decided 
to deprioritize both cluster 3 compounds, 63718298 and 72508471. 
 
 
 
 
 
 
 
 
 
 
 176 
 
Table 16. Selection process used to prioritize hits from the AR-TIF2 HCS campaign 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds that were confirmed in triplicate in the AR-TIF2 PPIB, were not cytotoxic or fluoresecent, and were 
inactive in all three counter screens were run in the AR-TIF2 PPIB in a concentration dependent manner. Those that 
confirmed in concentration response were then run in a PSA6.1-Luc reporter assay developed in C4-2 cells, and in growth 
inhibition assays run in 5 different PCa cell lines. Compounds that could inhibit AR’s transcriptional activity, and growth 
of PCa cell lines were run in an ALPHAScreen assay and radio ligand binding assay. Those that displayed favorable and 
potent biological activity in these assays were further prioritized with bioinformatics filters, and run in a set of 
characterization assays.  
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Figure 50. AR-TIF2 PPI inhibitor/disruptor hit analogs selected for testing in characterization assays 
Presented here are the chemical structures of hit compounds identified from the 50K Chembridge library 
plus their hit analogs which were prioritized based on their activities in the AR-TIF2 PPIB. PSA6.1 reporter 
assay in C4-2 cells, growth inhibition assays, and mammalian 2-hybrid assays. We characterized these 
compounds in a radio ligand binding assay, ALPHAScreen assay, PSA6.1-Luc reporter assay developed in 
PC3’s stably transfected with AR-FL, pGal4-AR-NTD transactivation assay, and PSA6.1-Luc and UBE2C-
Luc reporter assays developed in PC3’s stably transfected with AR-V7.  These compounds were grouped 
based on their structure into three different chemical clusters. Those within the blue border represent 
compounds from cluster 1. Those within the gray border represent compounds from cluster 2, and those 
identified with an orange border are from cluster 3.  
 
 
 
 
 
 
 
 
 
 
 178 
Table 17. IC50 results of selected AR-TIF2 PPI inhibitor/disruptor hit analogs tested in initial hit triage assays 
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Table 18. IC50 results of selected AR-TIF2 PPI inhibitor/disruptor hit analogs tested in mammalian 2-hybrid 
assays 
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Table 19. IC50 results of selected AR-TIF2 PPI inhibitor/disruptor hit analogs screened in PCa cell line growth 
inhibition assays 
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Figure 51. Performance of prioritized AR-TIF2 PPI inhibitor/disruptor hits in the AR-FL directed PSA6.1 
reporter assay performed in PC3-AR-FL-GFP cells 
A DHT-induced PSA6.1-LUC reporter-based assay was conducted with 10 hit analog compounds. PC3-
AR-FL-GFP cell lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC 
plasmid DNA (20 ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally 
incubated overnight at 5% CO2, 95% humidity, and 37°C. PC3-AR-FL-GFP cells transfected with the PSA-
6.1-LUC plasmid were exposed to the indicated concentrations of compounds for 3 h and were then treated 
with 25 nM DHT. The assay plate was returned to the incubator for an additional 24 h before BrightGlo 
reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
The PSA6.1-LUC RLU’s data for compound treated wells were normalized to maximum (25 nM DHT + 
0.5% DMSO, n=32) and minimum (0.5% DMSO, n=32) plate controls, and the % inhibition () was plotted 
on the left Y-axis as the mean +/- SD (n=3) values from triplicate wells for each compound concentration. 
The corresponding cell viability data for compound treated wells were normalized to 0.5% DMSO control 
wells (n=32), and the % cell viability () was plotted on the right Y-axis as the mean +/- SD (n = 3).  A) 
Representative plate control data for one run is plotted. The concentration dependent normalized % 
inhibition of the DHT-induced PSA6.1-LUC reporter activity for B) 98648798, C) 26996278, D) 55803564, 
E) 36998335, F) 60134988, G) 14977726, H) 21302587, I) 24843178, J) 63718298, and K) 72508471 are 
presented. Representative experimental data from one of two independent experiments are shown. 
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Figure 52. Performance of prioritized AR-TIF2 PPI inhibitor/disruptor hits in the H3-DHT radio ligand and 
TIF2 Box III LXXLL peptide ALPHAScreen binding assays 
H3-DHT Radioligand Binding Assay. Competitive displacement binding of H3-DHT to His6-AR-
LBD run with the ten analog hits. Five micrograms of His6-AR-LBD protein was added to the wells of 96-
well copper-coated plates and allowed to bind overnight at 4°C. Unbound protein was removed by 
aspiration; the plate was washed 3x with PBS-Tween 20 buffer and blocked for 1 h with 1 mg/mL BSA in 
PBS-Tween 20. After 3x washes with PBS-Tween 20 buffer, 10 nM H3-DHT was added to the wells of the 
plate in the presence or absence of the indicated concentrations of compounds and incubated at RT for 1 h. 
Unbound H3-DHT was removed by aspiration and washing, and micro-scintillation reagent was added to 
the wells, and the CPMs were captured on a TopCount NXT microtiter β-counter. β-emission RLU’s data 
for compound treated wells were normalized to maximum (0.5% DMSO, n=8) and minimum (10 µM cold 
DHT, n=8) plate controls, and the % inhibition  was plotted as the mean +/- SD (n=3) values from duplicate 
wells for each compound concentration. A) Representative plate control data for one run is plotted. The 
concentration dependent normalized % inhibition () of the H3-DHT bound to His6-AR-LBD for B) 
98648798, C) 26996278, D) 55803564, E) 36998335, F) 60134988, G) 14977726, H) 21302587, I) 
24843178, J) 63718298, and K) 72508471 are presented. Representative experimental data from one of 
two independent experiments are shown. 
TIF2 Box III LXXLL peptide ALPHAScreen assay. A competitive displacement binding of 
biotinylated-TIF2-box-III peptide to His6-AR-LBD was conducted with ten analog hits. Biotinylated-TIF2 
peptide was incubated with streptavidin donor beads for 30 min, in the dark, at RT, and then added to 384-
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well assay plates at a final concentration of 150 nM. Next, compound was added to the wells of the plate at 
the indicated concentrations, and incubated for 30 min, in the dark, at RT. Simultaneously, pET28a-His6-
AR-LBD (400ng/well) was incubated with DHT, and Ni2+ coated acceptor beads for 30 min. Finally, DHT 
bound pET28a-His6-AR-LBD, chelated to acceptor beads were mixed with streptavidin bound TIF2-
peptide in 384-well plates. After mixing the ALPHAScreen components, they were incubated for 1 hr at 
RT in the dark, and after, read on an envision plate reader. The ALPHASignal (CPMs) data for compound 
treated wells were normalized to maximum (0.5% DMSO, n=32) and minimum (0.5% DMSO and 75 µM 
unlabeled TIF2, n = 32) plate controls, and the % inhibition () was plotted as the mean +/- SD (n=3) 
values from triplicate wells for each compound concentration. A) Representative plate control data for one 
run is plotted. The concentration dependent normalized % inhibition of the AR-AF2::LXXLL-peptide 
binding for B) 98648798, C) 26996278, D) 55803564, E) 36998335, F) 60134988, G) 14977726, H) 
21302587, I) 24843178, J) 63718298, and K) 72508471 are presented. Representative experimental data 
from one of two independent experiments are shown. 
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Table 20. IC50 results of prioritized AR-TIF2 PPI inhibitor/disruptor hit analogs in AF-2 transactivation 
domain hit characterization assays that employ the AR-LBD 
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Figure 53. Performance of prioritized AR-TIF2 PPI inhibitor/disruptor hit analogs in the pGal4-AR-NTD 
transactivation assay 
HEK293 cells were transfected with pGAL4-AR-NTD (1-503) and 5xGal4-TATA-Luc, and 5,000 cells 
were seeded into the wells of 384-well assay plates, and cultured overnight at 37°C, 5% CO2, and 95% 
humidity. After 24 h cells were exposed to hit analog compounds at the indicated concentrations and 
incubated overnight. The assay plate was returned to the incubator for an additional 24 h before BrightGlo 
reagent was added to the plate and the RLUs were captured on a SpectraMax M5e microtiter plate reader. 
The M2H RLU’s data for compound treated wells were normalized to the 0.5% DMSO, n=32 plate controls, 
and the % inhibition () was plotted on the left Y-axis as the mean +/- SD (n = 3) values from triplicate 
wells for each compound concentration plotted on the left Y-axis. The corresponding cell viability data for 
compound treated wells were normalized to 0.5% DMSO control wells (n=64), and the % cell viability () 
was plotted on the right Y-axis as the mean +/- SD (n = 3) values from triplicate wells for each compound 
concentration plotted on the right Y-axis. A) Representative plate control data for the pGal4-AR-NTD 
transactivation assay are plotted in the presence or absence of DHT. The concentration dependent 
normalized % inhibition of pGal4-AR-NTD transcription (left-axis) and cell viability data (right Y-axis) 
for B) 98648798, C) 26996278, D) 55803564, E) 36998335, F) 60134988, G) 14977726, H) 21302587, I) 
24843178, J) 63718298, and K) 72508471 are presented. Representative experimental data from one of 
two independent experiments are shown. 
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Figure 54. Inhibition of the PSA6.1-Luc reporter assay to measure AR-V7’s transcriptional activity in the 
presence of AR-TIF2 PPI inhibitor/disruptor hit compound analogs 
A PSA6.1-LUC reporter-based assay was conducted with 10 hit analog compounds. PC3-AR-V7-GFP cell 
lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC plasmid DNA (20 
ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally incubated overnight 
at 5% CO2, 95% humidity, and 37°C. PC3-AR-V7-GFP cells transfected with the PSA6.1-LUC plasmid 
were exposed to the indicated concentrations of compounds before the assay plate was returned to the 
incubator for an additional 24 h before BrightGlo reagent was added to the plate and the RLUs were 
captured on a SpectraMax M5e microtiter plate reader. The PSA6.1-LUC RLU’s data for compound treated 
wells were normalized to plate controls (0.5% DMSO, n=32), and the % inhibition () was plotted on the 
left Y-axis was plotted as the mean +/- SD (n=3) values from triplicate wells for each compound 
concentration. The corresponding cell viability data for compound treated wells were normalized to 0.5% 
DMSO control wells (n=64), and the % cell viability () was plotted on the right Y-axis as the mean +/- 
SD (n = 3) values from triplicate wells for each compound concentration plotted on the right Y-axis. A) 
Representative plate control data for one run is plotted. The concentration dependent normalized % 
inhibition of the DHT-induced PSA6.1-LUC reporter activity for B) 98648798, C) 26996278, D) 55803564, 
E) 36998335, F) 60134988, G) 14977726, H) 21302587, I) 24843178, J) 63718298, and K) 72508471 are 
presented. Representative experimental data from one of two independent experiments are shown. 
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Figure 55. Inhibition of the UBE2C-Luc reporter assay to measure AR-V7’s transcriptional activity in the 
presence of AR-TIF2 PPI inhibitor/disruptor hit compound analogs 
A UBE2C-LUC reporter-based assay was conducted with 10 hit analog compounds to validate this assay. 
PC3-AR-V7-GFP cell lines were transiently bulk transfected with a 3:1 ratio of Fugene HD: PSA-6.1-LUC 
plasmid DNA (10 ng/well), then seeded into assay plates at a density of 3,000 cell per well, and finally 
incubated overnight at 5% CO2, 95% humidity, and 37°C. PC3-AR-V7-GFP cells transfected with the 
UBE2C-LUC plasmid were exposed to the indicated concentrations of compounds before the assay plate 
was returned to the incubator for an additional 24 h before BrightGlo reagent was added to the plate and 
the RLUs were captured on a SpectraMax M5e microtiter plate reader. The UBE2C-LUC RLU’s data for 
compound treated wells were normalized to plate controls (0.5% DMSO, n=32), and the % inhibition () 
was plotted on the left Y-axis as the mean +/- SD (n=3) values from triplicate wells for each compound 
concentration. The corresponding cell viability data for compound treated wells were normalized to 0.5% 
DMSO control wells (n=64), and the % cell viability () was plotted on the right Y-axis as the mean +/- 
SD (n = 3) values from triplicate wells for each compound concentration plotted on the right Y-axis.  A) 
Representative plate control data for one run is plotted. The concentration dependent normalized % 
inhibition of the DHT-induced UBE2C-LUC reporter activity for B) 98648798, C) 26996278, D) 
55803564, E) 36998335, F) 60134988, G) 14977726, H) 21302587, I) 24843178, J) 63718298, and K) 
72508471 are presented. Representative experimental data from one of two independent experiments are 
shown. 
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Table 21. IC50 results of prioritized AR-TIF2 PPI inhibitor/disruptor hit analogs in AF-1 transactivation 
domain hit characterization assays developed with the AR-NTD 
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  Perspectives, Limitations and Future Directions  
6.1 Perspectives 
Protein-Protein Interaction Inhibitors. Modulation of the activities of transcription factors 
(TFs) is viewed as a highly desirable therapeutic strategy because TFs are involved in the 
regulation of gene expression which controls major cellular functions involved in development, 
growth, and proliferation [181, 182]. TFs function in cells by binding to specific DNA sequences 
and orchestrating a complex and diverse set of protein-protein interactions that lead to the changes 
in gene expression which contribute to many disease states, including cancer. Although 
modulating the activities of TFs could have therapeutic potential for many diseases, the small 
molecule tools that are available to researchers remains limited and it is generally accepted that 
disrupting the protein-DNA and protein-protein interactions (PPIs) of TFs is challenging from both 
the drug discovery and development perspectives [181-183]. For example, the contact surfaces 
involved in PPIs are often large, flat, and seem to lack the pockets that ligands and small drug-like 
molecules typically bind to [184, 185]. Furthermore, rational drug design for targeting PPIs can be 
challenging especially when there is not an existing small molecule inhibitor to use as a starting 
point. It has also been reported that high-throughput screening does not routinely identify 
compounds that disrupt PPIs. Despite these observations, recent successes have indicated that 
disrupting PPIs with small molecules is achievable [183-186]. Advances in structure based drug 
design and the development of novel high-throughput screening assay formats have recently 
produced an uptick in small molecule PPI inhibitor discoveries. Nevertheless, the perception 
persists that PPI interfaces are flat, occur over very large surfaces, and present challenging targets 
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for drug-like molecules. Mutational studies have demonstrated that much smaller regions of amino 
acids at the PPI interface contribute most of the free binding energy. These regions are considered 
‘hotspots’ and they typically make up less than half of the PPI surface and provide a means for 
therapeutic intervention by small molecules or peptide mimetics [183-185]. For example, PPIs 
between the hMD2 E3 ligase and the tumor suppressor p53 regulate the degradation and expression 
levels of p53. hDM2 binds to a 15-residue alpha-helical region of p53 and the structure of the 
complex shows an interface that is largely hydrophobic. A mutational analysis of the 15-residues 
identified 3 dominant amino acids in the center of the interface, including Phe19, Trp23, and Leu 
26, that acted as a hot spot for compound binding. A combined HTS and medicinal chemistry 
optimization effort conducted by Roche identified a series of tetra-substituted imidazoles termed 
Nutlins. Specifically, Nutlin-3 disrupted hDM2-p53 complexes with high potency (IC50 of 90 nM) 
and demonstrated potent p53-stabilizing activity in vitro and inhibition of tumor xenograft growth 
in vivo [183]. Another example of a PPI that has been able to be modulate with a small molecule 
is the interaction between anti-apoptotic protein, Bcl-2, and pro-apoptotic protein BAD or BAK. 
BCL proteins are involved in apoptosis, and pro-apoptotic proteins (BAD or BAK) function is 
inhibited through their binding to anti-apoptotic protein (Bcl). This interaction is important as it’s 
been shown that there’s an upregulation of anti-apoptotic proteins seen in certain cancers which 
allows cells to escape cell death when targeted by certain chemotherapies. Therefore, inhibiting 
this interaction is a way to prevent cancer cells from avoiding death. Compound ABT-199 
represents a small molecule modification of ABT-737 which was identified by methods of NMR-
fragment discovery, and medicinal chemistry lead optimization efforts to mitigate adverse events 
seen with ABT-737. Currently, ABT-199 is in phase 1 clinical trials for the treatment of chronic 
lymphocytic leukemia [183].  
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One way to modulate the cellular functions of TF’s is to disrupt their interactions with 
transcriptional coactivators. Coactivators amplify AR transcription complex assembly and 
context-specific gene expression, and coactivator recruitment profiles influence the tissue-specific 
spatiotemporal gene expression responses to ligands [104, 187] Increased coactivator levels 
produce a more rapid transcriptional response and reduce ligand concentration requirements [187]. 
our lab is interested in finding novel therapeutics for the treatment of more advanced forms of 
prostate cancer (PCa) that inhibit or disrupt the PPI’s between the androgen receptor (AR) and one 
of its coactivators transcriptional intermediary factor 2 (TIF2). One way in which PCa patients are 
seen to relapse after treatment with standard of care therapeutics is due to the overexpression of a 
number of coactivators [49, 94, 96, 97]. Cumulative evidence suggests that elevated TIF2 
expression might be especially relevant to CRPC as TIF2 stabilizes AR-ligand binding, enhances 
receptor stability, and promotes both the recruitment of chromatin remodeling coactivators and 
assembly of the transcriptional machinery on the promoters of AR target genes [98]. Furthermore, 
the over-expression of TIF2 enhanced AR responses to androgens, compensating for reduced 
androgen levels [49, 96, 111]. Therefore, an inhibitor or disruptor of this disease relevant PPI could 
represent a strategy for preventing PCa progression. 
AR-TIF2 Protein-Protein Interaction Assay and HCS Campaign. We have developed and 
implemented a novel HCS assay to identify inhibitor and/or disruptors of the PPIs between the 
androgen receptor and one of its coactivators TIF2. The assay is a positional biosensor that utilizes 
recombinant adenoviruses to express the AF-2 containing AR-LBD as a chimeric fusion protein 
with RFP, and the box III LXXLL motifs from the nuclear receptor interacting domain of TIF2 as 
a chimeric fusion protein with GFP [118, 119, 127, 188]. The AR-RFP “prey” protein interaction 
partner shuttles between the cytoplasm and nucleus in a ligand dependent manner while the TIF2-
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GFP “bait” protein interaction partner is targeted to and anchored in the nucleoli within the cell 
nucleus [118, 119, 127, 188].  In unstimulated U-2 OS or PC3 cells co-infected with the AR-RFP 
and TIF2-GFP adenoviruses, AR-RFP expression is localized predominantly to the cytoplasm and 
TIF2-GFP expression is localized only to nucleoli within nuclei [118, 188]. After exposure to an 
AR agonist such as DHT, the AR-RFP biosensor traffics into the nucleus and then the PPIs 
between AR and TIF2 causes the AR-RFP to colocalize with the TIF2-GFP biosensor in nucleoli 
[118, 188]. Exposure to DHT dramatically alters the AR-RFP sub-cellular distribution phenotype 
observed in the Texas Red channel images from predominantly cytoplasmic to almost exclusively 
nucleolar. [118, 119, 127, 188] We used the AR-TIFs PPIB assay to screen 143,000 compounds 
that inhibited or disrupted AR-TIF2 PPIs [127]. After removing compounds that were false 
positives due to either cytotoxicity or auto-fluorescence in the FITC and Texas red channels, we 
implemented three counter screens to further refine and triage the active compound list. Our lab 
previously implemented the same HCS biosensor PPIB assay design and format to measure the 
PPIs between p53 and hDM2 and screened 220,000 compounds to find p53-hDM2 PPI inhibitors 
[122, 123]. The p53-hDM2 PPIB assay served as an AR-TIF2 counter screen to identify and 
eliminate compounds that interfere with the assay format or that behave as either non-selective or 
non-specific PPIs inhibitors [118]. The dexamethasone-induced GR-GFP translocation assay 
provided a counter screen to identify and eliminate compounds that were not selective for AR over 
GR, or that inhibited nuclear receptor trafficking from the cytoplasm into the nucleus [118, 189]. 
The AR-GFP nuclear localization assay provided a counter screen to identify and eliminate 
compounds that reduced AR expression levels and/or altered AR’s sub-cellular localization [118, 
190]. After eliminating cytotoxic and auto-fluorescent compounds and those that exhibited activity 
in the counter screens, a total of 178 (0.12%) hit compounds exhibited concentration dependent 
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inhibition and/or disruption of AR-TIF2 PPIs and produced calculable IC50’s in the AR-TIF2 PPIB 
assay [127]. The hit compounds were then tested in a PSA6.1-Luc reporter assay conducted in C4-
2 or 22Rv1 cells to confirm that they inhibited AR-mediated transcriptional activation, and in 
growth inhibition assays conducted in 5 different PCa cell lines, two AR null and three AR positive 
PCa cell lines. The growth inhibition assays were used to confirm that the hits killed PCa cells and 
to prioritize those that differentially inhibited the growth of AR positive cell lines. These hit 
characterization assays allowed us to triage the 178 AR-TIF2 PPI hits down to 38 prioritized 
compounds for medicinal chemistry evaluation and additional bioassay profiling;  2 from the 10K 
library, 18  from the 50K library, and 18  from the 83K library.  
Medicinal Chemistry Evaluation. The 38 prioritized hits from the AR-TIF2 PPIB HCS campaign 
were also evaluated from a cheminformatics and medicinal chemistry perspective. Compounds 
were manually clustered based on their structural similarities, which involved the identification of 
a maximum common substructure (MCS). These compounds were then assessed using 
cheminformatics and bioinformatics servers (as described in chapter 5). Compounds that failed 
these informatics filters were removed from further consideration.  The remaining compound 
clusters and singletons were queried in scifinder to ascertain if there was existing literature around 
the general scaffold and if any known biological activities would be undesirable. Through this 
assessment several chemotypes that considered as problematic were removed from further 
consideration. Compounds of unknown biological activity and/or mention in patent and peer-
reviewed literature were thought to be suitable candidates for further consideration. For example, 
all of the hits from the NCI 83K library were flagged as problematic/reactive compounds and were 
deprioritized. From the 143,000 compound AR-TIF2 PPIB HCS campaign and subsequent hit 
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characterization testing paradigm (see below), 5 hit compounds from the 50K library met our 
bioassay profile and chemical tractability criteria and were selected for further investigation.  
AR-TIF2 PPI Inhibitor/Disruptor Hit Characterization and Prioritization. During the 
development optimization and validation of the AR-TIF2 PPIB assay and characterization of hits 
identified in a pilot screen of the LOPAC set, we established that known AR antagonists 
inhibited/disrupted DHT-induced AR-TIF2 PPIs in a concentration dependent manner; including 
the anti-androgen PCa drugs flutamide, bicalutamide, enzalutamide, nilutamide and cyproterone 
acetate [118, 119, 188].  To determine if any of the 38 prioritized hits might also be antagonizing 
DHT binding to the AR receptor at its orthosteric ligand binding pocket, we developed and 
implemented an AR-LBD H3-DHT radioligand binding assay [118]. Initially, we used the AR-
LBD H3-DHT radioligand binding assay to characterize the hits identified in the LOPAC HCS and 
were able to show that in addition to nilutamide and cyproterone acetate, the eight other nuclear 
receptor hits also behaved as AR antagonists and competitively displaced H3-DHT binding to AR-
LBD even though they were classified as ligands of other nuclear receptors; progesterone, 
glucocorticoid, estrogen, mineralocorticoid, and farnesoid X (FXR) nuclear receptors [118]. The 
LOPAC nuclear receptor ligand hits lacked selectivity for AR and likely exhibited activity in the 
AR-TIF2 PPIB assay because they antagonized DHT binding to the AR-LBD containing AR-RFP 
biosensor. The six non-nuclear receptor ligand hits from the LOPAC set did not displace H3-DHT 
binding to AR-LBD but inhibited the GR-GFP translocation counter screen indicating that they 
were also not selective for AR, and likely inhibited some shared component of nuclear receptor 
trafficking from the cytoplasm into the nucleus [118]. Based on these data we deprioritized the 
AR-TIF2 PPI inhibitor/disruptor hits from the LOPAC set.  
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Originally, the strategy of our testing paradigm was to deprioritize any compound which behaved 
as an AR antagonist in the H3-DHT binding assay, because CRPC patients inevitably develop 
resistance to the anti-androgens used in ADT and relapse [111, 191]. However, the AR AF2 
domain also serves as the binding site for steroid receptor coactivator (SRC)/p160 coactivator 
LXXLL motifs, and we therefore developed an assay to measure the binding of a peptide 
containing the LXXLL motif located in box III of TIF2’s nuclear interaction domain (NID) to the 
AR-LBD. When we tested the 38 prioritized AR-TIF2 PPIB hit compounds in both the AR-LBD 
H3-DHT and LXXLL-peptide binding assays (Figure 56, on pg. 204), we found that many of the 
compounds exhibited concentration dependent responses in both assays, even though some may 
not have achieved ≥50% inhibition and failed to produce calculable IC50s. A subset of the 
compounds that were active in both the AR-TIF2 PPIB and AR-LBD::LXXLL-peptide binding 
assays were also active in the H3-DHT binding assay, albeit with less potent IC50’s. The apparent 
rightward shift in potencies between the H3-DHT binding assay and both the AR-TIF2 PPIB and 
AR-LBD::LXXLL-peptide binding assays may indicate that such compounds don’t directly 
antagonize binding to the orthosteric ligand binding pocket of AR, but rather may instead bind to 
a distinct allosteric site that negatively impacts both AR-TIF2 PPIs and ligand binding. Small 
molecules that bind to allosteric sites on AR to change the structures of the AF-2 and AF-1 domains 
on AR could inhibit the coactivator recruitment and transcriptional activity of AR-FL and/or AR-
V7 and might also have a negative impact on ligand binding. Negative allosteric modulators have 
been successfully used in lieu of orthosteric antagonists to achieve the same biological response, 
and thus may represent an alternative to the stereotypical PPI surface disruptors that tend to be 
non-drug like and/or chemically intractable [192]. Therefore, we modified our selection criteria to 
include some compounds that exhibited evidence of concentration dependent inhibition of H3-
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DHT binding to the AR-LBD. Hit compounds would be prioritized if they were active in the AR-
TIF2 PPIB and AR-LBD::LXXLL-peptide binding assays and displayed no evidence of 
antagonism in the H3-DHT binding assay. However, AR-TIF2 PPI hits that were active in the AR-
TIF2 PPIB and both the H3-DHT and LXXLL-peptide binding assays would also be prioritized, 
especially those that were substantially less potent in the H3-DHT binding assay and might 
therefore be negative allosteric modulators. However, hits with compounds that demonstrated 
activity in both the AR-TIF2 PPIB and H3-DHT binding assays, but were inactive in the AR-
LBD::LXXLL-peptide binding assay would still be deprioritized as likely AR antagonists. 
Twenty-three of the 38 prioritized AR-TIF2 inhibitor/disruptor hits from the AR-TIF2 PPIB HCS 
campaign failed to exhibit activity in both the H3-DHT and LXXLL-peptide AR-LBD binding 
assays, and because this was a less desirable biological profile these compounds were not 
progressed (Figure 57A, on pg. 205). Additionally, 6 more of the hits showed concentration 
dependent activity in both the AR-TIF2 PPIB and H3-DHT binding assays (Figure 57B), but 
because they were inactive in the LXXLL-peptide AR-LBD binding assay they were deprioritized 
as likely AR antagonists. Three of the AR-TIF2 PPI hits were active in the AR-TIF2 PPIB and 
LXXLL-peptide AR-LBD binding assays but were not antagonists in the H3-DHT binding assay 
(Figure 57C), and 6 more exhibited concentration dependent activity in all three assays (Figure 
57D). Nine of the 38 prioritized hits from the AR-TIF2 PPIB HCS campaign therefore exhibited 
desirable biological profiles and were also considered suitable starting points for a medicinal 
chemistry hit to lead optimization effort.  
AR-TIF2 PPI Inhibitor/Disruptor Hit Selection for Lead Optimization – AF-2 and AF-1 
Profiling. The chemical structures of the 5 prioritized AR-TIF2 PPI inhibitor/disruptor hits from 
the 50K library were used to perform a similarity search query of the ChemBridge 410K core 
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library database, and 20 structurally related analogs from 3 chemical clusters were selected for 
purchase (Figures 58-60, on pgs. 206-208). After the 25 compounds were profiled in the AR-TIF2 
PPIB, C4-2-PSA6.1-Luc reporter, and 5 PCa cell lines growth inhibition assays, 18 of the most 
potent compounds, the 5 parent hits and 13 analogs, were then profiled in the H3-DHT and TIF2 
Box III LXXLL peptide binding assays. 5 of the 13 analogs were active in the AR-TIF2 PPIB 
assay only, 2 were active in both the AR-TIF2 PPIB and LXXLL peptide binding assays, and 6 
were active in all three assays (Figure 61, on pg. 209). We selected 10 compounds, 4 of the parent 
hits and 6 analogs from three clusters for further testing in our suite of AF-2 and AF-1 bioassays. 
From cluster 1, we selected the two parent compounds 98648798 and 5580364 along with the 
26996278 analog that were active in the AR-TIF2 PPIB and both the H3-DHT and LXXLL-peptide 
binding assays.  From cluster 2, we selected the parent compounds 1497726 and 36998335 and 
three analogs 21302587, 60134988 and 24843178 that were active in all three assays. From cluster 
3 we chose analogs 63718298 and 72508471. Compound 63718298 was active in all 3 assays 
while 72508471 was only active in the AR-TIF2 PPIB assay.  
Mammalian 2-hybrid (M2H) assays are the gold standard assays to measure nuclear receptor 
coactivator recruitment [139, 140, 142], and they provided an orthogonal assay format to measure 
AR-TIF2 PPIs and to evaluate selectivity versus SRC1. All ten of the selected AR-TIF2 hit 
compounds produced IC50’s in both the TIF2 and SRC1 M2H assays confirming that they block 
DHT-induced AR-LBD interactions with both coactivators (Figure 62, on pg. 210). However, none 
of the hits exhibited selectivity for TIF2 versus SRC1. The PC3-AR-FL-PSA6.1-Luc reporter 
assay provided an independent confirmation that the AR-TIF2 PPI inhibitor/disruptor hits 
inhibited AR mediated transcription. Nine of the 10 prioritized AR-TIF2 PPI inhibitor/disruptor 
hits showed evidence of inhibiting DHT-induced AR-FL-mediated transcriptional activation 
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(Figure 62). Compound 21302587 from cluster 2 was inactive in the AR-FL driven PSA6.1-Luc 
reporter assay at ≤100 µM.   
It’s been demonstrated that AR-V7 splice variants which contain only the AF-1 domain of AR also 
require coactivators to recruit the general transcriptional machinery and activate gene transcription 
[79, 81, 105]. AR-NTD mediated assays will allow us to identify AR-TIF2 PPI inhibitor/disruptor 
hits that also block AF-1 mediated AR transcriptional activity and might therefore be effective 
against AR splice variants. However, during the development of mammalian 2-hybrid assays using 
the pGal4-AR-NTD with the VP16-TIF2 and VP16-SRC1 coactivator constructs, we observed that 
transcriptional activation was independent of either coactivator.  As expected, because of the lack 
of a ligand binding domain pGal4-AR-NTD’s transcriptional activity was also independent of 
DHT. AR-NTD’s transcriptional activity was constitutively activated in HEK-293 cells, and all 10 
of the AR-TIF2 hits inhibited AF-1 mediated transcriptional activity (Figure 63, on pg. 211). The 
expression of splice variants such as AR-V7 are upregulated in CRPC patients that relapse after 
receiving ADT therapy [71, 78]. We tested the 10 AR-TIF2 hits in two reporter assays performed 
in PC3 cells stably expressing AR-V7-GFP. Since the PSA6.1-Luc reporter can be activated by 
AR-FL and AR splice variants such as AR-V7, we also included the UBE2C-Luc reporter because 
it can only be activated by AR splice variants. Nine of the 10 AR-TIF2 hits inhibited AR-V7 
mediated reporter activity, but only 8 inhibited both reporters (Figure 63). Only 8 of the AR-TIF2 
hits inhibited all three AF-1 mediated transcriptional activity assays. 
The cluster 1 hits (98648798, 26996278 and 55803564) produced calculable IC50s or demonstrated 
concentration dependent inhibition in both our panels of AF-2 and AF-1 domain transactivation 
assays.  While 26996278 was equipotent at inhibiting the growth of all 5 PCa cell lines, 55803564 
only produced GI50s against the 3 AR-positive cell lines, and 98648798 showed selectivity for 
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inhibiting the growth of 2/3 AR-positive PCa cell lines relative to AR-null cell lines. Figure 64 (on 
pg. 212) shows the bioassay activity profile of 55803564, a representative AR-TIF2 PPI hit from 
Cluster 1.  Three of the cluster 2 hits (14977726, 36998335 and 60134988) produced calculable 
IC50s or showed concentration dependent inhibition in the AF-2 domain transactivation assays.  
However, 21302587 and 24843178 only exhibited minimal or no activity in the AF-2 assays. Four 
of the 5 cluster 2 hits also produced calculable IC50s in the AF-1 domain transactivation assays, 
while 24843178 was active in only 2 of these assays. All five cluster 2 hits showed differential 
selectivity for PCa growth inhibition in either 3/3 or 2/3 AR-positive cell lines relative to AR-null 
cell lines. Although there is preliminary evidence of an emerging structure activity relationship 
(SAR) for the cluster 2 hits, additional analogs would have to be purchased or synthesized to 
establish this. Figure 65 (on pg. 213) shows the bioassay activity profile of 36998335, a 
representative AR-TIF2 PPI hit from Cluster 2.  Both the cluster 1 and 2 hit compound series 
exhibit the desired biological activity profiles with acceptable physiochemical properties and are 
under consideration as potential starting points for a medicinal chemistry hit to lead optimization 
effort. The cluster 3 hit 72508471 was not very active in the AF-2 and 2/3 AF-1 transactivation 
domain assays. This profile was surprising since it had produced calculable IC50’s in the DHT-
induced AR-TIF2 PPI formation assay, the TIF2 and SRC1 M2H assays, the C4-2-PAS6.1 reporter 
assay and showed some degree of differential selectivity toward AR-positive cell lines in PCa 
growth inhibition assays. 72508471 also exhibited strange biphasic concentration response curves 
in three of the assays. Compound 63718298, the other member of cluster 3, did not demonstrate 
any evidence of selectivity for AR expressing PCa cell lines and exhibited strange biphasic 
concentration response curves in some assays. Based on these data we deprioritized the cluster 3 
compounds. 
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Conclusions. The development and implementation of a suite of counter screens and hit 
characterization assays has enabled us to effectively triage the hits from the AR-TIF2 PPIB HCS 
campaign and identify two hit series that are now being considered as potential starting points for 
a future medicinal chemistry hit to lead optimization effort. The goal of these future studies will 
be to develop more potent and effective inhibitors of AR-TIF2 PPIs and subsequently these leads 
might be developed into new therapies for CRPC.  
6.2 Limitations 
The design of the constructs used to express the biosensors used in the AR-TIF2 PPIB HCS assay 
did not utilize full length AR or TIF2. The AR-RFP biosensor encodes AR-LBD residues 662-919 
and therefore is biased towards the C-terminal part of AR and the AF-2 transactivation domain. In 
addition to the N-terminal domain, the DNA binding domain and hinge regions of AR are missing 
for the AR-RFP biosensor. Similarly, the TIF2 residues 725-840 in the other biosensor only 
encodes a single box III LXXLL motif from the nuclear receptor interacting domain (NID) of 
TIF2, while the full-length protein encodes 3 LXXLL motifs and several other domains. Although 
the AR-TIF2 PPIB assay design was pragmatic and enabled us to screen 143K compounds, we 
will need to confirm that our hits will also inhibit or disrupt full-length AR-TIF2 PPIs. This will 
likely involve the development of full-length AR and TIF2 co-immunoprecipitation (co-IP) assays 
and potentially chromatin immunoprecipitation (ChIP) assays performed with AR and TIF2 
specific antibodies in PCa cell backgrounds. AR and TIF2 co-IP assays using recombinantly 
expressed and purified AR and TIF2 is another possibility  
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In addition, the AR-TIF2 PPIB assay requires exposure to agonists such as DHT to induce 
AR-TIF2 PPI formation which involves the trafficking of the AR-RFP from the cytoplasm into the 
nucleus and colocalization with the TIF2-GFP biosensor anchored in the nucleolus.  The AR-TIF2 
PPIB assay was therefore sensitive to inhibition by AR antagonists, compounds that disrupted the 
chaperone mediated maturation and folding of the biosensors, and molecules that blocked 
trafficking through the cytoplasm into the nuclear and nucleolar compartments or potentially that 
altered the sub-cellular targeting and localization of the biosensors. This required us to develop 
and implement the panel of counter screens and cell based and biochemical hit characterization 
assays described in this dissertation to identify and triage out non-PPI inhibitor/disruptor hits.   
Although our suite of cell based and biochemical assays have effectively enabled us to 
select two hit series as potential starting points for a future medicinal chemistry hit to lead 
optimization effort, none of the assays we have  implemented provide information on three critical 
questions; (1) do any of the hits bind directly to either of the AR or TIF2 protein interacting partners 
or both, (2) where on AR or TIF2 do the hits bind, and (3) how does the binding of the hits to either  
AR or TIF2 inhibit or disrupt AR-TIF2 PPIs? These will be critical questions to answer before 
embarking upon a medicinal chemistry hit-to-lead optimization effort and will likely involve the 
development of biophysical assays; surface plasmon resonance (SPR), isothermal calorimetry 
(ITC) and NMR assay for AR and TIF2. 
6.3 Future Directions 
We plan to develop full-length AR and TIF2 co-immunoprecipitation (co-IP) assays and potentially 
chromatin immunoprecipitation (ChIP) assays performed with AR and TIF2 specific antibodies in 
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PCa cell backgrounds. We will test compounds from the two prioritized hit series to confirm that 
they inhibit or disrupt full-length AR-TIF2 PPIs. In addition to the AR-LBD, we have expressed 
and partially purified recombinant AR and TIF2 in bacteria. We could use recombinantly expressed 
and purified AR and TIF2 in co-IP assays to confirm that compounds from the two prioritized hit 
series inhibit or disrupt full-length AR-TIF2 PPIs.  
Several biophysical techniques and assays can be used to confirm that small molecules 
bind to proteins. We could use recombinantly expressed and purified AR and TIF2 for these assays. 
Techniques such as surface plasmon resonance (SPR), isothermal calorimetry (ITC) and Nuclear 
Magnetic Resonance (NMR) will allow us to determine whether our hit compounds bind to AR, 
TIF2 or both, and to determine binding thermodynamics. SPR can be used to determine if our 
compound hits are binding to AR or to TIF2, and to measure real-time on and off binding kinetics 
to further prioritize hits based on their binding affinities. SPR involves the immobilization of a 
protein on a sensor chip, while compound is present in solution that flows over the surface to which 
the protein is bound. Interactions between the compound and target protein are determined by 
measuring changes in the refractive index at the sensor surface of bound protein induced by small 
molecule association and dissociation [193, 194]. Isothermal calorimetry (ITC) can be used to 
determine the thermodynamic binding properties of hit compounds. ITC is a gold standard for 
determining the affinity of biomolecular interactions. ITC directly measures heat that is generated 
upon protein::compound interaction. Heat is generated by the sequential addition of compound to 
the cell, which is measured over a given period. A binding isotherm is generated from this data, 
from which enthalpy and binding affinity can be derived, and free energy and entropy can be 
calculated. Once KD, enthalpy, and entropy values are determined, compound affinities, and 
enthalpic and entropic parameters for each protein can be compared [194]. Finally, NMR 
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spectroscopy will be used to detect whether interactions occur between our hits and AR or TIF2, 
and where this interaction takes place on the protein. Protein resonances represent one type of 
information that can be observed in an NMR-spectra which can detect physical interactions 
between proteins and compounds. Double isotope-labelling and additional experimentation, 
usually from triple-resonance approaches, can allow for the direct assessment of protein 
resonances, and ultimately unveils where on the protein an interaction may occur and also how 
this interaction is made [195]. Results from these assays will allow us to prioritize AR-TIF2 hit 
compounds that will move forward into lead optimization. Collectively, these assays will allow us 
to rank hit compounds based on their molecular target, binding affinities, and preliminary SAR.  
Based on the information that we learn from the biophysical studies and level of resolution on 
where the compounds bind to AR or TIF2 and the availability of crystal structures, we could use 
rational drug design, and computer aided platforms to predict how and where to modify 
compounds to exhibit tighter binding affinities. Ideally the two chemically tractable hit series we 
have identified will be pursued in a medicinal chemistry hit-to-lead optimization effort, and 1-2 of 
the most promising AR-TIF2 PPI disruptor leads would be tested in established castration resistant 
prostate cancer mouse xenograft models to demonstrate efficacy. 
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Figure 56. AR-TIF2 PPI inhibitor/disruptor hit characterization and prioritization bioactivity profiles 
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Figure 57. AR-TIF2 PPI inhibitor/disruptor hit compound profiles 
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Figure 58. 9864798 & 55803564 analogs 
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Figure 59. 14977726 & 36998335 analogs 
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Figure 60. 62209680 analogs 
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Figure 61. AR-TIF2 PPI parent hits & structurally related analog hit characterization profiles 
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Figure 62. AR AF-2 transactivation domain assay profiles 
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Figure 63. AR AF-1 transactivation domain assay profiles 
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Figure 64. Bioassay activity profile of a representative AR-TIF2 PPI hit from cluster 1 
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Figure 65. Bioassay activity profile of a representative AR-TIF2 PPI hit from cluster 2 
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